{
  "schema_version": 1,
  "source_checked": "2026-10-29",
  "scope": "Evidence records; not treatment or compounding instructions",
  "named_records": 152,
  "entries": [
    {
      "slug": "bremelanotide",
      "name": "Bremelanotide",
      "canonical_id": "bremelanotide",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "Melanocortin-receptor peptide studied in sexual-desire/arousal disorders. A small randomized crossover study in 18 premenopausal women reported some subjective response differences but no significant change in its vaginal-vasocongestion measurement.",
      "classification": "medicine",
      "regulatory_status": "United States: Vyleesi product labeling covers acquired, generalized hypoactive sexual desire disorder in specified premenopausal women, with exclusions and limitations. It is not labeled to enhance sexual performance. Product approval does not establish equivalence of unverified PT-141 products.",
      "evidence_summary": "Melanocortin-receptor peptide studied in sexual-desire/arousal disorders. A small randomized crossover study in 18 premenopausal women reported some subjective response differences but no significant change in its vaginal-vasocongestion measurement.",
      "evidence_level": "human randomized crossover study",
      "limitations": "A preliminary intranasal trial is not the current injected product, indication or safety profile; do not transfer route or regimen.",
      "reader_summary": {
        "why_people_are_interested": "Interest centers on low sexual desire that is distressing, rather than a general boost in sexual performance. Bremelanotide has a specific prescription-medicine role in that setting.",
        "what_it_is_used_or_studied_for": "Vyleesi is approved in the United States for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder. The label excludes several other explanations for low desire.",
        "what_human_evidence_shows": "A small randomized crossover study reported improvements in some subjective desire and arousal measures, but not its physiological measure of vaginal blood-flow response. That experimental intranasal study differs from the approved injected product.",
        "important_drawbacks": "Nausea is common. The current label also warns about temporary blood-pressure increases and darkened patches of skin, which did not always resolve in the available follow-up."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16839319/",
          "title": "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "16839319",
          "doi": "10.1111/j.1743-6109.2006.00268.x"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf",
          "title": "Vyleesi current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22bremelanotide%22&limit=5",
          "title": "FDA Drugs@FDA application records: bremelanotide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": false,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557",
          "display_title": "FDA: VYLEESI (AUTOINJECTOR) approval history (selected product)"
        }
      ]
    },
    {
      "slug": "trofinetide",
      "name": "Trofinetide",
      "canonical_id": "trofinetide",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "Peptide analogue studied in Rett syndrome. Two phase 2 randomized studies in pediatric and adolescent/adult females preceded later development and reported signals across selected caregiver/clinician measures.",
      "classification": "medicine",
      "regulatory_status": "United States: DAYBUE and DAYBUE STIX labeling covers Rett syndrome in adults and pediatric patients 2 years and older. Each product’s current label governs its formulation and safety; this is not a claim for other neurodevelopmental conditions.",
      "evidence_summary": "Peptide analogue studied in Rett syndrome. Two phase 2 randomized studies in pediatric and adolescent/adult females preceded later development and reported signals across selected caregiver/clinician measures.",
      "evidence_level": "human randomized phase 2 studies",
      "limitations": "Historical early trials are not a substitute for the current product label or later confirmatory evidence.",
      "reader_summary": {
        "why_people_are_interested": "For families affected by Rett syndrome, the interest is in improving symptoms of a serious neurodevelopmental condition and making a difference to daily life, rather than general wellness.",
        "what_it_is_used_or_studied_for": "Trofinetide is the active ingredient in DAYBUE and DAYBUE STIX, U.S.-approved oral products for adults and children age 2 and older with Rett syndrome.",
        "what_human_evidence_shows": "Randomized studies reported improvements on some clinician and caregiver assessments compared with placebo. These findings do not mean that every symptom improves or that the disease is cured.",
        "important_drawbacks": "Diarrhea, vomiting and weight loss are important drawbacks. The current product label also warns about aspiration and aspiration pneumonia after vomiting."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/30918097/",
          "title": "Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "30918097",
          "doi": "10.1212/wnl.0000000000007316",
          "pmcid": "PMC6550498"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/28964591/",
          "title": "A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "28964591",
          "doi": "10.1016/j.pediatrneurol.2017.07.002"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67e6f2d9-21f6-466f-9def-826c6a4b8257",
          "title": "Daybue, Daybue Stix current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22trofinetide%22&limit=5",
          "title": "FDA Drugs@FDA application records: trofinetide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217026",
          "display_title": "FDA: DAYBUE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "ziconotide",
      "name": "Ziconotide",
      "canonical_id": "ziconotide",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "A conotoxin-derived peptide investigated for severe chronic pain. A randomized intrathecal study found a modest average improvement over placebo and reported neurologic adverse effects including dizziness, confusion and abnormal gait.",
      "classification": "medicine",
      "regulatory_status": "United States: PRIALT labeling covers severe chronic pain in adults when intrathecal therapy is warranted and other specified treatments are intolerable or ineffective. This specialist route and population cannot be generalized to other uses.",
      "evidence_summary": "A conotoxin-derived peptide investigated for severe chronic pain. A randomized intrathecal study found a modest average improvement over placebo and reported neurologic adverse effects including dizziness, confusion and abnormal gait.",
      "evidence_level": "human randomized trial",
      "limitations": "Specialist intrathecal therapy; the source does not support consumer self-use or other delivery routes.",
      "reader_summary": {
        "why_people_are_interested": "The appeal is pain relief for people with severe, persistent pain when other options have not worked or cannot be tolerated. This is specialist pain care, not a routine wellness peptide.",
        "what_it_is_used_or_studied_for": "PRIALT contains ziconotide and is approved for specified adults who warrant therapy delivered into the fluid around the spinal cord and are intolerant of or refractory to other treatments.",
        "what_human_evidence_shows": "A randomized trial found a modest average improvement in pain scores over placebo. Some people had dizziness, confusion, abnormal walking or memory problems.",
        "important_drawbacks": "The label carries a boxed warning for severe psychiatric and neurological reactions and excludes patients with a history of psychosis. Delivery requires specialist equipment and supervision."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16716870/",
          "title": "A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "16716870",
          "doi": "10.1016/j.jpainsymman.2005.10.003"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1",
          "title": "PRIALT current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ziconotide%22&limit=5",
          "title": "FDA Drugs@FDA application records: ziconotide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021060",
          "display_title": "FDA: PRIALT approval history (selected product)"
        }
      ]
    },
    {
      "slug": "davunetide",
      "name": "Davunetide",
      "canonical_id": "davunetide",
      "entry_kind": "investigational-peptide",
      "aliases": [],
      "identity": "Also called NAP or AL-108. In a 63-participant schizophrenia trial, the primary cognition battery did not improve significantly versus placebo, although one functional-capacity measure differed. Separate mouse work explored axonal transport.",
      "classification": "investigational-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "Also called NAP or AL-108. In a 63-participant schizophrenia trial, the primary cognition battery did not improve significantly versus placebo, although one functional-capacity measure differed. Separate mouse work explored axonal transport.",
      "evidence_level": "human randomized trial plus animal research",
      "limitations": "Mixed endpoints and disease-specific experimental findings do not establish cognitive enhancement or a licensed indication.",
      "reader_summary": {
        "why_people_are_interested": "Davunetide attracted research interest because protecting nerve-cell function might help problems with thinking or everyday functioning in neurological and psychiatric conditions. That remains a research question.",
        "what_it_is_used_or_studied_for": "Also called NAP or AL-108, it has been tested in people with schizophrenia and studied in animal models of neurodegeneration. These are distinct settings, not one proven use.",
        "what_human_evidence_shows": "In a 63-person schizophrenia trial, the main thinking-skills test did not improve significantly compared with placebo. One measure of practical functional ability favored treatment.",
        "important_drawbacks": "The mixed results do not establish a cognitive enhancer or an approved treatment. Findings from mice cannot fill the gaps in human effectiveness or long-term safety."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/22169248/",
          "title": "Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "22169248",
          "doi": "10.1016/j.schres.2011.11.001"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/23631872/",
          "title": "NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "23631872",
          "doi": "10.1016/j.nbd.2013.04.012"
        }
      ]
    },
    {
      "slug": "nnz-2591",
      "name": "NNZ-2591",
      "canonical_id": "nnz-2591",
      "entry_kind": "investigational-compound",
      "aliases": [],
      "identity": "A diketopiperazine related to cyclic glycine-proline. Published studies examined ischemic injury and induced memory impairment in rats; they provide preclinical context rather than a human efficacy conclusion.",
      "classification": "investigational-compound",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A diketopiperazine related to cyclic glycine-proline. Published studies examined ischemic injury and induced memory impairment in rats; they provide preclinical context rather than a human efficacy conclusion.",
      "evidence_level": "animal studies",
      "limitations": "Human development is a separate evidence layer; these rat papers cannot establish treatment benefit or approval.",
      "reader_summary": {
        "why_people_are_interested": "NNZ-2591 interests researchers and families affected by rare developmental conditions because a treatment that improves communication, behavior or daily function could make a practical difference.",
        "what_it_is_used_or_studied_for": "It is an experimental small cyclic compound related to glycine and proline. Human research has included children with Phelan-McDermid syndrome, alongside earlier animal studies of brain injury and memory.",
        "what_human_evidence_shows": "An open-label study in 18 children reported improvements from the starting measurements on several clinician and caregiver assessments. There was no placebo group, so the study cannot establish how much improvement was caused by the medicine.",
        "important_drawbacks": "Most health problems reported during that small study were mild to moderate, but its size and design leave uncertainty about effectiveness and less common or long-term harms. Larger controlled studies are needed."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/17904590/",
          "title": "Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "17904590",
          "doi": "10.1016/j.neuropharm.2007.08.010"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/20188767/",
          "title": "NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "20188767",
          "doi": "10.1016/j.bbr.2010.02.039"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/41450730/",
          "title": "NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome: Single-Group, Open-Label, Phase 2 Trial Results.",
          "supports": "Open-label single-group phase 2 findings in 18 children with Phelan-McDermid syndrome; baseline changes do not establish a placebo-controlled treatment effect.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research; PubMed abstract",
          "read_scope": "Abstract-level verification; not an independent full-article review.",
          "pmid": "41450730",
          "checked_on": "2026-10-29",
          "doi": "10.1212/nxg.0000000000200338",
          "pmcid": "PMC12735298"
        }
      ]
    },
    {
      "slug": "trofinetide-predecessor-programs",
      "name": "Trofinetide (predecessor programs)",
      "canonical_id": "trofinetide-predecessor-programs",
      "entry_kind": "development-history",
      "aliases": [],
      "identity": "A history category rather than a separate medicine. An early rat experiment studied the natural IGF-1-derived tripeptide glycine-proline-glutamate (GPE), which must be distinguished from trofinetide and from other analogue programs.",
      "classification": "development-history",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A history category rather than a separate medicine. An early rat experiment studied the natural IGF-1-derived tripeptide glycine-proline-glutamate (GPE), which must be distinguished from trofinetide and from other analogue programs.",
      "evidence_level": "animal study; historical context",
      "limitations": "Historical GPE animal findings are separate from trofinetide’s human clinical evidence and approved-product information.",
      "alias_of": "trofinetide",
      "reader_summary": {
        "why_people_are_interested": "This entry explains the earlier scientific ideas behind a development program. It can help readers understand why related names appear in peptide research without treating them as the same medicine.",
        "what_it_is_used_or_studied_for": "Glycine-proline-glutamate, or GPE, is a naturally derived fragment associated with insulin-like growth factor 1. It is distinct from trofinetide and other modified compounds.",
        "what_human_evidence_shows": "The cited studies were in rats, not people. They reported protection of selected nerve-cell measures after experimentally induced injury, which helped motivate further research.",
        "important_drawbacks": "These historical experiments do not demonstrate a benefit from taking GPE or predict the results of a different analogue. They are background research, not an additional approved medicine."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/10719076/",
          "title": "N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "10719076",
          "doi": "10.1016/s0006-8993(00)01988-0"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11730700/",
          "title": "Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic-ischemic injury.",
          "supports": "Specific experimental population and result scope described by this primary paper; not evidence for approved treatment or a dose recommendation.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed byNLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11730700",
          "doi": "10.1016/s0006-8993(01)03148-1"
        }
      ]
    },
    {
      "slug": "epitalon",
      "name": "Epitalon",
      "canonical_id": "epitalon",
      "entry_kind": "research-peptide",
      "aliases": [],
      "identity": "Also spelled epithalon; the tetrapeptide sequence is AEDG. Published studies concern fruit-fly lifespan and neurogenic-marker expression in cultured human gingival mesenchymal stem cells.",
      "classification": "research-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction. The October 2026 HHS 503A draft-policy context describes conditional draft enforcement discretion; it does not confer FDA approval or blanket legal permission.",
      "evidence_summary": "Fly lifespan and cultured-cell experiments provide preclinical observations. A small human AEDG study reported changes in a urinary melatonin marker and blood-cell clock-gene expression, but did not assess sleep outcomes or demonstrate longer life.",
      "evidence_level": "Small human biomarker study plus animal and cell research",
      "limitations": "A biomarker change is not proof of improved sleep or longevity. Human study size and duration were limited, blinding was not specified, and the sublingual preparation does not establish the effects or safety of injections.",
      "reader_summary": {
        "why_people_are_interested": "Epitalon, also spelled epithalon, attracts interest around aging and sleep because researchers have studied cell activity and melatonin, a hormone involved in the sleep-wake cycle.",
        "what_it_is_used_or_studied_for": "It is a short peptide also called AEDG. Research includes lifespan experiments in fruit flies, laboratory cell studies and a small human study involving mostly night-shift workers.",
        "what_human_evidence_shows": "In a study involving 75 middle-aged women, a 40-person subgroup with low melatonin production received AEDG or placebo. AEDG increased a urine marker of melatonin production. The study did not measure how well or how long participants slept.",
        "important_drawbacks": "A hormone-marker change does not prove better sleep or a longer life. The study was short, blinding was not specified, and it used an under-the-tongue preparation rather than injections. Long-term benefit and safety remain uncertain."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11087911/",
          "title": "Effect of epitalon on the lifespan increase in Drosophila melanogaster.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Effect of epitalon on the lifespan increase in Drosophila melanogaster. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11087911",
          "doi": "10.1016/s0047-6374(00)00217-7"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32019204/",
          "title": "AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "32019204",
          "doi": "10.3390/molecules25030609",
          "pmcid": "PMC7037223"
        },
        {
          "url": "https://www.fda.gov/media/193345/download",
          "title": "FDA July 2026 PCAC scientific assessment: epitalon-related bulk drug substances",
          "supports": "Describes the 75-woman study and 40-person low-melatonin subgroup, sublingual preparation, biomarker change, missing sleep outcomes, short duration and unspecified blinding.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator scientific assessment / public statement",
          "read_scope": "Actual primary PDF pages25–26 on human clinical evidence and pages35–39 safety/conclusions read.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://www.pleiades.online/cgi-perl/search.pl?name=advger&number=1&page=53&type=abstract&year=21",
          "title": "AEDG Peptide Regulation of the Expression of Human Circadian Rhythm Genes upon Accelerated Aging of the Pineal Gland.",
          "supports": "Primary study abstract reports increased urinary melatonin metabolite and blood-cell circadian-gene expression changes; not demonstrated longevity or sleep benefit.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual publisher-hosted complete abstract read; no claim to have independently read full paper.",
          "checked_on": "2026-10-29",
          "doi": "10.1134/S2079057021010380"
        }
      ]
    },
    {
      "slug": "semax",
      "name": "Semax",
      "canonical_id": "semax",
      "entry_kind": "research-peptide",
      "aliases": [],
      "identity": "An ACTH-fragment analogue studied in neurobiology. Studies examined neurotrophin gene expression in rat glial cultures and BDNF/trkB-related responses in rat hippocampus.",
      "classification": "research-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction. The October 2026 HHS 503A draft-policy context describes conditional draft enforcement discretion; it does not confer FDA approval or blanket legal permission.",
      "evidence_summary": "An ACTH-fragment analogue studied in neurobiology. Studies examined neurotrophin gene expression in rat glial cultures and BDNF/trkB-related responses in rat hippocampus.",
      "evidence_level": "rat and cell-culture studies",
      "limitations": "The presence of mechanistic or animal findings does not establish cognitive improvement in humans or approval in any country.",
      "reader_summary": {
        "why_people_are_interested": "Semax attracts interest around recovery after brain injury and questions about memory because research has examined nerve-growth signals and functional recovery. Those are different questions from boosting everyday performance in healthy people.",
        "what_it_is_used_or_studied_for": "It is an analogue of a fragment of adrenocorticotropic hormone. Studies have examined rat brain signaling and its use alongside rehabilitation after ischemic stroke in people.",
        "what_human_evidence_shows": "A study involving 110 stroke patients reported faster improvement in a measure of daily function in the Semax groups. That finding concerns stroke rehabilitation and does not establish better memory or attention in otherwise healthy people.",
        "important_drawbacks": "The selected evidence does not settle general effectiveness or long-term safety. The dated October 2026 HHS draft policy discusses conditional compounding enforcement; it is not FDA approval of a cognitive treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11457573/",
          "title": "Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11457573",
          "doi": "10.1016/s0304-3940(01)01994-2"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16996037/",
          "title": "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "16996037",
          "doi": "10.1016/j.brainres.2006.07.108"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29798983/",
          "title": "[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].",
          "supports": "Study of 110 patients undergoing ischemic-stroke rehabilitation and reported Barthel daily-function changes; not healthy-adult cognitive enhancement.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research; PubMed abstract",
          "read_scope": "Abstract-level verification; not an independent full-article review.",
          "pmid": "29798983",
          "checked_on": "2026-10-29",
          "doi": "10.17116/jnevro20181183261-68"
        }
      ]
    },
    {
      "slug": "selank",
      "name": "Selank",
      "canonical_id": "selank",
      "entry_kind": "research-peptide",
      "aliases": [],
      "identity": "A tuftsin-family peptide. Published studies examined stress-related behavior in rodents and laboratory methods for tracing peptide breakdown.",
      "classification": "research-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A tuftsin-family peptide. Published studies examined stress-related behavior in rodents and laboratory methods for tracing peptide breakdown.",
      "evidence_level": "animal and laboratory studies",
      "limitations": "These sources do not establish clinical treatment of anxiety, long-term safety or an approved use.",
      "reader_summary": {
        "why_people_are_interested": "Selank interests researchers studying stress responses and anxiety-related biology. For an individual reader, the practical question is whether it improves symptoms in people, not only animal behavior.",
        "what_it_is_used_or_studied_for": "It is a peptide related to tuftsin. The cited work examined responses to stressful situations in rodents and how the peptide and related fragments break down in laboratory experiments.",
        "what_human_evidence_shows": "These sources do not show clinical anxiety treatment outcomes. Rodent behavior changed in one study; the other described peptide breakdown rather than a benefit patients could feel.",
        "important_drawbacks": "Those findings do not establish how well it works in people or its longer-term safety. A laboratory description calling a compound anxiolytic is not the same as evidence of an approved anxiety medicine."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/14969422/",
          "title": "Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "14969422",
          "doi": "10.1023/a:1025988519919"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16637290/",
          "title": "[Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation].",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: [Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation]. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "16637290"
        }
      ]
    },
    {
      "slug": "pt-141",
      "name": "PT-141",
      "canonical_id": "pt-141",
      "entry_kind": "alias",
      "aliases": [],
      "identity": "PT-141 is a development name associated with bremelanotide. Early human studies used experimental formulations; an online product named PT-141 should not be treated as interchangeable with a licensed bremelanotide product.",
      "classification": "alias",
      "regulatory_status": "United States: Vyleesi product labeling covers acquired, generalized hypoactive sexual desire disorder in specified premenopausal women, with exclusions and limitations. It is not labeled to enhance sexual performance. Product approval does not establish equivalence of unverified PT-141 products. This entry is an alias; it does not establish that products sold as PT-141 are the approved product.",
      "evidence_summary": "PT-141 is a development name associated with bremelanotide. Early human studies used experimental formulations; an online product named PT-141 should not be treated as interchangeable with a licensed bremelanotide product.",
      "evidence_level": "early human studies; alias",
      "limitations": "A different name does not verify composition, purity or equivalence to the licensed product.",
      "alias_of": "bremelanotide",
      "reader_summary": {
        "why_people_are_interested": "PT-141 is a development name for bremelanotide, so the interest is connected to sexual desire and arousal rather than a separate class of treatment.",
        "what_it_is_used_or_studied_for": "The approved bremelanotide product, Vyleesi, has a limited U.S. indication for certain premenopausal women with distressing acquired, generalized low sexual desire. Its label does not endorse sexual-performance enhancement.",
        "what_human_evidence_shows": "Early human studies reported some sexual-response effects, but they involved experimental formulations and selected populations. Those results do not establish that every product sold as PT-141 performs like Vyleesi.",
        "important_drawbacks": "The approved product can cause nausea, temporary blood-pressure changes and skin darkening. A familiar ingredient name does not verify the identity, purity or formulation of an unverified product."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16839319/",
          "title": "An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "16839319",
          "doi": "10.1111/j.1743-6109.2006.00268.x"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/12851303/",
          "title": "PT-141: a melanocortin agonist for the treatment of sexual dysfunction.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "12851303",
          "doi": "10.1111/j.1749-6632.2003.tb03167.x"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf",
          "title": "Vyleesi current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22bremelanotide%22&limit=5",
          "title": "FDA Drugs@FDA application records: bremelanotide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": false,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210557",
          "display_title": "FDA: VYLEESI (AUTOINJECTOR) approval history (selected product)"
        }
      ]
    },
    {
      "slug": "dsip",
      "name": "DSIP",
      "canonical_id": "dsip",
      "entry_kind": "research-peptide",
      "aliases": [],
      "identity": "Delta sleep-inducing peptide was explored in small early human sleep experiments. One double-blind crossover study involved six healthy volunteers and reported sleep-related observations.",
      "classification": "research-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "Delta sleep-inducing peptide was explored in small early human sleep experiments. One double-blind crossover study involved six healthy volunteers and reported sleep-related observations.",
      "evidence_level": "very small early human study",
      "limitations": "Small historical experiments do not establish a modern insomnia treatment, general effectiveness or long-term safety.",
      "reader_summary": {
        "why_people_are_interested": "DSIP, short for delta sleep-inducing peptide, attracts interest because of its name and early research on sleep. Whether it provides meaningful relief for present-day sleep problems is a separate question.",
        "what_it_is_used_or_studied_for": "It was investigated in small experiments measuring sleep and other physiological responses. The cited human work dates to the early 1980s.",
        "what_human_evidence_shows": "One double-blind crossover study involved six healthy volunteers and reported changes in sleep timing and sleep measurements. Another publication described several early human experiments, rather than a large modern insomnia trial.",
        "important_drawbacks": "Small, old studies cannot establish reliable benefit for a broad population or long-term safety. Their reported tolerability does not mean a currently marketed research product is safe or effective."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/6895513/",
          "title": "Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "6895513"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/6689058/",
          "title": "Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep.",
          "supports": "Specific experimental population and result scope described by this primary paper; not evidence for approved treatment or a dose recommendation.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed byNLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "6689058",
          "doi": "10.1159/000117964"
        }
      ]
    },
    {
      "slug": "dihexa",
      "name": "Dihexa",
      "canonical_id": "dihexa",
      "entry_kind": "research-compound",
      "aliases": [],
      "identity": "Also described as PNB-0408, an angiotensin-IV-related compound. Additional rat studies examined nerve repair and Huntington-like toxin injury; the latter reported no protection against the induced deficits.",
      "classification": "research-compound",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "Also described as PNB-0408, an angiotensin-IV-related compound. Additional rat studies examined nerve repair and Huntington-like toxin injury; the latter reported no protection against the induced deficits.",
      "evidence_level": "animal studies",
      "limitations": "Mixed preclinical findings do not establish human efficacy. Do not infer an approved nootropic or clinical safety.",
      "reader_summary": {
        "why_people_are_interested": "Dihexa has attracted interest around memory and nerve repair because it acts on pathways involved in cell growth and signaling. The available results need to be distinguished from claims of human cognitive enhancement.",
        "what_it_is_used_or_studied_for": "Also described as PNB-0408, it is an angiotensin-IV-related compound. The additional cited experiments tested combinations in nerve-injured rats and a toxin-induced model of Huntington-like symptoms.",
        "what_human_evidence_shows": "These papers were not human trials. A nerve-repair experiment reported improved motor outcomes with a combination involving stem cells, while the Huntington-like rat study found no protection against the induced deficits.",
        "important_drawbacks": "The findings are mixed and condition-specific. They do not show that people will remember better or recover from neurological disease, and they do not establish clinical safety."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34703584/",
          "title": "Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Stem cell, Granulocyte-Colony Stimulating Factor and/or Dihexa to promote limb function recovery in a rat sciatic nerve damage-repair model: Experimental animal studies. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "34703584",
          "doi": "10.1016/j.amsu.2021.102917",
          "pmcid": "PMC8524106"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/38489193/",
          "title": "Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "38489193",
          "doi": "10.3233/jhd-231507"
        }
      ]
    },
    {
      "slug": "cerebrolysin",
      "name": "Cerebrolysin",
      "canonical_id": "cerebrolysin",
      "entry_kind": "peptide-mixture",
      "aliases": [],
      "identity": "A peptide mixture studied in neurologic disorders, not one defined single peptide. A large acute-ischemic-stroke trial reported a neutral confirmatory endpoint; a separate trial studied combination treatment in stroke.",
      "classification": "peptide-mixture",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A peptide mixture studied in neurologic disorders, not one defined single peptide. A large acute-ischemic-stroke trial reported a neutral confirmatory endpoint; a separate trial studied combination treatment in stroke.",
      "evidence_level": "human randomized studies",
      "limitations": "Do not summarize mixed stroke evidence as proven recovery benefit or extend it to healthy people; approval depends on country and product.",
      "reader_summary": {
        "why_people_are_interested": "Cerebrolysin is discussed in neurological rehabilitation because researchers have asked whether it can improve recovery after injuries such as stroke. It is a mixture of peptides, not one precisely defined peptide.",
        "what_it_is_used_or_studied_for": "The cited human studies tested it in acute ischemic stroke, including a study combined with alteplase. That evidence cannot automatically be extended to other brain conditions or healthy people.",
        "what_human_evidence_shows": "A trial involving 1,070 patients found no significant difference on its main combined outcome. Another study stopped after an interim analysis did not show the expected benefit on its main day-90 disability measure.",
        "important_drawbacks": "Some secondary outcomes or subgroups appeared more favorable, but they do not erase the neutral main results. Product status varies by country and cannot be inferred from these trials alone."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/22282884/",
          "title": "Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "22282884",
          "doi": "10.1161/strokeaha.111.628537"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/23009193/",
          "title": "A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "23009193",
          "doi": "10.1111/j.1747-4949.2012.00901.x"
        }
      ]
    },
    {
      "slug": "afamelanotide",
      "name": "Afamelanotide",
      "canonical_id": "afamelanotide",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "A melanocortin analogue with a specific medicinal-product context. Published studies include long-term observations in erythropoietic protoporphyria and a combination trial with narrowband UVB in vitiligo.",
      "classification": "medicine",
      "regulatory_status": "United States: SCENESSE labeling covers increased pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. It is not a general cosmetic-tanning indication.",
      "evidence_summary": "A melanocortin analogue with a specific medicinal-product context. Published studies include long-term observations in erythropoietic protoporphyria and a combination trial with narrowband UVB in vitiligo.",
      "evidence_level": "human observational and randomized studies",
      "limitations": "An investigational combination study in vitiligo is not the same as an approved indication or evidence supporting consumer tanning products.",
      "reader_summary": {
        "why_people_are_interested": "The clearest medical interest is helping people with erythropoietic protoporphyria, a rare condition in which light exposure can cause painful skin reactions. This differs from using an unverified product to obtain a tan.",
        "what_it_is_used_or_studied_for": "The afamelanotide implant SCENESSE is U.S.-approved to increase pain-free light exposure in adults with a history of phototoxic reactions from that condition.",
        "what_human_evidence_shows": "An observational study of 115 patients reported better disease-specific quality of life during treatment. A separate randomized study tested afamelanotide alongside light therapy for vitiligo; that was a different research use.",
        "important_drawbacks": "The label warns about serious allergic reactions and increased pigmentation, including darkening of existing moles or freckles. Findings in one skin condition should not be treated as approval for another."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/25230094/",
          "title": "Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "25230094",
          "doi": "10.1001/jamadermatol.2014.1875"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/25494545/",
          "title": "Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "25494545",
          "doi": "10.1111/bjd.13598"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48",
          "title": "SCENESSE current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22afamelanotide%22&limit=5",
          "title": "FDA Drugs@FDA application records: afamelanotide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": false,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210797",
          "display_title": "FDA: SCENESSE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "bacitracin",
      "name": "Bacitracin",
      "canonical_id": "bacitracin",
      "entry_kind": "antibiotic-mixture",
      "aliases": [],
      "identity": "An antibiotic name covering product- and route-specific contexts. FDA determined that bacitracin for injection was withdrawn for safety or effectiveness reasons; that determination must not be generalized to every topical product containing bacitracin.",
      "classification": "antibiotic-mixture",
      "regulatory_status": "United States: FDA’s 2022 determination addresses withdrawal of bacitracin for injection for safety or effectiveness reasons. A separately retrieved topical combination label is an OTC-monograph record, not evidence of an individually approved injectable or blanket approval for every bacitracin product.",
      "evidence_summary": "An antibiotic name covering product- and route-specific contexts. FDA determined that bacitracin for injection was withdrawn for safety or effectiveness reasons; that determination must not be generalized to every topical product containing bacitracin.",
      "evidence_level": "official regulatory determination",
      "limitations": "Specify formulation and route. The injectable withdrawal does not itself describe the status of topical or ophthalmic products.",
      "reader_summary": {
        "why_people_are_interested": "Bacitracin is relevant to readers because the same antibiotic name can appear in very different products. Its route and formulation are essential to understanding what the product is for.",
        "what_it_is_used_or_studied_for": "Topical products may be labeled for first-aid infection prevention, while the former injectable product had a different medical role. A topical label is not an approval for injection.",
        "what_human_evidence_shows": "The primary source cited here is a regulatory safety determination, not a new effectiveness trial. FDA determined that bacitracin for injection had been withdrawn for safety or effectiveness reasons.",
        "important_drawbacks": "The injectable product raised serious kidney-toxicity and allergic-reaction concerns. That decision should not be extended to every topical or ophthalmic preparation, but it shows why the route cannot be ignored."
      },
      "sources": [
        {
          "url": "https://www.govinfo.gov/content/pkg/FR-2022-09-15/pdf/2022-19995.pdf",
          "title": "FDA: Determination That Bacitracin for Injection Was Withdrawn From Sale for Reasons of Safety or Effectiveness",
          "supports": "Route-specificwithdrawal for injection; not a statement about all topical or ophthalmic preparations.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA FederalRegisternotice",
          "read_scope": "full regulatory notice"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0070ea5f-434d-53a7-e063-6294a90abf18",
          "title": "health and .beyond Triple Antibiotic current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        }
      ]
    },
    {
      "slug": "dalbavancin-oritavancin-telavancin",
      "name": "Dalbavancin / Oritavancin / Telavancin",
      "canonical_id": "lipoglycopeptide-antibiotics",
      "entry_kind": "drug-group",
      "aliases": [],
      "identity": "Dalbavancin, oritavancin and telavancin are different lipoglycopeptide antibiotics. Randomized clinical studies examined each medicine in defined bacterial skin/skin-structure infection populations.",
      "classification": "drug-group",
      "regulatory_status": "United States: approval records exist for distinct dalbavancin, oritavancin and telavancin products. Their labeled bacterial-infection indications, age groups and safety limits differ; they are not interchangeable products.",
      "evidence_summary": "Dalbavancin, oritavancin and telavancin are different lipoglycopeptide antibiotics. Randomized clinical studies examined each medicine in defined bacterial skin/skin-structure infection populations.",
      "evidence_level": "separate human randomized trials",
      "limitations": "Keep each drug, product, infection indication and safety profile separate; a grouped heading does not make them interchangeable.",
      "reader_summary": {
        "why_people_are_interested": "These antibiotics interest clinicians treating certain bacterial infections, particularly when the bacteria and clinical situation fit the medicine. They are three separate drugs, not one interchangeable peptide.",
        "what_it_is_used_or_studied_for": "Dalbavancin, oritavancin and telavancin have product-specific approvals for defined infections. The cited randomized studies examined bacterial skin and skin-structure infections in selected patient groups.",
        "what_human_evidence_shows": "Each additional trial compared one of the drugs with an established antibiotic and reported comparable clinical results within the study design. A favorable comparison does not establish superiority or usefulness for every infection.",
        "important_drawbacks": "Safety and practical considerations differ. Telavancin carries major kidney-related and pregnancy-related warnings. The exact product, infection, organism and patient circumstances matter more than membership in the same antibiotic group."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/24897083/",
          "title": "Single-dose oritavancin in the treatment of acute bacterial skin infections.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Single-dose oritavancin in the treatment of acute bacterial skin infections. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "24897083",
          "doi": "10.1056/nejmoa1310422"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16231250/",
          "title": "Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "16231250",
          "doi": "10.1086/497271"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18444791/",
          "title": "Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "18444791",
          "doi": "10.1086/587896"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f4a5924-96d7-445a-b75f-2c0e1ffd2dea",
          "title": "Dalbavancin current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e755c40-6e73-4572-b474-4d8a131693d1",
          "title": "Kimyrsa current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5359b759-db7c-4672-9e8a-59c93869bd91",
          "title": "VIBATIV current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22dalbavancin%22&limit=5",
          "title": "FDA Drugs@FDA application records: dalbavancin",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021883",
          "display_title": "FDA: DALVANCE approval history (selected product)"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22oritavancin%22&limit=5",
          "title": "FDA Drugs@FDA application records: oritavancin",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214155",
          "display_title": "FDA: KIMYRSA approval history (selected product)"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22telavancin%22&limit=5",
          "title": "FDA Drugs@FDA application records: telavancin",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022407",
          "display_title": "FDA: VIBATIV approval history (selected product)"
        }
      ]
    },
    {
      "slug": "daptomycin",
      "name": "Daptomycin",
      "canonical_id": "daptomycin",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "A cyclic lipopeptide antibiotic. Randomized trials compared it with conventional therapy in complicated skin and skin-structure infections and found comparable clinical success in the studied population.",
      "classification": "medicine",
      "regulatory_status": "United States: daptomycin product labeling covers specified complicated skin/skin-structure infections and Staphylococcus aureus bloodstream infections in specified adult/pediatric populations. Use the exact product label for its limits; approval is not evidence for every infection.",
      "evidence_summary": "A cyclic lipopeptide antibiotic. Randomized trials compared it with conventional therapy in complicated skin and skin-structure infections and found comparable clinical success in the studied population.",
      "evidence_level": "human randomized trials",
      "limitations": "Antibiotic selection depends on the exact infection, organism and product label; this is not a treatment-selection guide.",
      "reader_summary": {
        "why_people_are_interested": "Daptomycin is considered in care for certain serious bacterial infections, including selected skin infections and bloodstream infections. It is an antibiotic medicine, not an anti-aging or general health peptide.",
        "what_it_is_used_or_studied_for": "Its U.S. product labeling covers specified complicated skin infections and Staphylococcus aureus bloodstream infections in defined adult and pediatric populations.",
        "what_human_evidence_shows": "Two randomized trials involving 1,092 patients with complicated skin infections reported clinical success comparable with conventional antibiotics in the evaluated population. This does not answer every bloodstream-infection question.",
        "important_drawbacks": "The product label warns about muscle injury, including severe muscle breakdown, and a serious inflammatory lung reaction called eosinophilic pneumonia. These risks are separate from whether the antibiotic is likely to work for the infection."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/15227611/",
          "title": "The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "15227611",
          "doi": "10.1086/420818"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f3f32a-fac1-4a8f-b205-4601046f0b5c",
          "title": "Daptomycin current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22daptomycin%22&limit=5",
          "title": "FDA Drugs@FDA application records: daptomycin",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217415",
          "display_title": "FDA: DAPTOMYCIN approval history (selected product)"
        }
      ]
    },
    {
      "slug": "difelikefalin",
      "name": "Difelikefalin",
      "canonical_id": "difelikefalin",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "A peripherally acting kappa-opioid-receptor agonist studied for itch associated with chronic kidney disease in adults receiving hemodialysis. Randomized phase 2 trials reported itch improvements alongside adverse events.",
      "classification": "medicine",
      "regulatory_status": "United States: KORSUVA labeling covers moderate-to-severe chronic-kidney-disease-associated pruritus in adults undergoing hemodialysis. This does not establish an indication for every cause of itch or every dialysis modality.",
      "evidence_summary": "A peripherally acting kappa-opioid-receptor agonist studied for itch associated with chronic kidney disease in adults receiving hemodialysis. Randomized phase 2 trials reported itch improvements alongside adverse events.",
      "evidence_level": "human randomized phase 2 studies",
      "limitations": "Do not generalize dialysis-related results to all causes of itching or other routes/formulations.",
      "reader_summary": {
        "why_people_are_interested": "Difelikefalin is relevant to people whose kidney-disease-related itching is severe enough to affect comfort, sleep or quality of life while receiving hemodialysis.",
        "what_it_is_used_or_studied_for": "KORSUVA is U.S.-approved for moderate-to-severe itching associated with chronic kidney disease in adults undergoing hemodialysis. That is a narrower situation than itching in general.",
        "what_human_evidence_shows": "Randomized phase 2 studies reported reduced itch severity compared with placebo, with some improvements in itch-related quality of life and sleep measurements. The results apply to the dialysis populations studied.",
        "important_drawbacks": "Treatment groups also experienced adverse effects. The studies reported problems including diarrhea, dizziness, nausea, sleepiness and falls. The benefit cannot be assumed for other causes of itching or other dialysis settings."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32405581/",
          "title": "Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "32405581",
          "doi": "10.1016/j.ekir.2020.01.006",
          "pmcid": "PMC7210745"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/35511180/",
          "title": "Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "35511180",
          "doi": "10.1001/jamanetworkopen.2022.10339",
          "pmcid": "PMC9073569"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c7b81f2-0fd3-47cb-8b0f-185e07f19c87",
          "title": "Korsuva current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22difelikefalin%22&limit=5",
          "title": "FDA Drugs@FDA application records: difelikefalin",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214916",
          "display_title": "FDA: KORSUVA approval history (selected product)"
        }
      ]
    },
    {
      "slug": "ecallantide",
      "name": "Ecallantide",
      "canonical_id": "ecallantide",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "A kallikrein-inhibiting peptide medicine studied in acute hereditary-angioedema attacks. Placebo-controlled trials investigated symptoms during defined attacks.",
      "classification": "medicine",
      "regulatory_status": "United States: KALBITOR labeling covers acute hereditary-angioedema attacks in patients 12 years and older. Current warnings and supervised-use requirements must be read in the product label.",
      "evidence_summary": "A kallikrein-inhibiting peptide medicine studied in acute hereditary-angioedema attacks. Placebo-controlled trials investigated symptoms during defined attacks.",
      "evidence_level": "human randomized trials",
      "limitations": "The studied condition and supervised product context matter; historical trial safety descriptions do not replace current warnings.",
      "reader_summary": {
        "why_people_are_interested": "Ecallantide is of interest to people managing hereditary angioedema because an acute attack can cause significant swelling and distress. Its role is specific to that condition.",
        "what_it_is_used_or_studied_for": "The U.S.-approved product KALBITOR treats acute hereditary-angioedema attacks in patients age 12 and older. It inhibits kallikrein, part of the pathway involved in these attacks.",
        "what_human_evidence_shows": "Placebo-controlled studies reported greater improvement in attack-symptom measures with ecallantide in the studied populations. These findings concern acute attacks, not general swelling or routine prevention.",
        "important_drawbacks": "The product carries a boxed warning for anaphylaxis, a potentially severe allergic reaction that can resemble the illness being treated. It requires administration by a healthcare professional with appropriate medical support."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/20568386/",
          "title": "EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "20568386",
          "doi": "10.1016/j.anai.2010.04.012"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/17559913/",
          "title": "Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "17559913",
          "doi": "10.1016/j.jaci.2007.04.028"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f56aec67-c662-477c-b866-bfc23e8809cf",
          "title": "Kalbitor current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ecallantide%22&limit=5",
          "title": "FDA Drugs@FDA application records: ecallantide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125277",
          "display_title": "FDA: KALBITOR approval history (selected product)"
        }
      ]
    },
    {
      "slug": "icatibant",
      "name": "Icatibant",
      "canonical_id": "icatibant",
      "entry_kind": "medicine",
      "aliases": [],
      "identity": "A bradykinin B2-receptor antagonist studied in hereditary angioedema. In the FAST-1/FAST-2 publication, one trial met its primary comparison and the placebo-controlled trial did not show a statistically significant primary-endpoint difference.",
      "classification": "medicine",
      "regulatory_status": "United States: SAJAZIR icatibant labeling covers acute hereditary-angioedema attacks in adults 18 years and older. Product-specific labeling does not establish treatment for all swelling or angioedema causes.",
      "evidence_summary": "A bradykinin B2-receptor antagonist studied in hereditary angioedema. In the FAST-1/FAST-2 publication, one trial met its primary comparison and the placebo-controlled trial did not show a statistically significant primary-endpoint difference.",
      "evidence_level": "human randomized trials",
      "limitations": "Do not flatten mixed trial comparisons into a universal success claim; current product indications remain separate.",
      "reader_summary": {
        "why_people_are_interested": "Icatibant is relevant to adults with hereditary angioedema who need treatment for an acute attack. It blocks a receptor for bradykinin, a signal involved in that type of swelling.",
        "what_it_is_used_or_studied_for": "U.S. icatibant product labeling covers acute hereditary-angioedema attacks in adults age 18 and older. This does not make it a treatment for every cause of swelling.",
        "what_human_evidence_shows": "The FAST-1 and FAST-2 trials gave mixed main-outcome results: the active-comparator trial showed a significant benefit, while the placebo comparison did not meet statistical significance for its main endpoint.",
        "important_drawbacks": "Injection-site reactions were very common in product trials. Swelling involving the throat remains a medical emergency; the product label stresses appropriate medical care rather than relying on the medicine alone."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/20818888/",
          "title": "Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "20818888",
          "doi": "10.1056/nejmoa0906393",
          "pmcid": "PMC4662377"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1756aca0-21a1-4898-8d6c-9666738db45c",
          "title": "SAJAZIR current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22icatibant%22&limit=5",
          "title": "FDA Drugs@FDA application records: icatibant",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213773",
          "display_title": "FDA: ICATIBANT ACETATE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "ltx-315",
      "name": "LTX-315",
      "canonical_id": "ltx-315",
      "entry_kind": "investigational-peptide",
      "aliases": [],
      "identity": "An investigational oncolytic 9-mer peptide. Published studies examined candidate selection and cell-death/immune mechanisms in laboratory or tumor models.",
      "classification": "investigational-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "An investigational oncolytic 9-mer peptide. Published studies examined candidate selection and cell-death/immune mechanisms in laboratory or tumor models.",
      "evidence_level": "preclinical pharmacology",
      "limitations": "Mechanistic tumor effects are not evidence of a licensed cancer treatment or benefits across cancer types.",
      "reader_summary": {
        "why_people_are_interested": "LTX-315 interests cancer researchers because destroying tumor cells locally might also help the immune system recognize a tumor. That is a development goal, not proof of a cancer cure.",
        "what_it_is_used_or_studied_for": "It is an experimental oncolytic peptide, meaning it is designed to damage cancer cells. The additional cited papers examined candidate selection and mechanisms of cell death.",
        "what_human_evidence_shows": "The cited evidence here is laboratory and tumor-model research, not a demonstration that patients live longer or that a cancer is cured. The work reported signals associated with immune-stimulating cell death.",
        "important_drawbacks": "Promising cell or tumor-model results do not establish benefit across cancers, human safety or an approved treatment. Clinical outcomes need to be evaluated separately for each study and cancer type."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26962684/",
          "title": "The oncolytic peptide LTX-315 triggers immunogenic cell death.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: The oncolytic peptide LTX-315 triggers immunogenic cell death. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "26962684",
          "doi": "10.1038/cddis.2016.47",
          "pmcid": "PMC4823948"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26982623/",
          "title": "Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "26982623",
          "doi": "10.1021/acs.jmedchem.5b02025"
        }
      ]
    },
    {
      "slug": "ghk-cu",
      "name": "GHK-Cu",
      "canonical_id": "ghk-cu",
      "entry_kind": "research-peptide-complex",
      "aliases": [],
      "identity": "A copper complex of glycyl-histidyl-lysine. Published research examined matrix-remodeling responses in cultured fibroblasts and a mouse model of pulmonary fibrosis.",
      "classification": "research-peptide-complex",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A named topical gel improved plantar-ulcer area closure when added to standardized diabetic wound care. A separate 13-person randomized post-laser study found no objective redness, wrinkle or overall skin-quality advantage, although patient ratings were higher. Cell and mouse studies provide mechanistic context.",
      "evidence_level": "Limited human topical studies and preclinical research",
      "limitations": "The human results concern specific topical formulations and patient settings. They do not establish that all cosmetic creams work, that aging is reversed, or that injected products are safe or effective.",
      "reader_summary": {
        "why_people_are_interested": "GHK-Cu is a copper-linked peptide of interest for skin appearance and wound repair. It is also called copper tripeptide-1. Its effects depend on the formulation and how it reaches the skin.",
        "what_it_is_used_or_studied_for": "Human research has tested topical products after laser skin resurfacing and a particular gel added to standard care for diabetic foot ulcers. These are different settings from everyday anti-aging skin care.",
        "what_human_evidence_shows": "In an older ulcer trial, the gel improved wound-area closure compared with its base gel alongside standard wound care. In a randomized post-laser study completed by 13 people, GHK-Cu did not show a significant objective improvement in redness, wrinkles or skin quality compared with the control regimen, although satisfaction was higher.",
        "important_drawbacks": "These results concern particular topical products and patient groups. They do not show that every copper-peptide cream works, that GHK-Cu reverses aging, or that injecting it is safe or effective."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11045606/",
          "title": "The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11045606",
          "doi": "10.1016/s0024-3205(00)00803-1"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/31809714/",
          "title": "Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "31809714",
          "doi": "10.1016/j.lfs.2019.117139"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16847171/",
          "title": "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.",
          "supports": "Randomized post-laser study with 13 completers: no significant objective difference in redness, wrinkles or skin quality; patient-reported satisfaction/skin-quality rating higher.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC and PubMed metadata inspected; not full-text review.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/17147644/",
          "title": "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.",
          "supports": "1994 multicenter randomized evaluator-blinded vehicle-controlled study of a named topical gel added to standardized wound care: greater plantar-ulcer area closure. Area closure is not the percentage of people with healed ulcers.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC and PubMed metadata inspected; sample size not reported in the inspected abstract, so omitted.",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "melanotan-ii",
      "name": "Melanotan II",
      "canonical_id": "melanotan-ii",
      "entry_kind": "research-peptide",
      "aliases": [],
      "identity": "A melanocortin agonist explored in early sexual-function research and sold through unregulated channels. A published case report documented systemic toxicity and rhabdomyolysis after an internet-purchased product.",
      "classification": "research-peptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A melanocortin agonist explored in early sexual-function research and sold through unregulated channels. A published case report documented systemic toxicity and rhabdomyolysis after an internet-purchased product.",
      "evidence_level": "small human experiments and case report",
      "limitations": "A case report cannot estimate event frequency, but demonstrates that safety must not be inferred from a tanning or sexual-function claim.",
      "reader_summary": {
        "why_people_are_interested": "Melanotan II draws attention around skin pigmentation and sexual response because it activates melanocortin receptors. Those biological effects have also led to potentially risky use of unverified products.",
        "what_it_is_used_or_studied_for": "It was examined in small early human sexual-function experiments. It is distinct from both afamelanotide and the approved bremelanotide product, even though the names are sometimes discussed together.",
        "what_human_evidence_shows": "A small crossover study in men reported erectile responses and increased reported desire, but also nausea. That does not establish a general-purpose sexual medicine or the safety of cosmetic tanning use.",
        "important_drawbacks": "A published case report documented severe systemic toxicity, muscle breakdown and kidney dysfunction after an internet-purchased product. One case cannot estimate frequency, but it is an important warning against assuming safety."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11035391/",
          "title": "Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11035391",
          "doi": "10.1038/sj.ijir.3900582"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/23121206/",
          "title": "Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "23121206",
          "doi": "10.3109/15563650.2012.740637"
        }
      ]
    },
    {
      "slug": "glutathione",
      "name": "Glutathione",
      "canonical_id": "glutathione",
      "entry_kind": "endogenous-tripeptide",
      "aliases": [],
      "identity": "An endogenous tripeptide involved in redox chemistry. A small open-label skin-lightening study assessed a specific preparation in 30 Filipino women; it did not establish effects of other formulations or routes.",
      "classification": "endogenous-tripeptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "An endogenous tripeptide involved in redox chemistry. A small open-label skin-lightening study assessed a specific preparation in 30 Filipino women; it did not establish effects of other formulations or routes.",
      "evidence_level": "small uncontrolled human study plus chemical identity",
      "limitations": "A short single-arm study cannot establish general effectiveness, long-term safety or safety of intravenous cosmetic use.",
      "reader_summary": {
        "why_people_are_interested": "Interest in glutathione often centers on antioxidant biology or cosmetic skin lightening. Those are different questions, and results from one preparation should not be treated as evidence for another.",
        "what_it_is_used_or_studied_for": "Glutathione is a naturally occurring three-amino-acid molecule involved in cellular redox processes. The additional human study cited here investigated a specific preparation used by 30 Filipino women.",
        "what_human_evidence_shows": "The study reported a reduction in measured skin-pigment indices during eight weeks. It was open-label and had no comparison group, so it cannot show how much change was caused by glutathione itself.",
        "important_drawbacks": "The study was small and short. It does not establish lasting cosmetic benefit, long-term safety, or the benefit or safety of intravenous products marketed for skin lightening."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26148180/",
          "title": "An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: An open-label, single-arm trial of the safety and efficacy of a novel preparation of glutathione as a skin-lightening agent in Filipino women. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "26148180",
          "doi": "10.1111/ijd.12999"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/124886",
          "title": "PubChem compound 124886: Glutathione",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "melanotan-i",
      "name": "Melanotan I",
      "canonical_id": "melanotan-i",
      "entry_kind": "historical-alias",
      "aliases": [],
      "identity": "Melanotan-I is a historical development name associated with the alpha-MSH analogue now known as afamelanotide. Older experimental studies examined pigmentation and pharmacokinetics in small groups of volunteers.",
      "classification": "historical-alias",
      "regulatory_status": "United States: SCENESSE labeling covers increased pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. It is not a general cosmetic-tanning indication. The historical Melanotan-I name is not a product-quality or interchangeability guarantee.",
      "evidence_summary": "Melanotan-I is a historical development name associated with the alpha-MSH analogue now known as afamelanotide. Older experimental studies examined pigmentation and pharmacokinetics in small groups of volunteers.",
      "evidence_level": "small historical human studies",
      "limitations": "A historical molecule name does not establish that an internet product is the licensed afamelanotide implant or shares its approved indication.",
      "alias_of": "afamelanotide",
      "reader_summary": {
        "why_people_are_interested": "Melanotan-I appears in older pigmentation research, which can make the name attractive to someone looking for a tan. Its medicinal history should not be confused with the quality or purpose of an internet product.",
        "what_it_is_used_or_studied_for": "It is a historical name associated with afamelanotide. The approved SCENESSE implant has a specific role in adults with erythropoietic protoporphyria, a rare condition causing painful reactions to light.",
        "what_human_evidence_shows": "Older, very small volunteer studies reported increased pigmentation and measured how experimental formulations moved through the body. Those findings were not trials establishing a safe consumer tanning product.",
        "important_drawbacks": "Formulation and route matter. SCENESSE can darken existing moles and freckles and carries hypersensitivity warnings; a product labeled Melanotan-I is not automatically equivalent to that approved implant."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11045725/",
          "title": "Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11045725",
          "doi": "10.1562/0031-8655(2000)072<0526:ieeati>2.0.co;2"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/9113347/",
          "title": "Skin pigmentation and pharmacokinetics of melanotan-I in humans.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Skin pigmentation and pharmacokinetics of melanotan-I in humans. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "9113347",
          "doi": "10.1002/(sici)1099-081x(199704)18:3<259::aid-bdd20>3.0.co;2-x"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48",
          "title": "SCENESSE current product labeling",
          "supports": "Product-specific indication and application identity; see concise regulatory_summary. No availability guarantee.",
          "additional_document_vs_comparator": false,
          "source_kind": "FDA SPL label via DailyMed/openFDA",
          "read_scope": "actual indication and product metadata sections read"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22afamelanotide%22&limit=5",
          "title": "FDA Drugs@FDA application records: afamelanotide",
          "supports": "Official original approval records and product-specific marketing-status fields; not all strengths/products are currently marketed. Indications come from the separate current label.",
          "additional_document_vs_comparator": false,
          "source_kind": "U.S.FDA original application/product database",
          "read_scope": "actual original-submission and product records read",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210797",
          "display_title": "FDA: SCENESSE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "acetyl-hexapeptide-8",
      "name": "Acetyl hexapeptide-8",
      "canonical_id": "acetyl-hexapeptide-8",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A cosmetic peptide also historically called acetylhexapeptide-3. A split-face trial evaluated it in a particular hyaluronic-acid microneedle formulation in 52 Korean women.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic peptide also historically called acetylhexapeptide-3. A split-face trial evaluated it in a particular hyaluronic-acid microneedle formulation in 52 Korean women.",
      "evidence_level": "small formulation-specific human study",
      "limitations": "Evidence for a delivery-system combination is not proof for every cream or isolated ingredient; cosmetic evidence is distinct from medicinal approval.",
      "reader_summary": {
        "why_people_are_interested": "Acetyl hexapeptide-8 is of interest in skincare because researchers have examined whether formulations containing it can improve the appearance of wrinkles. It has also been called acetyl hexapeptide-3.",
        "what_it_is_used_or_studied_for": "The cited clinical experiment tested the ingredient in a particular hyaluronic-acid microneedle patch, rather than establishing the effectiveness of every cream containing the same peptide.",
        "what_human_evidence_shows": "In a randomized split-face study involving 52 Korean women, wrinkles and hydration improved across groups. The peptide-containing patch showed greater wrinkle improvement than the patch alone on some comparisons.",
        "important_drawbacks": "This was a small, formulation-specific study. It does not establish that the isolated peptide works equally well in another delivery system or that it is equivalent to an injected wrinkle treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33911590/",
          "title": "Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "33911590",
          "doi": "10.5021/ad.2019.31.3.263",
          "pmcid": "PMC7992733"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/71587772",
          "title": "PubChem compound 71587772: Acetyl hexapeptide-3",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "palmitoyl-pentapeptide-4",
      "name": "Palmitoyl pentapeptide-4",
      "canonical_id": "palmitoyl-pentapeptide-4",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A palmitoylated cosmetic peptide. A 21-person randomized study examined a cream for crow’s feet; separate laboratory/animal work investigated enhanced delivery with a specific nanomicellar system.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A palmitoylated cosmetic peptide. A 21-person randomized study examined a cream for crow’s feet; separate laboratory/animal work investigated enhanced delivery with a specific nanomicellar system.",
      "evidence_level": "small human trial plus preclinical formulation study",
      "limitations": "Small samples and specialized formulations limit generalization; delivery-system results cannot establish all commercial products.",
      "reader_summary": {
        "why_people_are_interested": "The interest is whether a topical product can make fine lines, such as crow’s feet, less visible. Palmitoyl pentapeptide-4 is one cosmetic ingredient investigated for that purpose.",
        "what_it_is_used_or_studied_for": "The peptide has a fatty-acid attachment, which is part of its identity. The cited work tested both a cream in people and a specialized delivery system in laboratory and animal experiments.",
        "what_human_evidence_shows": "A small randomized study in 21 Indonesian women reported better results for the peptide cream on some appearance measures compared with the other study groups. The authors called for larger, longer studies.",
        "important_drawbacks": "The small sample limits confidence in how broadly the result applies. Results from a specialized formulation or an animal experiment cannot establish the performance of every cosmetic containing the ingredient."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/36909866/",
          "title": "Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "36909866",
          "pmcid": "PMC10005804"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39783908/",
          "title": "Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Bioactive Glycyrrhizic Acid Ionic Liquid Self-Assembled Nanomicelles for Enhanced Transdermal Delivery of Anti-Photoaging Signal Peptides. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "39783908",
          "doi": "10.1002/advs.202412581",
          "pmcid": "PMC11848569"
        }
      ]
    },
    {
      "slug": "copper-tripeptide-1",
      "name": "Copper tripeptide-1",
      "canonical_id": "copper-tripeptide-1",
      "entry_kind": "alias",
      "aliases": [],
      "identity": "Copper tripeptide-1 is a name used for the GHK copper complex. Keep the named complex distinct from uncomplexed GHK and from other metal or salt forms.",
      "classification": "alias",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A named topical gel improved plantar-ulcer area closure when added to standardized diabetic wound care. A separate 13-person randomized post-laser study found no objective redness, wrinkle or overall skin-quality advantage, although patient ratings were higher. Cell and mouse studies provide mechanistic context.",
      "evidence_level": "Limited human topical studies and preclinical research",
      "limitations": "The human results concern specific topical formulations and patient settings. They do not establish that all cosmetic creams work, that aging is reversed, or that injected products are safe or effective.",
      "alias_of": "ghk-cu",
      "reader_summary": {
        "why_people_are_interested": "GHK-Cu is a copper-linked peptide of interest for skin appearance and wound repair. It is also called copper tripeptide-1. Its effects depend on the formulation and how it reaches the skin.",
        "what_it_is_used_or_studied_for": "Human research has tested topical products after laser skin resurfacing and a particular gel added to standard care for diabetic foot ulcers. These are different settings from everyday anti-aging skin care.",
        "what_human_evidence_shows": "In an older ulcer trial, the gel improved wound-area closure compared with its base gel alongside standard wound care. In a randomized post-laser study completed by 13 people, GHK-Cu did not show a significant objective improvement in redness, wrinkles or skin quality compared with the control regimen, although satisfaction was higher.",
        "important_drawbacks": "These results concern particular topical products and patient groups. They do not show that every copper-peptide cream works, that GHK-Cu reverses aging, or that injecting it is safe or effective."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11045606/",
          "title": "The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "11045606",
          "doi": "10.1016/s0024-3205(00)00803-1"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/31809714/",
          "title": "Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "31809714",
          "doi": "10.1016/j.lfs.2019.117139"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16847171/",
          "title": "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.",
          "supports": "Randomized post-laser study with 13 completers: no significant objective difference in redness, wrinkles or skin quality; patient-reported satisfaction/skin-quality rating higher.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC and PubMed metadata inspected; not full-text review.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/17147644/",
          "title": "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.",
          "supports": "1994 multicenter randomized evaluator-blinded vehicle-controlled study of a named topical gel added to standardized wound care: greater plantar-ulcer area closure. Area closure is not the percentage of people with healed ulcers.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC and PubMed metadata inspected; sample size not reported in the inspected abstract, so omitted.",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "acetyl-octapeptide-3",
      "name": "Acetyl octapeptide-3",
      "canonical_id": "acetyl-octapeptide-3",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A cosmetic peptide included in a human study of a multi-ingredient hyaluronic-acid microneedle patch. The tested product also contained other peptides, adenosine and extracts.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic peptide included in a human study of a multi-ingredient hyaluronic-acid microneedle patch. The tested product also contained other peptides, adenosine and extracts.",
      "evidence_level": "formulation-specific human study",
      "limitations": "The study cannot isolate acetyl-octapeptide-3’s contribution or establish an injectable or medicinal use.",
      "reader_summary": {
        "why_people_are_interested": "Acetyl octapeptide-3 is of interest as an ingredient in skincare intended to improve the appearance of fine lines. The useful question is whether the finished formulation produces a noticeable benefit.",
        "what_it_is_used_or_studied_for": "The cited human study evaluated a hyaluronic-acid microneedle patch containing several ingredients, including acetyl octapeptide-3, other peptides, adenosine and extracts.",
        "what_human_evidence_shows": "Over the study period, investigators reported improvements in measured wrinkles, hydration, skin density and thickness. These results describe the complete tested patch, not an isolated effect from acetyl octapeptide-3.",
        "important_drawbacks": "The contribution of each ingredient was not separated. A favorable result for the combined patch does not establish equivalent results from a serum, a different patch or a product delivered by injection."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/31134751/",
          "title": "Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "31134751",
          "doi": "10.1111/jocd.13009"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/76283482",
          "title": "PubChem compound 76283482: Acetyl octapeptide-3",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "acetyl-tetrapeptide-5",
      "name": "Acetyl tetrapeptide-5",
      "canonical_id": "acetyl-tetrapeptide-5",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A cosmetic peptide investigated in a laboratory study of individual ingredients and mixtures in human skin fibroblasts. Chemical identity and cellular testing are separate from clinical results.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic peptide investigated in a laboratory study of individual ingredients and mixtures in human skin fibroblasts. Chemical identity and cellular testing are separate from clinical results.",
      "evidence_level": "cell-culture study plus chemical identity",
      "limitations": "Human fibroblasts are cells in a laboratory, not a clinical trial; claims about eye bags or swelling need their own human evidence.",
      "reader_summary": {
        "why_people_are_interested": "Acetyl tetrapeptide-5 is a cosmetic peptide whose biological activity has been investigated in skin-related laboratory experiments. Its presence on an ingredient list is a starting point for questions, not proof of a visible result.",
        "what_it_is_used_or_studied_for": "The cited research evaluated individual cosmetic peptides and mixtures in human skin fibroblasts, the cells that help produce and maintain the skin’s supporting material.",
        "what_human_evidence_shows": "The study reported changes in laboratory measures related to oxidative stress and skin-supporting proteins. It did not measure whether people developed fewer eye bags, less swelling or fewer wrinkles.",
        "important_drawbacks": "A cell-culture result cannot establish a cosmetic benefit a person will notice. The identity records also do not establish the concentration, delivery or effectiveness of a finished product."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33849044/",
          "title": "Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "33849044",
          "doi": "10.1159/000514496"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/11620163",
          "title": "PubChem compound 11620163: Acetyl tetrapeptide-5",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "carnosine",
      "name": "Carnosine",
      "canonical_id": "carnosine",
      "entry_kind": "endogenous-dipeptide",
      "aliases": [],
      "identity": "A dipeptide of beta-alanine and histidine. A biochemical study examined antioxidant activity of carnosine and related compounds in laboratory assays.",
      "classification": "endogenous-dipeptide",
      "regulatory_status": "Approval is not established by these cited research sources. Current regulatory status must be verified for the specific product, intended use and jurisdiction.",
      "evidence_summary": "A dipeptide of beta-alanine and histidine. A biochemical study examined antioxidant activity of carnosine and related compounds in laboratory assays.",
      "evidence_level": "biochemical laboratory study plus chemical identity",
      "limitations": "Antioxidant activity in an assay does not establish prevention of aging, disease treatment or a benefit of a particular supplement or cosmetic.",
      "reader_summary": {
        "why_people_are_interested": "Carnosine interests researchers because it can take part in chemical processes involving oxidation. That has motivated questions about aging and tissue protection, but a chemical effect is not the same as a proven health benefit.",
        "what_it_is_used_or_studied_for": "It is a dipeptide made from beta-alanine and histidine. The cited research examined antioxidant activity of carnosine and related molecules in laboratory assays.",
        "what_human_evidence_shows": "The experiment found antioxidant activity under the tested conditions. It did not show that people who use a carnosine supplement or skincare product live longer, avoid disease or develop fewer wrinkles.",
        "important_drawbacks": "These sources do not establish a useful dose, long-term benefit or the safety of every formulation. Claims about a particular supplement or cosmetic require human evidence for that actual use."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/3362866/",
          "title": "Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Antioxidant activity of carnosine, homocarnosine, and anserine present in muscle and brain. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "3362866",
          "doi": "10.1073/pnas.85.9.3175",
          "pmcid": "PMC280166"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/439224",
          "title": "PubChem compound 439224: Carnosine",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "dipeptide-diaminobutyroyl-benzylamide-diacetate",
      "name": "Dipeptide diaminobutyroyl benzylamide diacetate",
      "canonical_id": "dipeptide-diaminobutyroyl-benzylamide-diacetate",
      "entry_kind": "cosmetic-peptidomimetic",
      "aliases": [],
      "identity": "A cosmetic peptidomimetic associated with the name Syn-Ake. Published research used molecular modeling and laboratory tests rather than a human efficacy trial.",
      "classification": "cosmetic-peptidomimetic",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic peptidomimetic associated with the name Syn-Ake. Published research used molecular modeling and laboratory tests rather than a human efficacy trial.",
      "evidence_level": "in-silico and in-vitro study",
      "limitations": "Receptor docking or cell tests cannot establish a clinical wrinkle reduction or equivalence to botulinum toxin.",
      "reader_summary": {
        "why_people_are_interested": "This long ingredient name is associated with the cosmetic peptide mimic Syn-Ake. Interest centers on whether it might improve skin appearance, but the mechanism proposed in a laboratory does not establish that benefit.",
        "what_it_is_used_or_studied_for": "The cited study used computer modeling, antioxidant testing and laboratory safety assays to investigate interactions with proteins discussed in skin-aging research.",
        "what_human_evidence_shows": "That work did not test wrinkle improvement in people. Its reported protein-binding predictions and antioxidant activity are early research findings, not measured cosmetic results in a clinical trial.",
        "important_drawbacks": "Computer models and laboratory tests cannot establish equivalence to botulinum toxin, long-term safety or the performance of a finished cream. Those questions need direct evidence in the relevant people and formulation."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37349941/",
          "title": "Anti-aging activity of Syn-Ake peptide by <i>in silico</i> approaches and <i>in vitro</i> tests.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Anti-aging activity of Syn-Ake peptide by <i>in silico</i> approaches and <i>in vitro</i> tests. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "37349941",
          "doi": "10.1080/07391102.2023.2223681"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/71465152",
          "title": "PubChem compound 71465152: Dipeptide diaminobutyroyl benzylamide diacetate",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "hexapeptide-9",
      "name": "Hexapeptide-9",
      "canonical_id": "hexapeptide-9",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A defined cosmetic hexapeptide also associated with the name Collaxyl. The cited chemical identity records do not establish clinical anti-aging effects. Modified or cyclized derivatives are separate materials.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A defined cosmetic hexapeptide also associated with the name Collaxyl. The cited chemical identity records do not establish clinical anti-aging effects. Modified or cyclized derivatives are separate materials.",
      "evidence_level": "chemical identity records; clinical efficacy not established by these sources",
      "limitations": "Do not transfer a cyclized-derivative trial to ordinary hexapeptide-9 or describe chemical identity as proof of anti-aging efficacy.",
      "reader_summary": {
        "why_people_are_interested": "For someone comparing peptide skincare, the exact ingredient name matters. Regular hexapeptide-9 and a modified, cyclized version are different materials, so evidence about one should not automatically be assigned to the other.",
        "what_it_is_used_or_studied_for": "Hexapeptide-9 is a defined peptide also associated with the name Collaxyl. The cited authoritative records establish its identity and naming.",
        "what_human_evidence_shows": "These identity records do not report cosmetic treatment results in people. They do not answer whether an ordinary hexapeptide-9 formulation reduces wrinkles, improves firmness or changes skin hydration.",
        "important_drawbacks": "An ingredient name alone does not describe a finished product’s concentration, delivery or performance. A separate study is needed to establish a clinical benefit, and identity registration is not approval as a medicine."
      },
      "sources": [
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/16129319",
          "title": "PubChem compound 16129319: Hexapeptide-9",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        },
        {
          "url": "https://precision.fda.gov/uniisearch/srs/unii/L25414IE41",
          "title": "FDA GSRS substance identity: Hexapeptide-9",
          "supports": "Substance identity and aliases only; no evidence of clinical efficacy, productquality or FDA approval.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA Global Substance Registration System",
          "read_scope": "actual official substance record read"
        }
      ]
    },
    {
      "slug": "nonapeptide-1",
      "name": "Nonapeptide-1",
      "canonical_id": "nonapeptide-1",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A cosmetic peptide examined within combinations and delivery systems. A 46-person pilot compared a multi-ingredient melasma-maintenance product with sunscreen; its reported between-group severity/index differences were not statistically significant.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic peptide examined within combinations and delivery systems. A 46-person pilot compared a multi-ingredient melasma-maintenance product with sunscreen; its reported between-group severity/index differences were not statistically significant.",
      "evidence_level": "small combination human trial plus preclinical delivery research",
      "limitations": "The effect of nonapeptide-1 alone is not isolated; do not infer treatment of melasma from mechanism or combination claims.",
      "reader_summary": {
        "why_people_are_interested": "Nonapeptide-1 is of interest in products addressing uneven pigmentation. The clinically important question is whether a product improves the appearance of the relevant skin condition, rather than only changing a laboratory signal.",
        "what_it_is_used_or_studied_for": "The cited research includes a multi-ingredient melasma-maintenance product and an experimental delivery system containing green-tea-derived EGCG and nonapeptide-1.",
        "what_human_evidence_shows": "In a small pilot involving 46 people, the combination group improved on some measures, but reported between-group differences in severity and pigment measurements were not statistically significant. The ingredient’s individual contribution was not isolated.",
        "important_drawbacks": "Combination results cannot establish that nonapeptide-1 alone treats melasma. Laboratory delivery-system findings also do not prove visible benefits, safety or effectiveness of a commercial skincare product."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34379946/",
          "title": "A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "34379946",
          "doi": "10.25259/ijdvl_976_18"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39260749/",
          "title": "Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "39260749",
          "doi": "10.1016/j.ijpharm.2024.124690"
        }
      ]
    },
    {
      "slug": "oligopeptide-1",
      "name": "Oligopeptide-1",
      "canonical_id": "oligopeptide-1",
      "entry_kind": "ambiguous-cosmetic-name",
      "aliases": [],
      "identity": "This ingredient name requires a precise identity. sh-Oligopeptide-1 is associated with recombinant human epidermal growth factor (EGF), while the bare name can be used for a different peptide record. Confirm the full ingredient name and material before applying EGF research.",
      "classification": "ambiguous-cosmetic-name",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "This ingredient name requires a precise identity. sh-Oligopeptide-1 is associated with recombinant human epidermal growth factor (EGF), while the bare name can be used for a different peptide record. Confirm the full ingredient name and material before applying EGF research.",
      "evidence_level": "identity ambiguity; adjacent EGF formulation study",
      "limitations": "Do not equate every oligopeptide-1 listing with recombinant human EGF or infer the identity, purity or effect of a commercial ingredient.",
      "reader_summary": {
        "why_people_are_interested": "Oligopeptide-1 is a name worth clarifying before buying skincare or interpreting a study. Similar-looking ingredient names can refer to different materials, especially when growth-factor claims are involved.",
        "what_it_is_used_or_studied_for": "The name sh-Oligopeptide-1 is associated with recombinant human epidermal growth factor, or EGF. A bare oligopeptide-1 listing does not, by itself, establish that it is the same material.",
        "what_human_evidence_shows": "A small human study investigated EGF in a particular hyaluronic-acid microneedle patch and reported wrinkle improvements. It did not test every ingredient or product marketed under the bare oligopeptide-1 name.",
        "important_drawbacks": "If the identity differs, the study may not apply. The formulation, actual ingredient and delivery system need to match before a reported result can be used to support a product claim."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33911590/",
          "title": "Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "33911590",
          "doi": "10.5021/ad.2019.31.3.263",
          "pmcid": "PMC7992733"
        },
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/177865760",
          "title": "PubChem: SH-Oligopeptide-1 (rh-EGF)",
          "supports": "This record identifies sh-Oligopeptide-1/rh-EGF; it does not establish that bare oligopeptide-1 means the same ingredient.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem",
          "read_scope": "chemical identity record"
        }
      ]
    },
    {
      "slug": "palmitoyl-hexapeptide-12",
      "name": "Palmitoyl hexapeptide-12",
      "canonical_id": "palmitoyl-hexapeptide-12",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A palmitoylated cosmetic hexapeptide. The cited sources establish chemical identity and a peer-reviewed expert-panel safety assessment for specified peptide sequences and cosmetic practices. Neither establishes clinical anti-aging benefit.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A palmitoylated cosmetic hexapeptide. The cited sources establish chemical identity and a peer-reviewed expert-panel safety assessment for specified peptide sequences and cosmetic practices. Neither establishes clinical anti-aging benefit.",
      "evidence_level": "chemical identity and expert-panel cosmetic safety assessment; clinical efficacy not established by these sources",
      "limitations": "The safety assessment is bounded to its specified sequence and cosmetic-use practices. It does not establish effectiveness, approval, or safety of an injected/systemic product.",
      "reader_summary": {
        "why_people_are_interested": "Palmitoyl hexapeptide-12 appears in cosmetic research on skin-conditioning ingredients. A reader may be interested in whether that translates into a visible improvement, but safety assessment and effectiveness are different questions.",
        "what_it_is_used_or_studied_for": "It is a peptide with a fatty-acid attachment. The cited expert-panel assessment considered specific peptide sequences and cosmetic-use practices, rather than treating every similarly named material as identical.",
        "what_human_evidence_shows": "The additional sources here establish identity and discuss cosmetic safety. They do not report a human trial showing that the ingredient itself makes wrinkles less visible or skin firmer.",
        "important_drawbacks": "The panel’s conclusion was limited to the uses and concentrations it assessed. It does not establish effectiveness, approval as a medicine, or safety when injected or used systemically."
      },
      "sources": [
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/10212452",
          "title": "PubChem compound 10212452: Palmitoyl Hexapeptide-12",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        },
        {
          "url": "https://journals.sagepub.com/doi/10.1177/1091581818807863",
          "title": "Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics",
          "supports": "Assessmentscope includes only Hexapeptide12sequenceVGVAPG and listed derivatives. Conditionalcosmetic safety assessment; not clinicalefficacy, approvalor injectable/systemic safety.",
          "additional_document_vs_comparator": true,
          "source_kind": "CIR Expert Panel peer-reviewed safety assessment, International Journal of Toxicology",
          "read_scope": "actual full publisher article; abstract,scope,identity and cosmetic-use sections inspected",
          "doi": "10.1177/1091581818807863"
        }
      ]
    },
    {
      "slug": "palmitoyl-tetrapeptide-7",
      "name": "Palmitoyl tetrapeptide-7",
      "canonical_id": "palmitoyl-tetrapeptide-7",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A palmitoylated cosmetic peptide studied in blends. Studies assessed a peptide blend with imaging methods and a multi-component eye cream; neither isolates this ingredient’s effect.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A palmitoylated cosmetic peptide studied in blends. Studies assessed a peptide blend with imaging methods and a multi-component eye cream; neither isolates this ingredient’s effect.",
      "evidence_level": "human/explant blend studies",
      "limitations": "Combination findings and skin-imaging observations do not establish the effectiveness of every product containing the ingredient.",
      "reader_summary": {
        "why_people_are_interested": "Palmitoyl tetrapeptide-7 is investigated in skincare blends aimed at improving the appearance and condition of aging skin. Whether a person sees a difference depends on the formulation actually tested.",
        "what_it_is_used_or_studied_for": "The cited studies examined peptide blends using skin-imaging methods and a multi-component eye cream containing several active ingredients.",
        "what_human_evidence_shows": "The studies reported improvements in measures of skin structure or in hydration, elasticity and appearance during product use. They did not separate the effect of palmitoyl tetrapeptide-7 from the other ingredients.",
        "important_drawbacks": "The findings therefore belong to the tested combinations. They cannot show that every product containing this peptide works, or that the ingredient alone produces the reported changes."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/25817264/",
          "title": "Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "25817264",
          "doi": "10.1111/jocd.12135"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/38932444/",
          "title": "Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "38932444",
          "doi": "10.1111/srt.13790",
          "pmcid": "PMC11208285"
        }
      ]
    },
    {
      "slug": "palmitoyl-tripeptide-1",
      "name": "Palmitoyl tripeptide-1",
      "canonical_id": "palmitoyl-tripeptide-1",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "Also called Pal-GHK. Studies investigated skin distribution in a few volunteers and a timed combination regimen with baicalin involving 30 women.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "Also called Pal-GHK. Studies investigated skin distribution in a few volunteers and a timed combination regimen with baicalin involving 30 women.",
      "evidence_level": "small human formulation/permeation studies",
      "limitations": "Permeation is not efficacy, and a combined regimen cannot establish the ingredient’s isolated clinical effect.",
      "reader_summary": {
        "why_people_are_interested": "Palmitoyl tripeptide-1, also called Pal-GHK, attracts interest in skincare because of research connected with collagen and skin appearance. That interest needs to be separated from what has actually been demonstrated in people.",
        "what_it_is_used_or_studied_for": "One cited study examined where the ingredient reached in the outer skin layers. Another investigated a combined skincare regimen containing both this peptide and baicalin.",
        "what_human_evidence_shows": "A small study involving 30 women reported improvements in appearance and firmness measures with the combined regimen. The permeation study showed distribution in the outer skin, which is not itself proof of benefit.",
        "important_drawbacks": "Neither finding establishes the peptide’s isolated clinical effect. A combination regimen and a few-person distribution experiment cannot predict the performance of every formulation containing Pal-GHK."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/41527525/",
          "title": "Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "41527525",
          "doi": "10.1111/jocd.70638",
          "pmcid": "PMC12797011"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/42790608/",
          "title": "Permeation behaviour of cosmetic actives into the human stratum corneum.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Permeation behaviour of cosmetic actives into the human stratum corneum. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "42790608",
          "doi": "10.1016/j.ijpharm.2026.127447"
        }
      ]
    },
    {
      "slug": "palmitoyl-tripeptide-38",
      "name": "Palmitoyl tripeptide-38",
      "canonical_id": "palmitoyl-tripeptide-38",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A cosmetic lipopeptide investigated as part of multi-ingredient serums and moisturizers. Small human product studies reported changes in skin-appearance measures compared with baseline.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic lipopeptide investigated as part of multi-ingredient serums and moisturizers. Small human product studies reported changes in skin-appearance measures compared with baseline.",
      "evidence_level": "small multi-ingredient human studies",
      "limitations": "Open-label or uncontrolled product results do not isolate this peptide or establish general anti-aging benefit.",
      "reader_summary": {
        "why_people_are_interested": "Palmitoyl tripeptide-38 is of interest as part of skincare intended to improve visible signs of aging, such as fine lines or skin texture. The evidence concerns actual products, not just a promising ingredient name.",
        "what_it_is_used_or_studied_for": "The cited studies evaluated multi-ingredient serums or moisturizers containing the peptide alongside other substances, including plant-derived ingredients or vitamins.",
        "what_human_evidence_shows": "Small human product studies reported improvements in several skin-appearance measures compared with participants’ starting measurements. One was explicitly open-label, meaning participants and investigators knew the product being used.",
        "important_drawbacks": "Without isolating the ingredient or reliably separating product effects from other changes, these studies cannot establish how much benefit came from this peptide. The results do not apply automatically to other products."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26424007/",
          "title": "Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Biorevitalizing effect of a novel facial serum containing apple stem cell extract, pro-collagen lipopeptide, creatine, and urea on skin aging signs. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "26424007",
          "doi": "10.1111/jocd.12173"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26151786/",
          "title": "An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: An Open Label Clinical Trial of a Multi-Ingredient Anti-Aging Moisturizer Designed to Improve the Appearance of Facial Skin. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "26151786"
        }
      ]
    },
    {
      "slug": "pentapeptide-18",
      "name": "Pentapeptide-18",
      "canonical_id": "pentapeptide-18",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A cosmetic pentapeptide also associated with Leuphasyl. Laboratory work evaluated a D-tyrosine-modified derivative and nanoparticle formulations containing retinol and peptide.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A cosmetic pentapeptide also associated with Leuphasyl. Laboratory work evaluated a D-tyrosine-modified derivative and nanoparticle formulations containing retinol and peptide.",
      "evidence_level": "cell/model and formulation studies",
      "limitations": "A modified derivative is not the unmodified ingredient, and formulation stability is not clinical efficacy.",
      "reader_summary": {
        "why_people_are_interested": "Pentapeptide-18, also associated with the name Leuphasyl, is investigated in cosmetic formulation research. A reader may be interested in wrinkle-related claims, but the material tested and the outcome measured matter.",
        "what_it_is_used_or_studied_for": "The additional cited work examined a modified version with an added D-tyrosine and a formulation combining peptide with retinol in lipid nanoparticles.",
        "what_human_evidence_shows": "These studies did not demonstrate wrinkle reduction in people. One reported laboratory changes related to pigment production with the modified peptide; the other studied the formulation’s physical properties and stability.",
        "important_drawbacks": "A modified molecule is not identical to the original ingredient. Improved formulation stability is useful development work, but does not prove a cosmetic benefit, clinical safety or the effect of a finished product."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/31937863/",
          "title": "D-tyrosine adds an anti-melanogenic effect to cosmetic peptides.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: D-tyrosine adds an anti-melanogenic effect to cosmetic peptides. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "31937863",
          "doi": "10.1038/s41598-019-57159-3",
          "pmcid": "PMC6959337"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39337562/",
          "title": "Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18-Optimization, Characterization, and Cosmetic Application.",
          "supports": "The named primary publication and its actual abstract were inspected. Supported scope: Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18-Optimization, Characterization, and Cosmetic Application. Model/population and limitations are summarized in this entry; no regimen is recommended.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed primary publication indexed by NLM/EuropePMC",
          "read_scope": "abstract",
          "pmid": "39337562",
          "doi": "10.3390/ijms251810078",
          "pmcid": "PMC11432460"
        }
      ]
    },
    {
      "slug": "tripeptide-10-citrulline",
      "name": "Tripeptide-10 citrulline",
      "canonical_id": "tripeptide-10-citrulline",
      "entry_kind": "cosmetic-ingredient",
      "aliases": [],
      "identity": "A synthetic cosmetic peptide with a defined chemical identity. The cited authoritative identity records do not establish clinical efficacy or the properties of a particular formulation.",
      "classification": "cosmetic-ingredient",
      "regulatory_status": "Drug approval is not inferred from chemical identity, an ingredient name or cosmetic-formulation research. Product identity, purpose and jurisdiction must be established separately.",
      "evidence_summary": "A synthetic cosmetic peptide with a defined chemical identity. The cited authoritative identity records do not establish clinical efficacy or the properties of a particular formulation.",
      "evidence_level": "chemical identity records; clinical efficacy not established by these sources",
      "limitations": "An identity record is not a clinical study, safety assessment or product approval. Clinical claims require evidence for the actual ingredient and formulation.",
      "reader_summary": {
        "why_people_are_interested": "If you are comparing peptide skincare, tripeptide-10 citrulline is one ingredient name you may encounter. The practical question is whether a particular formulation improves the skin feature you care about.",
        "what_it_is_used_or_studied_for": "It is a defined cosmetic peptide whose identity can be checked against authoritative chemical records. That helps avoid confusing different ingredients with similar names.",
        "what_human_evidence_shows": "The sources used for this profile establish identity rather than treatment results in people. They therefore do not answer whether it improves wrinkles, hydration or firmness in a particular skincare product.",
        "important_drawbacks": "Identity registration is not a clinical trial, a complete safety assessment or approval as a medicine. Claims about visible benefits need evidence for the actual ingredient, formulation and way it is used."
      },
      "sources": [
        {
          "url": "https://pubchem.ncbi.nlm.nih.gov/compound/90479646",
          "title": "PubChem compound 90479646: Tripeptide-10 citrulline",
          "supports": "Identity/molecular representation only; no clinical efficacy, regulatory approval or product quality claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "NIH/NLM PubChem chemical record",
          "read_scope": "chemical identity record"
        },
        {
          "url": "https://precision.fda.gov/uniisearch/srs/unii/2732R0E76W",
          "title": "FDA GSRS substance identity: Tripeptide-10 citrulline",
          "supports": "Substance identity and aliases only; no evidence of clinical efficacy, productquality or FDA approval.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S.FDA Global Substance Registration System",
          "read_scope": "actual official substance record read"
        }
      ]
    },
    {
      "slug": "semaglutide",
      "name": "Semaglutide",
      "canonical_id": "semaglutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "GLP-1 receptor agonist studied in randomized trials in type 2 diabetes and in biopsy-confirmed nonalcoholic steatohepatitis.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "United States, checked 29 October 2026: Wegovy injection is approved for long-term weight management in adults with obesity, adults with overweight and a related condition, and patients aged 12 or older with obesity. It also reduces cardiovascular-event risk in adults with established cardiovascular disease and obesity or overweight. Its adult noncirrhotic MASH indication covers moderate-to-advanced liver scarring (F2–F3) and has accelerated approval. Wegovy tablets have specified adult weight-management and cardiovascular indications. Other semaglutide products have their own labeling.",
      "evidence_summary": "GLP-1 receptor agonist studied in randomized trials in type 2 diabetes and in biopsy-confirmed nonalcoholic steatohepatitis.",
      "evidence_level": "Human randomized trials",
      "limitations": "These sources concern defined disease populations and study formulations, not a general weight-loss or longevity recommendation. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Semaglutide is known for helping eligible people lose weight. Its medical uses depend on the particular product and formulation, rather than the ingredient name alone.",
        "what_it_is_used_or_studied_for": "Wegovy is used with dietary changes and physical activity for long-term weight management in specified patients. Certain Wegovy formulations also have approved heart-risk or liver-disease uses.",
        "what_human_evidence_shows": "In STEP 1, 1,961 adults with obesity or overweight and a related condition, without diabetes, received semaglutide or placebo alongside lifestyle support. Average weight loss at 68 weeks was 14.9% versus 2.4%. Results vary between people.",
        "important_drawbacks": "Nausea, diarrhea and vomiting are common. Label warnings include pancreatitis, gallbladder problems and dehydration-related kidney injury. Wegovy must not be used with a personal or family history of medullary thyroid cancer or the inherited condition MEN 2."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/27633186/",
          "title": "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "27633186",
          "doi": "10.1056/nejmoa1607141"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33185364/",
          "title": "A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "33185364",
          "doi": "10.1056/nejmoa2028395"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SEMAGLUTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching SEMAGLUTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316",
          "display_title": "FDA: Wegovy tablets approval history (selected product)"
        },
        {
          "url": "https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b",
          "title": "Wegovy current U.S. prescribing information, revised June 2026",
          "supports": "Product- and formulation-specific indications, age limits, current MASH accelerated approval, common adverse effects and major warnings.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator record / prescribing information",
          "read_scope": "Current prescribing label: indications, contraindications, warnings and selected trial context inspected.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/",
          "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity.",
          "supports": "STEP 1: 1,961 adults without diabetes, 68-week randomized comparison plus lifestyle support, mean weight loss 14.9% versus 2.4%; gastrointestinal discontinuation greater than placebo.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC; publisher full text inaccessible (403).",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "tirzepatide",
      "name": "Tirzepatide",
      "canonical_id": "tirzepatide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Dual GIP and GLP-1 receptor agonist examined in phase 3 trials in adults with type 2 diabetes.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "United States, checked 29 October 2026: Zepbound is approved for long-term weight management in adults with obesity, or overweight with a related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro is approved for blood-sugar control in adults and children aged 10 or older with type 2 diabetes, and cardiovascular-risk reduction in adults with type 2 diabetes at high risk. These are product-specific indications.",
      "evidence_summary": "Dual GIP and GLP-1 receptor agonist examined in phase 3 trials in adults with type 2 diabetes.",
      "evidence_level": "Human randomized trials",
      "limitations": "Diabetes trial results do not establish suitability, safety or outcomes for an individual or an unregulated product. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Tirzepatide can produce substantial weight loss and improve blood sugar in appropriate patients. It acts on two hormone pathways, called GIP and GLP-1, involved in appetite and glucose regulation.",
        "what_it_is_used_or_studied_for": "Zepbound is used with dietary changes and physical activity for long-term weight management in eligible adults. It is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Mounjaro has separate diabetes and cardiovascular labeling.",
        "what_human_evidence_shows": "SURMOUNT-1 enrolled 2,539 adults with obesity or overweight and a related condition, without diabetes. At 72 weeks, average weight loss across the tirzepatide groups was 15.0% to 20.9%, versus 3.1% with placebo.",
        "important_drawbacks": "Nausea, diarrhea and vomiting are common. Serious label warnings include pancreatitis and dehydration-related kidney injury. Zepbound must not be used with a personal or family history of medullary thyroid cancer or MEN 2. It can also affect oral contraceptive effectiveness."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34170647/",
          "title": "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "34170647",
          "doi": "10.1056/nejmoa2107519"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34186022/",
          "title": "Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "34186022",
          "doi": "10.1016/s0140-6736(21)01324-6"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TIRZEPATIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching TIRZEPATIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806",
          "display_title": "FDA: ZEPBOUND approval history (selected product)"
        },
        {
          "url": "https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b",
          "title": "Zepbound current U.S. prescribing information, revised August 2026",
          "supports": "Adult weight-management and obesity-associated sleep-apnea indications; common adverse effects, thyroid-cancer-history contraindication, pancreatitis, kidney injury and oral-contraceptive interaction.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator record / prescribing information",
          "read_scope": "Current prescribing label: indications, contraindications, warnings and selected trial context inspected.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0",
          "title": "Mounjaro current U.S. prescribing information, revised August 2026",
          "supports": "Type 2 diabetes indication in adults and children aged 10 or older, and specified adult type 2 diabetes cardiovascular-risk indication.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator record / prescribing information",
          "read_scope": "Current prescribing label: indications, contraindications, warnings and selected trial context inspected.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
          "title": "Tirzepatide Once Weekly for the Treatment of Obesity.",
          "supports": "SURMOUNT-1: 2,539 adults without diabetes, 72-week randomized comparison; 15.0% to 20.9% mean weight loss across tirzepatide groups versus 3.1% placebo; common gastrointestinal adverse effects.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full PubMed abstract and matching Europe PMC abstract read; not full-text review.",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "dasiglucagon",
      "name": "Dasiglucagon",
      "canonical_id": "dasiglucagon",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Soluble glucagon analogue examined for glucose recovery in controlled hypoglycemia studies in adults and children with type 1 diabetes.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records list discontinued products. Product: ZEGALOGUE; ZEGALOGUE (AUTOINJECTOR). Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Soluble glucagon analogue examined for glucose recovery in controlled hypoglycemia studies in adults and children with type 1 diabetes.",
      "evidence_level": "Human randomized trials",
      "limitations": "The cited trials used defined clinical formulations under controlled conditions; they are not instructions for managing a hypoglycemic emergency. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Dasiglucagon was developed to make treatment of dangerously low blood sugar easier, using a liquid formulation ready for emergency use.",
        "what_it_is_used_or_studied_for": "It is a modified version of glucagon, the hormone that raises blood sugar, studied in adults and children with type 1 diabetes.",
        "what_human_evidence_shows": "In a pediatric trial, median blood-sugar recovery took 10 minutes with dasiglucagon versus 30 minutes with placebo. Adult research also found a rapid response comparable to standard glucagon.",
        "important_drawbacks": "Nausea was common in the adult study. Controlled low-blood-sugar experiments cannot capture every emergency situation. The checked US FDA product entries list Zegalogue as discontinued, so availability needs separate confirmation."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29273578/",
          "title": "Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "29273578",
          "doi": "10.2337/dc17-1402"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33934456/",
          "title": "Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "33934456",
          "doi": "10.1111/pedi.13220",
          "pmcid": "PMC8361970"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DASIGLUCAGON%22&limit=100",
          "title": "Drugs@FDA application/product records matching DASIGLUCAGON",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214231",
          "display_title": "FDA: ZEGALOGUE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "enlicitide",
      "name": "Enlicitide",
      "canonical_id": "enlicitide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Oral PCSK9 inhibitor with a macrocyclic peptide structure and nonpeptide elements. A phase 3 trial studied LDL-cholesterol lowering in adults with heterozygous familial hypercholesterolemia.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: LIPFENDRA. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Oral PCSK9 inhibitor with a macrocyclic peptide structure and nonpeptide elements. A phase 3 trial studied LDL-cholesterol lowering in adults with heterozygous familial hypercholesterolemia.",
      "evidence_level": "Human randomized trial and synthesis research",
      "limitations": "A synthesis report is identity/manufacturing evidence, not clinical efficacy evidence. Current product authorization must be checked separately. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Enlicitide interests people who need additional lowering of LDL cholesterol, often called bad cholesterol, and would prefer an oral option.",
        "what_it_is_used_or_studied_for": "It blocks PCSK9, a protein involved in how the body clears LDL cholesterol. The included trial studied adults with inherited high cholesterol despite existing treatment.",
        "what_human_evidence_shows": "At 24 weeks, LDL cholesterol fell by about 58% with enlicitide while rising slightly with placebo. Participants were already taking statins, and many also took another cholesterol medicine.",
        "important_drawbacks": "Lower cholesterol is not the same outcome as directly showing fewer heart attacks. These results apply to the trial population, and medicine selection still depends on overall cardiovascular risk and existing treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/41206969/",
          "title": "Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "41206969",
          "doi": "10.1001/jama.2025.20620",
          "pmcid": "PMC12598580"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/40123407/",
          "title": "Total Synthesis of Enlicitide Decanoate.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "40123407",
          "doi": "10.1021/jacs.4c15966"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ENLICITIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching ENLICITIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220848",
          "display_title": "FDA: LIPFENDRA approval history (selected product)"
        }
      ]
    },
    {
      "slug": "ga-68-dotatate",
      "name": "Ga-68 dotatate",
      "canonical_id": "ga-68-dotatate",
      "entry_kind": "radiopharmaceutical",
      "aliases": [],
      "identity": "Gallium-labeled somatostatin-receptor imaging tracer examined with PET/CT in people with neuroendocrine tumors.",
      "classification": "radiopharmaceutical",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: NETSPOT. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Gallium-labeled somatostatin-receptor imaging tracer examined with PET/CT in people with neuroendocrine tumors.",
      "evidence_level": "Human diagnostic imaging studies",
      "limitations": "A diagnostic radiotracer is distinct from a therapeutic peptide or a wellness injection; these imaging cohorts do not establish treatment benefit. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Gallium-68 dotatate can help doctors locate certain neuroendocrine tumors and understand how far they have spread.",
        "what_it_is_used_or_studied_for": "It is a radioactive imaging tracer used with PET/CT scans, rather than a supplement or a medicine intended to shrink tumors.",
        "what_human_evidence_shows": "In a prospective study of 131 patients, it detected more tumor lesions than the comparison imaging methods. Another small study found that its usefulness varied with tumor type and grade.",
        "important_drawbacks": "A scan result does not itself treat cancer. Different tumors take up different tracers, and the strongest imaging approach can depend on tumor biology. Specialist interpretation and the wider diagnostic picture remain essential."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26712231/",
          "title": "Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "26712231",
          "doi": "10.1200/jco.2015.64.0987",
          "pmcid": "PMC4872030"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18383518/",
          "title": "Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "18383518",
          "doi": "10.1002/cncr.23469"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DOTATATE%22&limit=100",
          "title": "Drugs@FDA application/product records matching DOTATATE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208547",
          "display_title": "FDA: NETSPOT approval history (selected product)"
        }
      ]
    },
    {
      "slug": "glucagon",
      "name": "Glucagon",
      "canonical_id": "glucagon",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Peptide hormone examined in rescue formulations for severe hypoglycemia and in investigational dual-hormone closed-loop systems.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: BAQSIMI; GLUCAGON; GVOKE HYPOPEN; GVOKE KIT; GVOKE PFS. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Peptide hormone examined in rescue formulations for severe hypoglycemia and in investigational dual-hormone closed-loop systems.",
      "evidence_level": "Human randomized trials",
      "limitations": "The sources cover different formulations and delivery systems; their results and instructions cannot be transferred between products. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Glucagon matters because severe low blood sugar can become an emergency when a person cannot safely eat or drink.",
        "what_it_is_used_or_studied_for": "It is a natural hormone used in rescue medicines to raise blood sugar. Researchers also study it alongside insulin in automated diabetes systems.",
        "what_human_evidence_shows": "Two trials found a ready-to-use glucagon autoinjector restored blood sugar within 30 minutes at a rate comparable to a traditional emergency kit. A small automated-system study reduced low blood sugar around exercise.",
        "important_drawbacks": "The automated system also increased time with high blood sugar in some comparisons, and nausea led some participants to withdraw. Results for one formulation or device do not automatically apply to another."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34620618/",
          "title": "Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "34620618",
          "doi": "10.1136/bmjdrc-2021-002137",
          "pmcid": "PMC8499286"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32907828/",
          "title": "Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "32907828",
          "doi": "10.2337/dc19-2267"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22GLUCAGON%22&limit=100",
          "title": "Drugs@FDA application/product records matching GLUCAGON",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210134",
          "display_title": "FDA: BAQSIMI approval history (selected product)"
        }
      ]
    },
    {
      "slug": "lanreotide",
      "name": "Lanreotide",
      "canonical_id": "lanreotide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Somatostatin analogue examined in neuroendocrine-tumor trials, including long-term open-label extension evidence.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: LANREOTIDE ACETATE; SOMATULINE DEPOT. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Somatostatin analogue examined in neuroendocrine-tumor trials, including long-term open-label extension evidence.",
      "evidence_level": "Human randomized trial and extension",
      "limitations": "Open-label extension findings differ from randomized comparisons; specialist disease evidence is not a general anti-aging indication. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Lanreotide interests patients with certain neuroendocrine tumors because treatment may help keep disease stable for longer.",
        "what_it_is_used_or_studied_for": "It mimics somatostatin, a hormone that slows some hormone-release signals. The included studies examine tumor control rather than general wellness or weight loss.",
        "what_human_evidence_shows": "A long-term extension study supported sustained tumor-control benefits in selected pancreatic and intestinal neuroendocrine tumors. An earlier randomized comparison found similar tumor-growth effects among the treatments tested, with modest response rates.",
        "important_drawbacks": "Extension studies can favor people who were already doing well enough to continue. Diarrhea was reported, and longer disease control does not mean that a tumor has been cured or that every tumor type responds."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/12860945/",
          "title": "Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "12860945",
          "doi": "10.1200/jco.2003.12.142"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26743120/",
          "title": "Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "26743120",
          "doi": "10.1530/erc-15-0490",
          "pmcid": "PMC4740728"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22LANREOTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching LANREOTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218217",
          "display_title": "FDA: LANREOTIDE ACETATE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "linaclotide",
      "name": "Linaclotide",
      "canonical_id": "linaclotide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Minimally absorbed peptide guanylate cyclase-C agonist examined in randomized constipation and irritable-bowel-syndrome-with-constipation trials.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: LINACLOTIDE; LINZESS. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Minimally absorbed peptide guanylate cyclase-C agonist examined in randomized constipation and irritable-bowel-syndrome-with-constipation trials.",
      "evidence_level": "Human randomized trials",
      "limitations": "The cited studies assess specific bowel disorders over defined periods, not an unrestricted gut-health benefit. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Linaclotide is relevant to people whose constipation also causes abdominal discomfort or pain.",
        "what_it_is_used_or_studied_for": "It acts mainly in the intestine to increase fluid movement and is studied in chronic constipation and irritable bowel syndrome with constipation.",
        "what_human_evidence_shows": "Randomized trials found improvements in bowel symptoms, and the irritable-bowel trial also found less abdominal pain over at least 12 weeks. These are direct patient-symptom outcomes rather than laboratory markers alone.",
        "important_drawbacks": "Diarrhea was the most common unwanted effect in the irritable-bowel trial and led 5.7% of linaclotide recipients to stop treatment, versus 0.3% with placebo. Longer-term benefits and risks need to be judged alongside the cause of constipation."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/22986440/",
          "title": "A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "22986440",
          "doi": "10.1038/ajg.2012.255",
          "pmcid": "PMC3504311"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/21830967/",
          "title": "Two randomized trials of linaclotide for chronic constipation.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "21830967",
          "doi": "10.1056/nejmoa1010863"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22LINACLOTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching LINACLOTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211255",
          "display_title": "FDA: LINACLOTIDE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "liraglutide",
      "name": "Liraglutide",
      "canonical_id": "liraglutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "GLP-1 analogue examined in randomized type 2 diabetes studies and a phase 2 nonalcoholic-steatohepatitis trial.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: LIRAGLUTIDE; SAXENDA; VICTOZA; XULTOPHY 100/3.6. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "GLP-1 analogue examined in randomized type 2 diabetes studies and a phase 2 nonalcoholic-steatohepatitis trial.",
      "evidence_level": "Human randomized trials",
      "limitations": "The cited indication, formulation and population must remain separate; the research papers are not a current prescribing label. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Liraglutide interests people looking to improve type 2 diabetes control, particularly when weight is also a concern.",
        "what_it_is_used_or_studied_for": "It mimics GLP-1, a hormone involved in blood sugar and appetite. Researchers have also examined it in fatty-liver inflammation.",
        "what_human_evidence_shows": "A diabetes trial found better average blood-sugar improvement than the exenatide regimen tested. A small liver trial found more resolution of inflammatory fatty-liver disease than placebo.",
        "important_drawbacks": "The liver study was an early trial and called for larger, longer studies. Results for a particular diabetes comparison cannot establish that liraglutide is the best option for everyone, or that it reliably reverses advanced liver scarring."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26608256/",
          "title": "Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "26608256",
          "doi": "10.1016/s0140-6736(15)00803-x"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/19515413/",
          "title": "Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "19515413",
          "doi": "10.1016/s0140-6736(09)60659-0"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22LIRAGLUTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching LIRAGLUTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212552",
          "display_title": "FDA: LIRAGLUTIDE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "lutetium-lu-177-dotatate",
      "name": "Lutetium Lu-177 dotatate",
      "canonical_id": "lutetium-lu-177-dotatate",
      "entry_kind": "radiopharmaceutical",
      "aliases": [],
      "identity": "Peptide-targeted radionuclide therapy examined in neuroendocrine-tumor studies, including quality-of-life outcomes and renal-toxicity follow-up.",
      "classification": "radiopharmaceutical",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: BEXLUTRY; BRAVNETSA; LUTATHERA. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Peptide-targeted radionuclide therapy examined in neuroendocrine-tumor studies, including quality-of-life outcomes and renal-toxicity follow-up.",
      "evidence_level": "Human randomized-trial analysis and observational follow-up",
      "limitations": "This is specialist radiopharmaceutical research. Small observational renal cohorts do not replace current product safety information. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Lutetium-177 dotatate is relevant to selected patients with neuroendocrine tumors when doctors want to deliver radiation directly to tumor-associated targets.",
        "what_it_is_used_or_studied_for": "It combines a targeting peptide with a radioactive treatment. This is a cancer therapy, distinct from gallium-68 dotatate imaging.",
        "what_human_evidence_shows": "In a randomized trial analysis, patients receiving it took longer to experience worsening in overall health, physical function and several symptoms than patients receiving high-dose octreotide.",
        "important_drawbacks": "The treatment requires specialist assessment and monitoring. Kidney-radiation research highlights the importance of individual risk factors. Benefits shown in progressive midgut neuroendocrine tumors do not automatically apply to every cancer, and improved quality of life does not establish cure."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29878866/",
          "title": "Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "29878866",
          "doi": "10.1200/jco.2018.78.5865",
          "pmcid": "PMC6366953"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18427807/",
          "title": "Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "18427807",
          "doi": "10.1007/s00259-008-0778-1"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DOTATATE%22&limit=100",
          "title": "Drugs@FDA application/product records matching DOTATATE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218525",
          "display_title": "FDA: BEXLUTRY approval history (selected product)"
        }
      ]
    },
    {
      "slug": "octreotide",
      "name": "Octreotide",
      "canonical_id": "octreotide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Somatostatin-receptor-ligand medicine examined in acromegaly trials comparing oral, injectable or surgical approaches.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: BYNFEZIA PEN; MYCAPSSA; OCTREOTIDE ACETATE; OCTREOTIDE ACETATE (PRESERVATIVE FREE); SANDOSTATIN; SANDOSTATIN LAR. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Somatostatin-receptor-ligand medicine examined in acromegaly trials comparing oral, injectable or surgical approaches.",
      "evidence_level": "Human randomized trials",
      "limitations": "The cited trials involve different formulations and selected acromegaly populations; oral and injectable products are not automatically interchangeable. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Octreotide can interest people with acromegaly, a condition in which too much growth hormone causes changes in the body and significant health problems.",
        "what_it_is_used_or_studied_for": "It reduces hormone-release signals. The included studies compare oral and injectable treatment and examine medical treatment alongside surgery.",
        "what_human_evidence_shows": "In selected patients already controlled on injectable treatment, oral octreotide maintained control at a comparable level. A separate comparison found better surgical success at 24 weeks, while the difference at 48 weeks was not statistically significant.",
        "important_drawbacks": "The findings do not make tablets, injections and surgery interchangeable for every patient. Existing response, tumor characteristics and specialist assessment affect the choice and the chance of controlling hormone levels."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34953531/",
          "title": "Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "34953531",
          "doi": "10.1016/s2213-8587(21)00296-5"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/19178516/",
          "title": "Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "19178516",
          "doi": "10.1111/j.1365-2265.2008.03441.x"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22OCTREOTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching OCTREOTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213224",
          "display_title": "FDA: BYNFEZIA PEN approval history (selected product)"
        }
      ]
    },
    {
      "slug": "plecanatide",
      "name": "Plecanatide",
      "canonical_id": "plecanatide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Uroguanylin analogue that activates guanylate cyclase-C receptors; studied in healthy volunteers and in phase 3 irritable-bowel-syndrome-with-constipation trials.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: TRULANCE. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Uroguanylin analogue that activates guanylate cyclase-C receptors; studied in healthy volunteers and in phase 3 irritable-bowel-syndrome-with-constipation trials.",
      "evidence_level": "Human randomized trials",
      "limitations": "A short healthy-volunteer pharmacology study and disease efficacy trials answer different questions; neither supplies personal treatment advice. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Plecanatide is of interest when constipation and abdominal discomfort interfere with daily life.",
        "what_it_is_used_or_studied_for": "It acts in the intestine through a pathway that increases fluid secretion. The included research includes irritable bowel syndrome with constipation and early human pharmacology.",
        "what_human_evidence_shows": "Phase 3 trials found improvement in both constipation symptoms and abdominal pain compared with placebo. An early volunteer study found little measurable movement of the medicine into the bloodstream.",
        "important_drawbacks": "Diarrhea was the most common unwanted effect in the phase 3 trials, reported by about 4% with plecanatide versus 1% with placebo. Limited bloodstream exposure does not mean unwanted effects are impossible, and not everyone experienced meaningful symptom relief."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29545635/",
          "title": "Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "29545635",
          "doi": "10.1038/s41395-018-0026-7"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/23625291/",
          "title": "Plecanatide, an oral guanylate cyclase C agonist acting locally in the gastrointestinal tract, is safe and well-tolerated in single doses.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "23625291",
          "doi": "10.1007/s10620-013-2684-z"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PLECANATIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching PLECANATIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208745",
          "display_title": "FDA: TRULANCE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "setmelanotide",
      "name": "Setmelanotide",
      "canonical_id": "setmelanotide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Melanocortin-4 receptor agonist studied in rare POMC- and leptin-receptor-deficiency obesity.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: IMCIVREE. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Melanocortin-4 receptor agonist studied in rare POMC- and leptin-receptor-deficiency obesity.",
      "evidence_level": "Small human interventional studies",
      "limitations": "These early studies involved two or three people with rare genetic disorders. They cannot be generalized to common obesity. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Setmelanotide can matter to people with rare inherited conditions that cause severe, persistent hunger and early-onset obesity.",
        "what_it_is_used_or_studied_for": "It activates a brain pathway involved in hunger regulation. The included studies involve specific POMC or leptin-receptor deficiencies, not ordinary weight gain.",
        "what_human_evidence_shows": "Very small early studies reported substantial reductions in hunger and body weight in two people with POMC deficiency and three with leptin-receptor deficiency.",
        "important_drawbacks": "These findings are important for narrowly defined genetic conditions, but such tiny studies cannot predict results for the general population. A diagnosis and appropriate genetic assessment are central to understanding whether the research is relevant to an individual."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/27468060/",
          "title": "Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "27468060",
          "doi": "10.1056/nejmoa1512693"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29736023/",
          "title": "MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "29736023",
          "doi": "10.1038/s41591-018-0015-9"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SETMELANOTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching SETMELANOTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213793",
          "display_title": "FDA: IMCIVREE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "sincalide",
      "name": "Sincalide",
      "canonical_id": "sincalide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Peptide diagnostic stimulus studied in gallbladder-ejection-fraction measurement during cholescintigraphy.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: KINEVAC; SINCALIDE. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Peptide diagnostic stimulus studied in gallbladder-ejection-fraction measurement during cholescintigraphy.",
      "evidence_level": "Human diagnostic-method studies",
      "limitations": "The studies show that measurement depends on the testing method. This reference provides no imaging protocol or diagnostic threshold. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Sincalide is relevant when doctors need to investigate how well the gallbladder empties, rather than to improve everyday digestion.",
        "what_it_is_used_or_studied_for": "It stimulates gallbladder contraction during a diagnostic scan, helping clinicians measure the proportion of bile released.",
        "what_human_evidence_shows": "Healthy-volunteer studies showed that the way sincalide is administered can strongly affect the test result. Slower administration produced more consistent normal values than short administration in the included comparisons.",
        "important_drawbacks": "This is a diagnostic tool, not a treatment for gallstones or a general digestive supplement. Test methods and interpretation matter because inconsistent stimulation can make a normal gallbladder appear abnormal. Administration belongs in a supervised clinical setting."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/1552338/",
          "title": "Calculation of a gallbladder ejection fraction: advantage of continuous sincalide infusion over the three-minute infusion method.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "1552338"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11687683/",
          "title": "Normal values for sincalide cholescintigraphy: comparison of two methods.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "11687683",
          "doi": "10.1148/radiol.2212010154"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SINCALIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching SINCALIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017697",
          "display_title": "FDA: KINEVAC approval history (selected product)"
        }
      ]
    },
    {
      "slug": "teduglutide",
      "name": "Teduglutide",
      "canonical_id": "teduglutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "GLP-2 analogue examined in people with short bowel syndrome, including a placebo-controlled study of parenteral-support requirements.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: GATTEX KIT. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "GLP-2 analogue examined in people with short bowel syndrome, including a placebo-controlled study of parenteral-support requirements.",
      "evidence_level": "Human interventional studies",
      "limitations": "Evidence in short bowel syndrome does not establish a benefit for people without that disorder or justify changing parenteral support independently. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Teduglutide is relevant to people with short bowel syndrome who cannot absorb enough fluid or nutrients after major intestinal loss.",
        "what_it_is_used_or_studied_for": "It mimics GLP-2, a hormone that supports the intestinal lining, with the aim of improving absorption and reducing dependence on intravenous support.",
        "what_human_evidence_shows": "A 24-week placebo-controlled study found reductions in the amount of intravenous support needed and in the number of days it was required. Early research also found improved intestinal fluid absorption.",
        "important_drawbacks": "Reducing intravenous support is not the same as eliminating it for everyone. These findings concern a serious intestinal-failure condition, and ongoing nutrition management and specialist monitoring remain essential."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16099790/",
          "title": "Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "16099790",
          "doi": "10.1136/gut.2004.061440",
          "pmcid": "PMC1774653"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/22982184/",
          "title": "Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "22982184",
          "doi": "10.1053/j.gastro.2012.09.007"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TEDUGLUTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching TEDUGLUTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203441",
          "display_title": "FDA: GATTEX KIT approval history (selected product)"
        }
      ]
    },
    {
      "slug": "terlipressin",
      "name": "Terlipressin",
      "canonical_id": "terlipressin",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Vasopressin analogue studied with albumin in people with cirrhosis and hepatorenal syndrome.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: TERLIVAZ. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Vasopressin analogue studied with albumin in people with cirrhosis and hepatorenal syndrome.",
      "evidence_level": "Human randomized trials",
      "limitations": "This is specialist acute-disease evidence; cardiovascular complications were reported, and the older papers do not replace a current safety label. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Terlipressin is relevant when advanced liver disease causes a dangerous decline in kidney function called hepatorenal syndrome.",
        "what_it_is_used_or_studied_for": "In the United States, Terlivaz is approved to improve kidney function in adults with hepatorenal syndrome and rapidly worsening kidney function. It is a hospital treatment, not a general kidney-health supplement.",
        "what_human_evidence_shows": "Randomized studies found improved kidney function compared with the control treatments in people with cirrhosis and hepatorenal syndrome.",
        "important_drawbacks": "The US prescribing information carries a boxed warning for serious or fatal breathing failure and requires careful oxygen monitoring. Improving kidney function does not by itself establish longer survival, so the benefit must be weighed against substantial risks."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18471513/",
          "title": "A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "18471513",
          "doi": "10.1053/j.gastro.2008.02.014",
          "pmcid": "PMC3730280"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18471512/",
          "title": "Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "18471512",
          "doi": "10.1053/j.gastro.2008.02.024"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TERLIPRESSIN%22&limit=100",
          "title": "Drugs@FDA application/product records matching TERLIPRESSIN",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022231",
          "display_title": "FDA: TERLIVAZ approval history (selected product)"
        },
        {
          "url": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-improve-kidney-function-adults-hepatorenal-syndrome",
          "title": "FDA approves treatment to improve kidney function in adults with hepatorenal syndrome",
          "supports": "Specific US approved indication for Terlivaz; serious or fatal respiratory failure risk; oxygen monitoring.",
          "read_scope": "Official product-specific FDA approval and safety information, not a class inference.",
          "source_kind": "U.S. Food and Drug Administration",
          "additional_document_vs_comparator": false
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a35b86c-f451-4fac-8499-43019e4da354",
          "title": "TERLIVAZ (terlipressin) US prescribing information, updated October 23, 2026",
          "supports": "Boxed warning: serious or fatal respiratory failure; assess oxygenation and monitor respiratory status.",
          "read_scope": "Product-specific current label warning; not a complete independent label review.",
          "source_kind": "DailyMed, U.S. National Library of Medicine; official product prescribing information",
          "additional_document_vs_comparator": false
        }
      ]
    },
    {
      "slug": "tesamorelin",
      "name": "Tesamorelin",
      "canonical_id": "tesamorelin",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Growth-hormone-releasing-hormone analogue examined in HIV-associated abdominal fat accumulation and a small study of growth-hormone pulsatility.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: EGRIFTA. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Growth-hormone-releasing-hormone analogue examined in HIV-associated abdominal fat accumulation and a small study of growth-hormone pulsatility.",
      "evidence_level": "Human randomized trial and small physiology study",
      "limitations": "Disease-specific fat-distribution outcomes and short physiology studies do not establish general weight-loss or longevity use. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Tesamorelin interests people with HIV-associated excess deep abdominal fat, a specific pattern that differs from general weight gain.",
        "what_it_is_used_or_studied_for": "It stimulates the body’s growth-hormone release. The included research examines deep abdominal fat and liver fat in people with HIV, plus hormone effects in a small physiology study.",
        "what_human_evidence_shows": "A six-month randomized study found less deep abdominal fat and a modest reduction in liver fat compared with placebo.",
        "important_drawbacks": "Blood sugar rose early in treatment in that study, although longer-term differences were not significant there. The study was small and did not establish the long-term health consequences of reducing liver fat. These findings do not establish a general anti-aging treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/25038357/",
          "title": "Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "25038357",
          "doi": "10.1001/jama.2014.8334",
          "pmcid": "PMC4363137"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/20943777/",
          "title": "Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "20943777",
          "doi": "10.1210/jc.2010-1587",
          "pmcid": "PMC3038486"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TESAMORELIN%22&limit=100",
          "title": "Drugs@FDA application/product records matching TESAMORELIN",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505",
          "display_title": "FDA: EGRIFTA approval history (selected product)"
        }
      ]
    },
    {
      "slug": "retatrutide",
      "name": "Retatrutide",
      "canonical_id": "retatrutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Single peptide agonist of GIP, GLP-1 and glucagon receptors studied in phase 2 type 2 diabetes trials and a body-composition substudy.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "United States, checked 29 October 2026: retatrutide remains investigational. FDA states that it is not a component of an FDA-approved drug and cannot be used in compounding under federal law. Clinical trial results do not make products sold as retatrutide approved medicines.",
      "evidence_summary": "Single peptide agonist of GIP, GLP-1 and glucagon receptors studied in phase 2 type 2 diabetes trials and a body-composition substudy.",
      "evidence_level": "Human randomized trial and substudy",
      "limitations": "The substudy is not an independent replication of the parent trial. These sources do not establish current product authorization. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Retatrutide draws attention for potentially substantial weight loss while also improving blood sugar.",
        "what_it_is_used_or_studied_for": "It is an experimental medicine that activates three hormone pathways: GIP, GLP-1 and glucagon. The included studies involve adults with type 2 diabetes.",
        "what_human_evidence_shows": "A phase 2 trial found meaningful improvements in blood sugar and body weight. A body-composition analysis found more body-fat reduction than placebo or dulaglutide.",
        "important_drawbacks": "Stomach-and-bowel adverse events affected 35% of retatrutide recipients versus 13% with placebo in the main trial. Some weight lost was lean tissue. The body-composition analysis is not an independent trial, and long-term safety remains a separate question."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37385280/",
          "title": "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "37385280",
          "doi": "10.1016/s0140-6736(23)01053-x"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/40609566/",
          "title": "Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "40609566",
          "doi": "10.1016/s2213-8587(25)00092-0"
        },
        {
          "url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
          "title": "FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss",
          "supports": "Current retatrutide-specific statement: not a component of an approved drug and cannot be used in compounding under federal law; separate from conditional policies about other peptides.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator scientific assessment / public statement",
          "read_scope": "Actual current primary FDA page read, especially retatrutide/cagrilintide section.",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "cagrilintide",
      "name": "Cagrilintide",
      "canonical_id": "cagrilintide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Long-acting amylin analogue developed through peptide structure-activity research and examined alone or alongside semaglutide in metabolic-disease research.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Long-acting amylin analogue developed through peptide structure-activity research and examined alone or alongside semaglutide in metabolic-disease research.",
      "evidence_level": "Peptide-development research and human randomized trial",
      "limitations": "Cagrilintide alone and the cagrilintide-semaglutide combination are different research interventions; combination findings cannot be assigned to one component. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Cagrilintide attracts interest as a possible additional way to support weight loss through the body’s fullness signals.",
        "what_it_is_used_or_studied_for": "It is a long-acting version of amylin, a hormone released with food intake. Researchers study it alone and in combination with semaglutide.",
        "what_human_evidence_shows": "In a type 2 diabetes trial, the combination produced more weight loss than either component alone. It improved blood sugar more than cagrilintide alone, but that comparison did not show a significant advantage over semaglutide for blood sugar.",
        "important_drawbacks": "Combination benefits cannot all be attributed to cagrilintide by itself. Longer-term benefits, tolerability and the treatment setting need to be judged from the relevant clinical evidence."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34288673/",
          "title": "Development of Cagrilintide, a Long-Acting Amylin Analogue.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "34288673",
          "doi": "10.1021/acs.jmedchem.1c00565"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37364590/",
          "title": "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "37364590",
          "doi": "10.1016/s0140-6736(23)01163-7"
        }
      ]
    },
    {
      "slug": "amycretin",
      "name": "Amycretin",
      "canonical_id": "amycretin",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [
        "Zenagamtide"
      ],
      "identity": "Unimolecular GLP-1 and amylin-pathway agonist; the later clinical paper calls it zenagamtide, formerly amycretin. Evidence includes rodent studies and a phase 2 type 2 diabetes trial.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Unimolecular GLP-1 and amylin-pathway agonist; the later clinical paper calls it zenagamtide, formerly amycretin. Evidence includes rodent studies and a phase 2 type 2 diabetes trial.",
      "evidence_level": "Preclinical and human randomized trial",
      "limitations": "Animal metabolic findings and human trial findings must remain separate. A development name is not evidence of marketing approval. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Amycretin, also called zenagamtide, is attracting interest as a possible future approach to weight and blood-sugar management.",
        "what_it_is_used_or_studied_for": "It combines activity on GLP-1 and amylin-related pathways in one molecule. Researchers are studying whether this can build on the effects of either pathway alone.",
        "what_human_evidence_shows": "A phase 2 trial in people with type 2 diabetes found greater improvements in average blood sugar than placebo over 36 weeks. Separate rodent studies found weight and metabolic effects.",
        "important_drawbacks": "Animal liver and weight findings cannot be treated as established human benefits. Phase 2 success also does not settle long-term safety, broader patient outcomes or which patients would benefit most."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/40706446/",
          "title": "The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "40706446",
          "doi": "10.1016/j.ebiom.2025.105862",
          "pmcid": "PMC12309853"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/42532080/",
          "title": "Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "42532080",
          "doi": "10.1016/s0140-6736(26)01248-1"
        }
      ]
    },
    {
      "slug": "apraglutide",
      "name": "Apraglutide",
      "canonical_id": "apraglutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Long-acting GLP-2 analogue examined in pharmacology experiments and a small randomized trial in adults with short bowel syndrome-associated intestinal failure.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Long-acting GLP-2 analogue examined in pharmacology experiments and a small randomized trial in adults with short bowel syndrome-associated intestinal failure.",
      "evidence_level": "Preclinical pharmacology and human randomized trial",
      "limitations": "The early clinical trial enrolled eight adults; it does not establish use for general gut health or allow independent changes to parenteral support. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Apraglutide is of interest to people with short bowel syndrome who need intravenous fluid or nutrition because their remaining intestine cannot absorb enough.",
        "what_it_is_used_or_studied_for": "It is a long-acting GLP-2 analogue intended to improve the intestine’s ability to absorb fluid and nutrients.",
        "what_human_evidence_shows": "In a small randomized study of adults with short bowel syndrome-associated intestinal failure, urine output increased, supporting improved fluid absorption.",
        "important_drawbacks": "Urine output is an indirect sign of absorption, not proof that a person can stop intravenous support. The accompanying pharmacology research includes animals and does not establish clinical benefit on its own. Larger, longer studies are needed to judge durable outcomes and safety."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34287970/",
          "title": "Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "34287970",
          "doi": "10.1002/jpen.2223",
          "pmcid": "PMC9292678"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32075870/",
          "title": "Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "32075870",
          "doi": "10.1124/jpet.119.262238"
        }
      ]
    },
    {
      "slug": "brilacidin",
      "name": "Brilacidin",
      "canonical_id": "brilacidin",
      "entry_kind": "Peptide mimetic",
      "aliases": [
        "PMX30063"
      ],
      "identity": "Defensin-mimetic antimicrobial research compound investigated in bacterial mechanism experiments and a rabbit eye-infection model. It is peptide-related rather than a conventional peptide chain.",
      "classification": "Peptide mimetic",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Defensin-mimetic antimicrobial research compound investigated in bacterial mechanism experiments and a rabbit eye-infection model. It is peptide-related rather than a conventional peptide chain.",
      "evidence_level": "Preclinical laboratory and animal research",
      "limitations": "Bacterial and rabbit findings do not establish clinical efficacy, human safety or an approved treatment indication. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Brilacidin interests researchers looking for new ways to fight difficult bacterial infections, including infections resistant to familiar antibiotics.",
        "what_it_is_used_or_studied_for": "It imitates aspects of natural antimicrobial defense molecules and has been investigated for effects on bacterial membranes. It is not a conventional peptide chain.",
        "what_human_evidence_shows": "The sources included here show antibacterial activity in laboratory experiments and benefit in a rabbit model of a resistant bacterial eye infection. They do not establish a treatment benefit in people.",
        "important_drawbacks": "An effective laboratory concentration or an animal eye result cannot determine whether a human infection will respond. Human clinical efficacy, safety and the appropriate treatment setting need separate evidence."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/24936592/",
          "title": "Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "24936592",
          "doi": "10.1128/aac.02955-14",
          "pmcid": "PMC4135847"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/26501484/",
          "title": "An Independent Evaluation of a Novel Peptide Mimetic, Brilacidin (PMX30063), for Ocular Anti-infective.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "26501484",
          "doi": "10.1089/jop.2015.0098",
          "pmcid": "PMC4742993"
        }
      ]
    },
    {
      "slug": "cagrisema",
      "name": "CagriSema",
      "canonical_id": "cagrisema",
      "entry_kind": "combination",
      "aliases": [],
      "identity": "Combination of cagrilintide and semaglutide, not a single peptide. Two phase 3 reports examine it in adults with type 2 diabetes.",
      "classification": "combination",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Combination of cagrilintide and semaglutide, not a single peptide. Two phase 3 reports examine it in adults with type 2 diabetes.",
      "evidence_level": "Human randomized trials",
      "limitations": "The combination and its individual components are not interchangeable; trial publication does not by itself establish regulatory approval. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "CagriSema attracts interest because combining two appetite-related medicines may improve weight and blood-sugar outcomes.",
        "what_it_is_used_or_studied_for": "It combines cagrilintide and semaglutide; it is not a separate single peptide. The included phase 3 studies involve adults with type 2 diabetes.",
        "what_human_evidence_shows": "One trial found better average blood-sugar reduction than semaglutide alone. Another found improved blood sugar and reduced body weight when added to basal insulin, compared with placebo.",
        "important_drawbacks": "Gastrointestinal disorders were the most common unwanted effects in the active treatment groups. Findings in these diabetes populations do not automatically establish the same benefit for everyone seeking weight loss, and the combination must be considered alongside existing medicines."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/42251859/",
          "title": "Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "42251859",
          "doi": "10.1016/s2213-8587(26)00125-7"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/42251856/",
          "title": "Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "42251856",
          "doi": "10.1016/s0140-6736(26)01022-6"
        }
      ]
    },
    {
      "slug": "glepaglutide",
      "name": "Glepaglutide",
      "canonical_id": "glepaglutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Long-acting GLP-2 analogue examined in randomized short-bowel-syndrome studies of intestinal absorption, transit and motility.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Long-acting GLP-2 analogue examined in randomized short-bowel-syndrome studies of intestinal absorption, transit and motility.",
      "evidence_level": "Human randomized trials",
      "limitations": "Several reports arise from a small phase 2 program; they should not be counted as multiple large independent trials. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Glepaglutide is of interest to people with short bowel syndrome who struggle to absorb enough fluid and nutrients.",
        "what_it_is_used_or_studied_for": "It is a long-acting version of the intestinal-support hormone GLP-2. Researchers are studying whether it can improve absorption and reduce intestinal fluid losses.",
        "what_human_evidence_shows": "An early randomized study found improved intestinal absorption at some of the tested treatment levels. Related research suggested slower movement through the gut, which may help explain improved absorption.",
        "important_drawbacks": "Early improvements in absorption do not guarantee lasting independence from intravenous support. The studies were limited in size and duration, so longer trials are needed to clarify the overall balance of benefit and unwanted effects."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/30880176/",
          "title": "Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "30880176",
          "doi": "10.1016/s2468-1253(19)30077-9"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32022286/",
          "title": "Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "32022286",
          "doi": "10.1002/jpen.1767"
        }
      ]
    },
    {
      "slug": "larazotide-acetate",
      "name": "Larazotide acetate",
      "canonical_id": "larazotide-acetate",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Oral peptide studied as a tight-junction regulator in people with celiac disease, including gluten-challenge and persistent-symptom trials.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Oral peptide studied as a tight-junction regulator in people with celiac disease, including gluten-challenge and persistent-symptom trials.",
      "evidence_level": "Human randomized trials",
      "limitations": "Research in celiac disease does not establish a treatment for nonspecific intestinal symptoms or replace a prescribed gluten-free diet. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Larazotide interests people with celiac disease who continue to have symptoms despite following a gluten-free diet.",
        "what_it_is_used_or_studied_for": "It is an experimental oral peptide intended to influence the barriers between intestinal cells. Researchers have studied persistent symptoms and responses to a controlled gluten challenge.",
        "what_human_evidence_shows": "Trials found improvement in some symptoms, but results were mixed. In one gluten-challenge study, a main test of intestinal permeability did not differ significantly from placebo.",
        "important_drawbacks": "It should not be presented as permission to eat gluten or as a replacement for a gluten-free diet. Symptom improvement and a proposed intestinal-barrier mechanism are different from demonstrating consistent control of celiac disease."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/25683116/",
          "title": "Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "25683116",
          "doi": "10.1053/j.gastro.2015.02.008",
          "pmcid": "PMC4446229"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/23163616/",
          "title": "Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "23163616",
          "doi": "10.1111/apt.12147"
        }
      ]
    },
    {
      "slug": "mazdutide",
      "name": "Mazdutide",
      "canonical_id": "mazdutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [
        "IBI362",
        "LY3305677"
      ],
      "identity": "Dual GLP-1 and glucagon receptor agonist, also called IBI362 or LY3305677, studied in randomized trials in Chinese adults with overweight or obesity.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Dual GLP-1 and glucagon receptor agonist, also called IBI362 or LY3305677, studied in randomized trials in Chinese adults with overweight or obesity.",
      "evidence_level": "Human randomized trials",
      "limitations": "The study jurisdiction and participant population must be stated; these papers do not determine current authorization in the United States. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Mazdutide attracts interest for weight reduction through a combination of appetite-related and metabolic hormone pathways.",
        "what_it_is_used_or_studied_for": "It activates GLP-1 and glucagon receptors. The included trials involved Chinese adults with overweight or obesity.",
        "what_human_evidence_shows": "In a 24-week randomized trial, average weight loss ranged from roughly 7% to 11% across treatment groups, compared with a small weight increase with placebo.",
        "important_drawbacks": "Diarrhea and nausea were among the common unwanted effects. Results from a defined population and limited follow-up do not settle long-term outcomes or predict an individual response. Regulatory availability also depends on country and cannot be inferred from publication of a successful trial."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/38092790/",
          "title": "A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "38092790",
          "doi": "10.1038/s41467-023-44067-4",
          "pmcid": "PMC10719339"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/36247927/",
          "title": "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "36247927",
          "doi": "10.1016/j.eclinm.2022.101691",
          "pmcid": "PMC9561728"
        }
      ]
    },
    {
      "slug": "pemvidutide",
      "name": "Pemvidutide",
      "canonical_id": "pemvidutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Dual GLP-1 and glucagon receptor agonist examined in a randomized study of people with metabolic dysfunction-associated steatotic liver disease.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Dual GLP-1 and glucagon receptor agonist examined in a randomized study of people with metabolic dysfunction-associated steatotic liver disease.",
      "evidence_level": "Human randomized trial",
      "limitations": "The cited short trial assessed liver-fat-related outcomes in a defined cohort; it does not establish universal weight-loss benefit or current authorization. No dosing or self-treatment protocol is provided. The research paper and registry record describe the same trial, rather than independent replications.",
      "reader_summary": {
        "why_people_are_interested": "Pemvidutide attracts interest for reducing excess liver fat as well as body weight in people with metabolic liver disease.",
        "what_it_is_used_or_studied_for": "It activates GLP-1 and glucagon pathways and has been studied in people with metabolic dysfunction-associated steatotic liver disease, commonly called fatty liver disease.",
        "what_human_evidence_shows": "A randomized trial found greater reductions in liver fat, markers of liver inflammation and body weight than placebo.",
        "important_drawbacks": "Less liver fat is encouraging, but it does not by itself prove prevention of cirrhosis or longer survival. The linked registration and research paper describe the same trial. Longer-term outcomes, side effects and current treatment availability require separate assessment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39002641/",
          "title": "Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "39002641",
          "doi": "10.1016/j.jhep.2024.07.006"
        },
        {
          "url": "https://clinicaltrials.gov/study/NCT05006885",
          "title": "ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)",
          "supports": "Confirms the registered phase 1 randomized study of ALT-801/pemvidutide in people with fatty liver disease, actual enrollment 95; links to the same PMID 39002641 research publication already included.",
          "additional_document_vs_comparator": true,
          "source_kind": "ClinicalTrials.gov, US National Library of Medicine; sponsor-submitted primary trial registration",
          "read_scope": "Registry and research publication describe the same study and must not be counted as two independent trials. No study results were posted in this registry response."
        }
      ]
    },
    {
      "slug": "petrelintide",
      "name": "Petrelintide",
      "canonical_id": "petrelintide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Long-acting human amylin analogue described in medicinal-chemistry work and two randomized phase 1 pharmacology trials.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Long-acting human amylin analogue described in medicinal-chemistry work and two randomized phase 1 pharmacology trials.",
      "evidence_level": "Peptide-development research and human phase 1 trials",
      "limitations": "Early tolerability and pharmacology results require later-stage confirmation and do not establish an approved indication. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Petrelintide interests researchers seeking another way to support weight management, potentially with a different tolerability profile from existing medicines.",
        "what_it_is_used_or_studied_for": "It is a long-acting version of amylin, a natural hormone involved in feeling full after eating.",
        "what_human_evidence_shows": "Two early randomized human studies reported clinically relevant weight loss and relatively few gastrointestinal adverse events. The results supported further clinical development.",
        "important_drawbacks": "Early studies cannot establish that it is safer or more effective than established medicines in everyday care. The suggestion of improved stomach-and-bowel tolerability needs direct confirmation, and larger, longer trials are needed to establish durable benefits and detect less common unwanted effects."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/41217931/",
          "title": "Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "41217931",
          "doi": "10.1021/acs.jmedchem.5c01185",
          "pmcid": "PMC12670398"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/42017294/",
          "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "42017294",
          "doi": "10.1111/dom.70753",
          "pmcid": "PMC13243934"
        }
      ]
    },
    {
      "slug": "pn-943",
      "name": "PN-943",
      "canonical_id": "pn-943",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Oral integrin-targeting peptide studied for pharmacokinetics and target engagement in healthy volunteers. A separate completed phase 2 ulcerative colitis trial is registered, without posted results in the cited registry response.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Oral integrin-targeting peptide studied for pharmacokinetics and target engagement in healthy volunteers. A separate completed phase 2 ulcerative colitis trial is registered, without posted results in the cited registry response.",
      "evidence_level": "Human phase 1 pharmacology studies",
      "limitations": "Healthy-volunteer target engagement is not evidence of clinical disease benefit or current regulatory approval. No dosing or self-treatment protocol is provided. A completed registry entry is evidence of a trial, not evidence that treatment succeeded.",
      "reader_summary": {
        "why_people_are_interested": "PN-943 interests researchers looking for an oral treatment that targets intestinal inflammation while limiting exposure elsewhere in the body.",
        "what_it_is_used_or_studied_for": "It targets an integrin pathway involved in immune-cell movement and has been studied for ulcerative colitis, an inflammatory disease of the colon.",
        "what_human_evidence_shows": "A healthy-volunteer study found low bloodstream exposure and evidence that the drug engaged its intended target. A separate phase 2 ulcerative-colitis trial is listed as completed, without posted results in the cited registration.",
        "important_drawbacks": "Target engagement is not proof that symptoms or inflammation improve. The included human evidence does not establish a successful ulcerative-colitis treatment or justify replacing existing care."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33942566/",
          "title": "Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "33942566",
          "doi": "10.1002/cpdd.946",
          "pmcid": "PMC8597174"
        },
        {
          "url": "https://clinicaltrials.gov/study/NCT04504383",
          "title": "PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)",
          "supports": "Documents a completed registered phase 2 randomized study in active ulcerative colitis, with actual enrollment 169; registration alone does not establish a positive result.",
          "additional_document_vs_comparator": true,
          "source_kind": "ClinicalTrials.gov, US National Library of Medicine; sponsor-submitted primary trial registration",
          "read_scope": "Sponsor-submitted study design and completion metadata only; no inference of efficacy or regulatory approval. No study results were posted in this registry response."
        }
      ]
    },
    {
      "slug": "survodutide",
      "name": "Survodutide",
      "canonical_id": "survodutide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [
        "BI 456906"
      ],
      "identity": "Dual glucagon and GLP-1 receptor agonist, also called BI 456906, examined in randomized phase 2 studies in obesity and type 2 diabetes.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Dual glucagon and GLP-1 receptor agonist, also called BI 456906, examined in randomized phase 2 studies in obesity and type 2 diabetes.",
      "evidence_level": "Human randomized trials",
      "limitations": "The cited studies involve defined research cohorts and regimens; they are not dosing instructions or an approval determination. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Survodutide attracts interest for improving body weight and blood sugar through two complementary hormone pathways.",
        "what_it_is_used_or_studied_for": "It activates glucagon and GLP-1 receptors. The included phase 2 studies examine adults with obesity and adults with type 2 diabetes.",
        "what_human_evidence_shows": "The studies found reductions in body weight, and the diabetes trial also found improved average blood sugar. The degree of weight loss varied with the treatment group.",
        "important_drawbacks": "Gastrointestinal adverse events were common in the diabetes trial. Phase 2 improvements do not establish long-term health outcomes or mean that all people will tolerate treatment. Findings from the particular comparison regimens should not be turned into a universal superiority claim."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/38330987/",
          "title": "Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "38330987",
          "doi": "10.1016/s2213-8587(23)00356-x"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/38095657/",
          "title": "Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "38095657",
          "doi": "10.1007/s00125-023-06053-9",
          "pmcid": "PMC10844353"
        }
      ]
    },
    {
      "slug": "bpc-157",
      "name": "BPC-157",
      "canonical_id": "bpc-157",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Fifteen-amino-acid research peptide investigated in rat gastric-injury experiments and rat tendon-cell/explant models.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "United States, checked 29 October 2026: BPC-157 is not an FDA-approved treatment. HHS has released a narrowly conditional 503A compounding policy covering specified BPC-157 identities. Its companion notice describes the policy as draft and nonbinding; publication is scheduled for 30 October. This does not establish clinical effectiveness or make all products marketed as BPC-157 equivalent.",
      "evidence_summary": "Animal and tendon-cell studies report repair-related effects. A small retrospective knee-pain report found subjective improvement without a control group or validated functional outcomes; a separate two-person intravenous pilot provides only very limited short-term safety observations.",
      "evidence_level": "Small uncontrolled human reports and preclinical research",
      "limitations": "Reported pain improvement does not establish tendon repair, and small short-duration human reports cannot establish general safety or treatment efficacy. Exact formulation, route and study population matter.",
      "reader_summary": {
        "why_people_are_interested": "BPC-157 attracts interest for injury recovery and digestive problems because animal experiments suggest effects on tissue repair. Those findings have led to questions about whether it can help people heal.",
        "what_it_is_used_or_studied_for": "It is a 15-amino-acid research peptide. Human reports include knee pain and a very small intravenous safety pilot; animal and cell studies have examined stomach injury and tendon-repair processes.",
        "what_human_evidence_shows": "In a clinic chart review, 11 of 12 people who received BPC-157 alone reported improved knee pain. There was no comparison group or validated measurement of function. This did not demonstrate tendon repair. A separate intravenous pilot reported no short-term side effects in two adults who had previously received it.",
        "important_drawbacks": "These small, uncontrolled reports cannot establish treatment benefit or detect uncommon or long-term harms. The intravenous pilot lasted only days. A conditional draft compounding policy does not make BPC-157 an FDA-approved treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/9298922/",
          "title": "The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "9298922",
          "doi": "10.1016/s0014-2999(97)01033-9"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/21030672/",
          "title": "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "21030672",
          "doi": "10.1152/japplphysiol.00945.2010"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34324435/",
          "title": "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.",
          "supports": "Retrospective chart review: 17 identified, 16 reached by phone; 12 received BPC-157 alone, with 11 reporting pain improvement. Four received BPC-157 plus TB4 and must not be pooled as BPC-only evidence. No specific validated functional or quality-of-life measurements.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC; independent planning agent also inspected the actual full PDF.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/40131143/",
          "title": "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.",
          "supports": "Two adults with prior intravenous BPC-157 exposure had brief observation and biomarker monitoring; no short-term side effects reported. This cannot establish general or long-term safety.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research",
          "read_scope": "Actual full indexed abstract read through Europe PMC; not an independent full-article review.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://www.fda.gov/media/193343/download",
          "title": "FDA July 2026 PCAC scientific assessment: BPC-157-related bulk drug substances",
          "supports": "Describes small human studies, limited safety monitoring, uncertain molecular forms and inability to infer long-term safety; distinguishes bulk evaluation from approval.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator scientific assessment / policy record",
          "read_scope": "Actual primary PDF sections on clinical safety, pharmacokinetics, Appendix 1 and identity inspected.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf",
          "title": "HHS policy regarding 503A compounding using certain peptide bulk drug substances",
          "supports": "Conditional compounding policy, specified identities and single-active-ingredient condition; compounded products are not FDA-approved.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator scientific assessment / policy record",
          "read_scope": "Actual cached PDF text inspected; central policy scope independently reviewed by quality agent.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://public-inspection.federalregister.gov/2026-22192.pdf",
          "title": "HHS notice of availability, FR Doc 2026-22192",
          "supports": "Draft/nonbinding status and scheduled 30 October 2026 publication.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator scientific assessment / policy record",
          "read_scope": "Actual source previously inspected by central independent quality review; current proposal preserves that reviewed dated scope.",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "kpv",
      "name": "KPV",
      "canonical_id": "kpv",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [
        "Lysine-proline-valine"
      ],
      "identity": "Lysine-proline-valine tripeptide corresponding to the C-terminal segment of alpha-MSH, examined in mouse inflammation and rabbit fever experiments.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Lysine-proline-valine tripeptide corresponding to the C-terminal segment of alpha-MSH, examined in mouse inflammation and rabbit fever experiments.",
      "evidence_level": "Preclinical animal research",
      "limitations": "Animal experiments do not establish human anti-inflammatory efficacy or safety. Any conditional compounding policy is not FDA approval. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "KPV attracts research interest because it may influence inflammation without using the full-length hormone from which it is derived.",
        "what_it_is_used_or_studied_for": "It is a three-amino-acid fragment of alpha-MSH, a hormone involved in several body signals. The included studies examine inflammation and fever in animals.",
        "what_human_evidence_shows": "The cited experiments found reduced ear swelling in mice and reduced fever in rabbits. They are not trials showing symptom relief in people.",
        "important_drawbacks": "An anti-inflammatory effect in an animal model does not establish that KPV treats human bowel disease, skin disease or another inflammatory condition. The potential benefit remains a research question, and human safety and effectiveness cannot be inferred from these experiments."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/2550304/",
          "title": "Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "2550304",
          "doi": "10.1096/fasebj.3.11.2550304"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/6333677/",
          "title": "Effect of alpha-MSH 11-13 (lysine-proline-valine) on fever in the rabbit.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "6333677",
          "doi": "10.1016/0196-9781(84)90027-5"
        }
      ]
    },
    {
      "slug": "aod-9604",
      "name": "AOD-9604",
      "canonical_id": "aod-9604",
      "entry_kind": "Research compound related to a growth hormone fragment",
      "aliases": [],
      "identity": "Growth-hormone-fragment-related compound discussed in an FDA advisory review of proposed compounding substances. FDA staff described limitations of the obesity studies and lack of significant weight loss in several reviewed comparisons.",
      "classification": "Research compound related to a growth hormone fragment",
      "regulatory_status": "Jurisdiction: United States. Product: AOD-9604-related bulk substances. Indication: Historical 2024 compounding review for obesity. Note: An advisory transcript is not FDA product approval, current legal permission or a current all-jurisdiction status determination.",
      "evidence_summary": "Growth-hormone-fragment-related compound discussed in an FDA advisory review of proposed compounding substances. FDA staff described limitations of the obesity studies and lack of significant weight loss in several reviewed comparisons.",
      "evidence_level": "Human-development evidence reviewed in historic FDA advisory proceedings",
      "limitations": "Historical FDA staff review is not a modern full peer-reviewed clinical evidence base. It does not justify efficacy or safety claims for present-day formulations. Free-base and acetate identity were distinguished in the proceeding; do not assume one name identifies an interchangeable product. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "AOD-9604 is discussed for potential fat-loss effects, but the clinical evidence deserves particular caution.",
        "what_it_is_used_or_studied_for": "It is a modified growth-hormone fragment, distinct from the native hGH 176–191 sequence. FDA scientists reviewed it in connection with proposed pharmacy compounding uses.",
        "what_human_evidence_shows": "In the reviewed obesity evidence, FDA staff described important limitations and a lack of significant weight loss in several trial comparisons. That is a reason to question confident weight-loss promises.",
        "important_drawbacks": "The agency’s 2024 briefing and meeting discussion were scientific advisory materials, not proof of benefit or current permission to use a product. Free-base and acetate forms also require careful identification."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/media/185641/download",
          "title": "FDA Pharmacy Compounding Advisory Committee transcript, December 4 2024, Topic 2: AOD-9604-related bulk drug substances",
          "supports": "FDA staff reviewed AOD-9604 identity, effectiveness-study limitations and safety concerns; source is historical advisory material, not current approval or compounding permission.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA-hosted primary advisory-meeting transcript",
          "read_scope": "Historic regulatory discussion, not a2026 legal-status determination."
        },
        {
          "url": "https://www.fda.gov/media/183584/download",
          "title": "FDA Briefing Document: Evaluation of AOD-9604-Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee",
          "supports": "Pages 3–7 of the staff memorandum distinguish AOD-9604 free base and acetate, describe AOD-9604 as hGH 177–191 plus an N-terminal tyrosine, and explain the agency advisory evaluation context.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, original agency staff evaluation memorandum",
          "read_scope": "Historical November 2024 staff evaluation, separate from the December meeting transcript. The cover states FDA had not issued a final determination; this document is not current approval or permission."
        }
      ]
    },
    {
      "slug": "5-amino-1mq",
      "name": "5-Amino-1MQ",
      "canonical_id": "5-amino-1mq",
      "entry_kind": "Nonpeptide small molecule",
      "aliases": [],
      "identity": "Small-molecule NNMT inhibitor rather than a peptide. Additional primary studies examine cancer-cell activity and tumor models.",
      "classification": "Nonpeptide small molecule",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Small-molecule NNMT inhibitor rather than a peptide. Additional primary studies examine cancer-cell activity and tumor models.",
      "evidence_level": "Preclinical cell and animal research",
      "limitations": "Cell-line and mouse tumor findings do not establish weight-loss, muscle-recovery or cancer-treatment benefit in humans. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "5-Amino-1MQ draws interest because blocking the enzyme NNMT might affect cell metabolism, a topic relevant to several experimental treatments.",
        "what_it_is_used_or_studied_for": "Despite appearing in peptide discussions, it is a small molecule rather than a peptide. The sources included here examine cancer cells and tumor-related mechanisms.",
        "what_human_evidence_shows": "One laboratory study found reduced growth of cervical-cancer cells. Other research examined NNMT-related biology in bladder-cancer models. These findings do not demonstrate a benefit from taking 5-Amino-1MQ in people.",
        "important_drawbacks": "Laboratory anticancer activity cannot establish a safe cancer treatment, and it does not establish human fat-loss or anti-aging benefits. Human effectiveness and safety need direct clinical evidence."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33645410/",
          "title": "Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "33645410",
          "doi": "10.1080/01443615.2020.1854696"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39067875/",
          "title": "NAD+ metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "39067875",
          "doi": "10.1136/jitc-2024-009281",
          "pmcid": "PMC11284830"
        }
      ]
    },
    {
      "slug": "fragment-176-191",
      "name": "Fragment 176-191",
      "canonical_id": "fragment-176-191",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Native hGH 176–191 fragment examined in rat glucose and insulin experiments and in a breast-cancer cell nanoparticle experiment. These studies do not establish a human fat-loss treatment.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Native hGH 176–191 fragment examined in rat glucose and insulin experiments and in a breast-cancer cell nanoparticle experiment. These studies do not establish a human fat-loss treatment.",
      "evidence_level": "Animal and cell experiments",
      "limitations": "The native 176–191 sequence and the modified peptide AOD-9604 must not be treated as interchangeable evidence. Animal glucose/insulin findings and cell experiments do not demonstrate clinical fat loss, safety or benefit in people. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Fragment 176–191 is discussed for possible metabolic or fat-loss effects, but the exact molecule and the outcome measured are important.",
        "what_it_is_used_or_studied_for": "It is a native end fragment of human growth hormone. It should not be assumed to be identical to the modified peptide AOD-9604.",
        "what_human_evidence_shows": "The included research examines rat glucose and insulin responses and a breast-cancer cell experiment involving nanoparticles. Neither study demonstrates clinical weight loss in people.",
        "important_drawbacks": "The rat study actually found short-lived blood-sugar increases and changes in insulin response, rather than establishing a desirable fat-loss treatment. Cell and animal findings cannot establish human benefit, long-term safety or an appropriate treatment regimen."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/35783198/",
          "title": "Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "35783198",
          "doi": "10.2147/dddt.s367586",
          "pmcid": "PMC9249349"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/645904/",
          "title": "Hyperglycemic action of synthetic C-terminal fragments of human growth hormone.",
          "supports": "Direct study of synthetic native hGH 176–191 among other C-terminal fragments in normal rats; supports the distinction between animal glucose/insulin physiology and clinical fat-loss claims.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; core metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level animal-study verification. Rat metabolic findings do not establish human efficacy or safety.",
          "pmid": "645904",
          "doi": "10.1152/ajpendo.1978.234.5.e521"
        }
      ]
    },
    {
      "slug": "cyclosporine",
      "name": "Cyclosporine",
      "canonical_id": "cyclosporine",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Calcineurin-inhibitor immunosuppression research includes randomized kidney-transplant regimen comparisons and observational graft-survival analyses.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records include prescription products. Product: CYCLOSPORINE; GENGRAF; NEORAL; SANDIMMUNE. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Calcineurin-inhibitor immunosuppression research includes randomized kidney-transplant regimen comparisons and observational graft-survival analyses.",
      "evidence_level": "Human randomized and observational studies",
      "limitations": "These are transplant populations and combination regimens; research findings do not support unsupervised immune modulation or describe every formulation. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Cyclosporine is relevant to people who need suppression of immune activity, especially in transplant care where rejection can threaten a donated organ.",
        "what_it_is_used_or_studied_for": "It reduces certain immune-cell signals. The included studies examine kidney-transplant treatment regimens and changes in graft survival over time.",
        "what_human_evidence_shows": "A large randomized comparison found that a tacrolimus-based regimen had advantages over the cyclosporine-based regimens tested for several transplant outcomes. This helps place cyclosporine among treatment options rather than showing it is always best.",
        "important_drawbacks": "These are complex combinations of medicines, so an outcome cannot be attributed to one drug alone. Suppressing immunity requires specialist monitoring and a careful balance between treatment benefit and unwanted effects."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18094377/",
          "title": "Reduced exposure to calcineurin inhibitors in renal transplantation.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "18094377",
          "doi": "10.1056/nejmoa067411"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/10699159/",
          "title": "Improved graft survival after renal transplantation in the United States, 1988 to 1996.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "10699159",
          "doi": "10.1056/nejm200003023420901"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22CYCLOSPORINE%22&limit=100",
          "title": "Drugs@FDA application/product records matching CYCLOSPORINE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=065017",
          "display_title": "FDA: CYCLOSPORINE approval history (selected product)"
        }
      ]
    },
    {
      "slug": "enfuvirtide",
      "name": "Enfuvirtide",
      "canonical_id": "enfuvirtide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [
        "T-20"
      ],
      "identity": "Synthetic peptide HIV fusion inhibitor also called T-20, examined in treatment-experienced HIV-1 patients and early resistance research.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: United States. Classification: FDA records list discontinued products. Product: FUZEON. Indication: Not assigned from application metadata; consult current product labeling. Note: Original application approval and marketing-status fields were inspected. These records do not approve every use, research product, compounded formulation or product with a similar name; listing is not an inventory/availability guarantee. A discontinued listing does not by itself establish withdrawal of approval.",
      "evidence_summary": "Synthetic peptide HIV fusion inhibitor also called T-20, examined in treatment-experienced HIV-1 patients and early resistance research.",
      "evidence_level": "Human randomized trial and resistance research",
      "limitations": "The trials concern defined antiretroviral regimens; resistance and treatment selection require specialist management. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Enfuvirtide is relevant to HIV treatment when previous antiretroviral medicines have stopped working adequately.",
        "what_it_is_used_or_studied_for": "It blocks an early step in HIV entering cells and was studied as an addition to an individually optimized background regimen.",
        "what_human_evidence_shows": "In treatment-experienced people with HIV-1, adding enfuvirtide improved viral suppression and immune-system measures over 24 weeks compared with the background regimen alone.",
        "important_drawbacks": "Early research also documented rapid emergence of resistance, highlighting the importance of an effective combination regimen. It is not a stand-alone cure or a general immune booster. The checked US FDA Fuzeon product entry is listed as discontinued, so present availability requires separate confirmation."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/12773645/",
          "title": "Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "12773645",
          "doi": "10.1056/nejmoa035211"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/12019106/",
          "title": "Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "12019106",
          "doi": "10.1128/aac.46.6.1896-1905.2002",
          "pmcid": "PMC127242"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ENFUVIRTIDE%22&limit=100",
          "title": "Drugs@FDA application/product records matching ENFUVIRTIDE",
          "supports": "Specific original-application approval and current marketing-status fields for the listed products; not indication or formulation equivalence.",
          "additional_document_vs_comparator": true,
          "source_kind": "U.S. FDA, openFDA Drugs@FDA database",
          "read_scope": "FDA database metadata, not a full current prescribing-label review.",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021481",
          "display_title": "FDA: FUZEON approval history (selected product)"
        }
      ]
    },
    {
      "slug": "polymyxin-b-colistin",
      "name": "Polymyxin B / Colistin",
      "canonical_id": "polymyxin-b-colistin",
      "entry_kind": "Grouped peptide-derived antibiotics",
      "aliases": [],
      "identity": "Grouped antibiotic entry: polymyxin B has human pharmacokinetic research, while colistin appears as a comparator in a serious bacterial-infection trial.",
      "classification": "Grouped peptide-derived antibiotics",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Grouped antibiotic entry: polymyxin B has human pharmacokinetic research, while colistin appears as a comparator in a serious bacterial-infection trial.",
      "evidence_level": "Human pharmacokinetic and randomized studies",
      "limitations": "Polymyxin B, colistin and colistimethate formulations must not be treated as one interchangeable drug; infection-site, organism and toxicity considerations remain clinical decisions. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Polymyxin B and colistin matter mainly in specialist treatment of serious bacterial infections when resistance limits other options.",
        "what_it_is_used_or_studied_for": "They are related antibiotics but are not interchangeable names for one medicine. The included sources cover polymyxin B drug-handling research and a trial using colistin as a comparison treatment.",
        "what_human_evidence_shows": "In the infection trial, a newer antibiotic combination met the study’s criterion for comparable survival outcomes to colistin. The polymyxin B study helped characterize how the medicine behaves in seriously ill patients.",
        "important_drawbacks": "Kidney toxicity occurred in 38% of the colistin group versus 13% with the newer combination in that trial. This does not describe every use of either antibiotic. Infection type, the exact medicine and close clinical monitoring matter."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/23697744/",
          "title": "Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "23697744",
          "doi": "10.1093/cid/cit334"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37182534/",
          "title": "Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK).",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "37182534",
          "doi": "10.1016/s1473-3099(23)00184-6"
        }
      ]
    },
    {
      "slug": "aviptadil",
      "name": "Aviptadil",
      "canonical_id": "aviptadil",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Vasoactive intestinal peptide formulation examined in pulmonary-hypertension physiology and a randomized critical-COVID-19 study.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Vasoactive intestinal peptide formulation examined in pulmonary-hypertension physiology and a randomized critical-COVID-19 study.",
      "evidence_level": "Human interventional studies",
      "limitations": "Different disease settings and formulations are not interchangeable. These sources do not establish current U.S. authorization or general lung-health benefit. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Aviptadil attracts research interest because it may affect lung blood vessels and inflammatory responses during severe lung disease.",
        "what_it_is_used_or_studied_for": "It is a synthetic version of vasoactive intestinal peptide. The included studies examine pulmonary hypertension and critical COVID-19 respiratory failure.",
        "what_human_evidence_shows": "A small pulmonary-hypertension study found modest, short-lived effects. An early COVID-19 trial missed its main outcome. A later US trial involving 461 treated participants was stopped for futility and found no clear improvement in its main 90-day outcome.",
        "important_drawbacks": "Encouraging secondary results do not overturn unsuccessful main outcomes. The later negative trial strengthens the need for caution; these studies do not establish a dependable treatment for severe lung disease."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/18978135/",
          "title": "Inhalation of vasoactive intestinal peptide in pulmonary hypertension.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "18978135",
          "doi": "10.1183/09031936.00050008"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/36044317/",
          "title": "The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "36044317",
          "doi": "10.1097/ccm.0000000000005660",
          "pmcid": "PMC9555831"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/37348524/",
          "title": "Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial",
          "additional_document_vs_comparator": false,
          "supports": "Material later negative human clinical efficacy context; not an additional-source novelty claim.",
          "read_scope": "Abstract-level verification; no treatment protocol reproduced.",
          "source_kind": "Primary randomized clinical research indexed by PubMed"
        }
      ]
    },
    {
      "slug": "murepavadin",
      "name": "Murepavadin",
      "canonical_id": "murepavadin",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Antipseudomonal peptidomimetic examined in human renal-impairment pharmacokinetics and bacterial LptD-target mechanism research.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Antipseudomonal peptidomimetic examined in human renal-impairment pharmacokinetics and bacterial LptD-target mechanism research.",
      "evidence_level": "Human pharmacology and preclinical mechanism research",
      "limitations": "Pharmacokinetic tolerability and bacterial mechanism experiments do not establish clinical infection-treatment efficacy or approval. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Murepavadin interests researchers seeking more targeted treatments for serious infections caused by Pseudomonas bacteria.",
        "what_it_is_used_or_studied_for": "It is an experimental antibiotic that interferes with an essential part of the bacterial outer membrane.",
        "what_human_evidence_shows": "The included human study examined drug exposure and tolerability, not whether infections were cured. People with reduced kidney function had higher and longer-lasting exposure to the medicine. Laboratory research helps explain its bacterial target.",
        "important_drawbacks": "Understanding how a medicine behaves in the body is necessary, but it is not proof that it improves survival or clears infection. Kidney-function differences matter, and clinical efficacy and the overall safety balance need separate evidence."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/30012756/",
          "title": "Pharmacokinetics, Tolerability, and Safety of Murepavadin, a Novel Antipseudomonal Antibiotic, in Subjects with Mild, Moderate, or Severe Renal Function Impairment.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "30012756",
          "doi": "10.1128/aac.00490-18",
          "pmcid": "PMC6125514"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29359918/",
          "title": "A Peptidomimetic Antibiotic Interacts with the Periplasmic Domain of LptD from Pseudomonas aeruginosa.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "29359918",
          "doi": "10.1021/acschembio.7b00822"
        }
      ]
    },
    {
      "slug": "nangibotide",
      "name": "Nangibotide",
      "canonical_id": "nangibotide",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "TREM-1-pathway peptide modulator studied in first-in-human safety/pharmacokinetics and a phase 2a septic-shock trial.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "TREM-1-pathway peptide modulator studied in first-in-human safety/pharmacokinetics and a phase 2a septic-shock trial.",
      "evidence_level": "Human phase 1 and randomized phase 2a studies",
      "limitations": "Early sepsis research does not establish a survival benefit, a general immune-boosting use or current product approval. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Nangibotide interests researchers trying to reduce the damaging immune response that can accompany septic shock, a life-threatening reaction to infection.",
        "what_it_is_used_or_studied_for": "It targets the TREM-1 immune-signaling pathway and has been studied in healthy volunteers and hospitalized patients with septic shock.",
        "what_human_evidence_shows": "An early trial in 49 patients found no significant increase in reported adverse events compared with placebo, but it also did not show significant improvement in the measured disease-response outcomes.",
        "important_drawbacks": "A small early trial cannot establish survival benefit or rule out uncommon harms. Findings that justify more research should not be described as proof that the medicine treats sepsis successfully or helps general immune health."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32468087/",
          "title": "Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "32468087",
          "doi": "10.1007/s00134-020-06109-z"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29885068/",
          "title": "A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "29885068",
          "doi": "10.1111/bcp.13668",
          "pmcid": "PMC6138490"
        }
      ]
    },
    {
      "slug": "thymosin-alpha-1",
      "name": "Thymosin alpha-1",
      "canonical_id": "thymosin-alpha-1",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Immunomodulatory peptide examined in a randomized severe-pancreatitis trial and a small open-label proof-of-concept study in immune-deficiency patients.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Immunomodulatory peptide examined in a randomized severe-pancreatitis trial and a small open-label proof-of-concept study in immune-deficiency patients.",
      "evidence_level": "Human randomized and small open-label studies",
      "limitations": "The pancreatitis trial did not establish its primary infection-prevention benefit; a small uncontrolled mood study cannot establish general efficacy or safety. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Thymosin alpha-1 attracts interest because it influences immune function and has been explored in illnesses involving altered immune responses.",
        "what_it_is_used_or_studied_for": "The included human studies examine severe pancreatitis and a very small group with immune deficiency and depression.",
        "what_human_evidence_shows": "A 508-patient pancreatitis trial did not significantly reduce infected pancreatic tissue. A later phase 3 sepsis trial also found no clear mortality benefit: 23.4% died within 28 days with thymosin alpha-1 versus 24.1% with placebo. A five-person uncontrolled mood study remains preliminary.",
        "important_drawbacks": "The larger negative trials do not support a broad promise of stronger immunity. The tiny uncontrolled mood findings answer a different question and need larger placebo-controlled confirmation."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/35713670/",
          "title": "Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "35713670",
          "doi": "10.1007/s00134-022-06745-7",
          "pmcid": "PMC9205279"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39867848/",
          "title": "Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency patients with depression.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "39867848",
          "doi": "10.1016/j.bbih.2024.100934",
          "pmcid": "PMC11762651"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/39814420/",
          "title": "The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial",
          "additional_document_vs_comparator": false,
          "supports": "Material later negative human clinical efficacy context; not an additional-source novelty claim.",
          "read_scope": "Abstract-level verification; no treatment protocol reproduced.",
          "source_kind": "Primary randomized clinical research indexed by PubMed"
        }
      ]
    },
    {
      "slug": "ll-37",
      "name": "LL-37",
      "canonical_id": "ll-37",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Human antimicrobial peptide examined in atopic-dermatitis tissue research and experimental antibacterial studies of mesenchymal stem-cell secretions.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Human antimicrobial peptide examined in atopic-dermatitis tissue research and experimental antibacterial studies of mesenchymal stem-cell secretions.",
      "evidence_level": "Human observational tissue and preclinical research",
      "limitations": "Studying endogenous expression or secreted peptide activity is not a clinical trial of injected LL-37 and does not establish such treatment benefit. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "LL-37 interests researchers because it is part of the body’s natural defense against microbes and may help explain differences in susceptibility to infection.",
        "what_it_is_used_or_studied_for": "It is a human antimicrobial peptide studied in skin tissue, cell experiments and animal infection models.",
        "what_human_evidence_shows": "A human skin study found lower levels in atopic dermatitis than in psoriasis. Laboratory work showed antibacterial activity, and experiments linked LL-37 to some antibacterial effects of stem-cell secretions.",
        "important_drawbacks": "Measuring a naturally occurring peptide is different from showing that administering it treats disease. These studies do not establish LL-37 as a safe treatment for eczema, infection or general immune support in people."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/12374875/",
          "title": "Endogenous antimicrobial peptides and skin infections in atopic dermatitis.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "12374875",
          "doi": "10.1056/nejmoa021481"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/20945332/",
          "title": "Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "20945332",
          "doi": "10.1002/stem.544",
          "pmcid": "PMC3293245"
        }
      ]
    },
    {
      "slug": "thymulin",
      "name": "Thymulin",
      "canonical_id": "thymulin",
      "entry_kind": "Peptide or peptide-derived compound",
      "aliases": [],
      "identity": "Zinc-associated thymic peptide factor studied in human zinc deficiency and experiments on the metal dependence of its biological activity.",
      "classification": "Peptide or peptide-derived compound",
      "regulatory_status": "Jurisdiction: Not independently assessed. Note: Research publications establish the described study context, not current regulatory authorization or market availability.",
      "evidence_summary": "Zinc-associated thymic peptide factor studied in human zinc deficiency and experiments on the metal dependence of its biological activity.",
      "evidence_level": "Human physiology and biochemical research",
      "limitations": "Endogenous-hormone measurements and metal-binding experiments do not establish benefit or safety from administering a thymulin product. No dosing or self-treatment protocol is provided.",
      "reader_summary": {
        "why_people_are_interested": "Thymulin attracts interest because it links zinc status with aspects of immune-cell function.",
        "what_it_is_used_or_studied_for": "It is a peptide factor associated with the thymus, an organ involved in immune-system development. Its biological activity depends on binding zinc.",
        "what_human_evidence_shows": "Small human studies found reduced thymulin activity in mild zinc deficiency, which improved after zinc supplementation. The researchers also observed changes in immune-cell measurements.",
        "important_drawbacks": "This does not show that taking thymulin treats an immune disease or slows aging. Correcting zinc deficiency and administering a thymic peptide are different interventions. The small physiology studies do not establish durable health benefits or the safety of thymulin treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/3262625/",
          "title": "Serum thymulin in human zinc deficiency.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "3262625",
          "doi": "10.1172/jci113717",
          "pmcid": "PMC442670"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/6957870/",
          "title": "Contribution of zinc and other metals to the biological activity of the serum thymic factor.",
          "supports": "Compound identity, study design and population summarized in this entry; no personalized indication or product-status inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary research indexed by PubMed; metadata and abstract retrieved from Europe PMC",
          "read_scope": "Abstract-level verification; full article not independently reviewed here.",
          "pmid": "6957870",
          "doi": "10.1073/pnas.79.17.5370",
          "pmcid": "PMC346898"
        }
      ]
    },
    {
      "slug": "albiglutide",
      "name": "Albiglutide",
      "canonical_id": "albiglutide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Eperzan/Tanzeum; albiglutide",
      "classification": "Recombinant GLP-1–albumin fusion protein",
      "regulatory_status": "EU Eperzan authorisation withdrawn 29 October 2018 at sponsor request for commercial reasons; FDA Purple Book lists Tanzeum marketing status Disc and original approval 15 April 2014.",
      "evidence_summary": "A historically approved type 2 diabetes medicine; withdrawal and approval records do not support current availability or longevity use.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Albiglutide is relevant mainly when understanding the history of GLP-1 medicines for type 2 diabetes.",
        "what_it_is_used_or_studied_for": "It was developed to improve blood-sugar control by mimicking a natural hormone, with a longer-lasting protein structure.",
        "what_human_evidence_shows": "It previously received US and EU authorization for diabetes treatment. The sources here establish its historical clinical role and later product withdrawal, rather than quantifying an individual person’s likely response.",
        "important_drawbacks": "Eperzan’s EU authorization was withdrawn for commercial reasons, and the FDA lists Tanzeum as discontinued. Historical approval does not mean it is currently available, and a commercial withdrawal does not by itself mean the medicine was ineffective."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/documents/assessment-report/public-statement-eperzan-withdrawal-marketing-authorisation-european-union_en.pdf",
          "title": "EMA Eperzan withdrawal public statement",
          "supports": "EU authorisation withdrawal 29 October 2018, commercial reasons; statement 23 November 2018",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator decision"
        },
        {
          "url": "https://purplebooksearch.fda.gov/index.cfm?blaNo=125431&event=productdetails",
          "title": "FDA Purple Book Tanzeum BLA 125431",
          "supports": "Identity, original US approval 15 April 2014 and discontinued marketing status",
          "additional_document_vs_comparator": true,
          "source_kind": "regulatory database"
        }
      ]
    },
    {
      "slug": "corticotropin",
      "name": "Corticotropin",
      "canonical_id": "corticotropin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Corticotropin; repository corticotropin; Acthar Gel",
      "classification": "ACTH-related pituitary peptide preparation",
      "regulatory_status": "FDA orphan database records approved infantile-spasm indication 15 October 2010; other labeled uses require the current product label.",
      "evidence_summary": "Acthar is a naturally sourced complex peptide mixture, not a single synthetic wellness peptide. The additional FDA approval record establishes a specific clinical indication, not general immune or anti-aging benefits.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Corticotropin is relevant in specialized treatment, including infantile spasms, a serious seizure disorder in very young children.",
        "what_it_is_used_or_studied_for": "Repository corticotropin is a complex hormone-related preparation that stimulates adrenal activity; it is not a single synthetic wellness peptide.",
        "what_human_evidence_shows": "FDA records document approval for the specific infantile-spasm indication. That establishes a defined clinical use, not evidence that it broadly improves immunity, energy or healthy aging.",
        "important_drawbacks": "The prescribing information describes substantial steroid-related effects and important restrictions, including some infections and uncontrolled high blood pressure. Treatment requires specialist supervision, and the exact product and disease matter when interpreting any benefit claim."
      },
      "sources": [
        {
          "url": "https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=168103",
          "title": "FDA orphan designation and approval record: repository corticotropin",
          "supports": "Approved infantile-spasm indication 15 October 2010; a designation alone would not establish approval",
          "additional_document_vs_comparator": true,
          "source_kind": "regulatory approval record"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22CORTICOTROPIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA022432 (H.P. ACTHAR GEL)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022432",
          "display_title": "FDA: H.P. ACTHAR GEL approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b48ddec-e815-45f4-9ca0-5c0daaf56f30",
          "title": "DailyMed ACTHAR (REPOSITORY CORTICOTROPIN) INJECTION ACTHAR (REPOSITORY CORTICOTROPIN) INJECTION [KEENOVA ARD LLC]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "cosyntropin",
      "name": "Cosyntropin",
      "canonical_id": "cosyntropin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Cosyntropin is synthetic ACTH(1–24), a diagnostic corticotropin analogue rather than repository corticotropin.",
      "classification": "Diagnostic peptide / adrenal stimulation agent",
      "regulatory_status": "United States: CORTROSYN NDA016750 has an original approval record dated 22 April 1970; current product labeling is diagnostic. Other jurisdictions and actual supply require separate checks.",
      "evidence_summary": "Two additional human diagnostic studies show that cortisol assay method changes interpretation of the short cosyntropin test. These are test-validation studies, not evidence that cosyntropin treats fatigue or adrenal disease.",
      "evidence_level": "",
      "limitations": "Assay-specific diagnostic thresholds are not interchangeable. This directory provides no test protocol or self-treatment advice.",
      "reader_summary": {
        "why_people_are_interested": "Cosyntropin is useful when clinicians need to find out whether the adrenal glands can make enough cortisol.",
        "what_it_is_used_or_studied_for": "It is a synthetic fragment of ACTH used to stimulate cortisol release during a diagnostic test. It is not a treatment for ordinary tiredness.",
        "what_human_evidence_shows": "Human diagnostic studies show that the laboratory method used to measure cortisol changes how the test should be interpreted. A result judged using the wrong reference range can be misleading.",
        "important_drawbacks": "A stimulation test helps answer a diagnostic question; it does not itself correct an adrenal disorder. Symptoms, other medicines and assay-specific interpretation need to be assessed together by a clinician."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/33768189/",
          "title": "New Cutoffs for the Biochemical Diagnosis of Adrenal Insufficiency after ACTH Stimulation using Specific Cortisol Assays.",
          "supports": "Retrospective 110-patient comparison of cortisol assays following ACTH stimulation; interpretation depends on the assay.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "33768189",
          "doi": "10.1210/jendso/bvab022"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29452421/",
          "title": "The Short Cosyntropin Test Revisited: New Normal Reference Range Using LC-MS/MS.",
          "supports": "Reference ranges derived from healthy subjects and referred patients using LC-MS/MS; not a therapeutic trial.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "29452421",
          "doi": "10.1210/jc.2017-02602"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22COSYNTROPIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA016750 (CORTROSYN)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016750",
          "display_title": "FDA: CORTROSYN approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c424fac-b114-41f6-aba8-cf710a34c26c",
          "title": "CORTROSYN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [HENRY SCHEIN, INC.]",
          "supports": "Identity, product-specific labeled indications and evidence scope; does not establish benefit for unrelated wellness uses.",
          "additional_document_vs_comparator": false,
          "source_kind": "official prescribing information"
        }
      ]
    },
    {
      "slug": "dulaglutide",
      "name": "Dulaglutide",
      "canonical_id": "dulaglutide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Dulaglutide; Trulicity",
      "classification": "GLP-1 receptor agonist fusion protein",
      "regulatory_status": "EU-authorised Trulicity for type 2 diabetes; US indications differ in detail and are product-label specific.",
      "evidence_summary": "EMA assessment discusses adult/pediatric type 2 diabetes studies and cardiovascular outcomes. Do not generalise those disease-population findings to healthy people.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Dulaglutide interests people with type 2 diabetes who need better blood-sugar control and, in some cases, lower cardiovascular risk.",
        "what_it_is_used_or_studied_for": "Trulicity mimics GLP-1 and has specific diabetes and cardiovascular indications in its US prescribing information.",
        "what_human_evidence_shows": "Regulator-reviewed trials found improved blood-sugar control. In a large cardiovascular study, major events occurred in 12.0% with dulaglutide versus 13.4% with placebo over about five years.",
        "important_drawbacks": "Nausea, vomiting and diarrhea are common. The US label also carries a thyroid-tumor warning based on animal findings, with specific restrictions for certain thyroid-cancer histories; the human risk is uncertain. Benefits in diabetes do not establish healthy-person enhancement."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity",
          "title": "EMA European public assessment report: Trulicity",
          "supports": "EU-authorised Trulicity for type 2 diabetes; US indications differ in detail and are product-label specific. EMA assessment discusses adult/pediatric type 2 diabetes studies and cardiovascular outcomes. Do not generalise those disease-population findings to healthy people.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DULAGLUTIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA125469 (TRULICITY)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125469",
          "display_title": "FDA: Trulicity approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309",
          "title": "DailyMed TRULICITY (DULAGLUTIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "elamipretide",
      "name": "Elamipretide",
      "canonical_id": "elamipretide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Elamipretide; Forzinity; SS-31",
      "classification": "Synthetic mitochondrial-targeting tetrapeptide",
      "regulatory_status": "FDA accelerated approval 19 September 2025 for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg.",
      "evidence_summary": "FDA trial snapshot describes 12 patients in a randomized crossover study and its open-label extension. The randomized primary endpoints were not superior to placebo; approval relied on an intermediate muscle-strength endpoint and requires confirmatory benefit verification.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Elamipretide interests researchers studying mitochondria, the energy-producing structures inside cells, but its approved use is narrowly defined.",
        "what_it_is_used_or_studied_for": "In the US, Forzinity received accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.",
        "what_human_evidence_shows": "The small randomized study did not beat placebo on its main walking-distance and fatigue outcomes. Approval relied on a muscle-strength measure, with longer open-label observations informing the assessment.",
        "important_drawbacks": "Confirmatory clinical benefit still needs verification. This rare-disease approval does not establish an anti-aging, general energy or athletic-performance treatment. A small uncontrolled extension cannot provide the same certainty as a successful randomized trial."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-forzinity",
          "title": "FDA Drug Trials Snapshot: Forzinity",
          "supports": "Original 19 September 2025 approval population,12 patient randomized crossover and extension, primary-endpoint limitations",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator clinical assessment"
        },
        {
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000Approv.pdf",
          "title": "FDA Forzinity accelerated approval letter NDA 215244",
          "supports": "Specific Barth-syndrome indication and accelerated-approval status 19 September 2025",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator approval letter"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75",
          "title": "DailyMed FORZINITY (ELAMIPRETIDE HYDROCHLORIDE) INJECTION [STEALTH BIOTHERAPEUTICS INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "exenatide",
      "name": "Exenatide",
      "canonical_id": "exenatide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Exenatide; Byetta; Bydureon formulations are distinct products",
      "classification": "GLP-1 receptor agonist peptide",
      "regulatory_status": "EU Byetta authorisation withdrawn 1 January 2026 for commercial reasons. This is not a blanket worldwide or molecule-wide withdrawal statement.",
      "evidence_summary": "EMA confirms prior type 2 diabetes indication. Do not equate a brand withdrawal with proof the molecule lacks biological activity or with current US availability.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Exenatide is relevant to blood-sugar treatment in type 2 diabetes and to understanding earlier GLP-1 medicines.",
        "what_it_is_used_or_studied_for": "It mimics a hormone involved in glucose control. Different formulations and combination products are separate medicines and should not be treated as one interchangeable product.",
        "what_human_evidence_shows": "Its past authorization reflects a defined diabetes use. The regulator sources included here focus on that clinical role and product status rather than supplying a new head-to-head benefit estimate.",
        "important_drawbacks": "The EU authorization for Byetta was withdrawn in January 2026 for commercial reasons. That does not determine the availability or status of every exenatide product worldwide, and it is not evidence for general weight-loss or wellness use."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/byetta",
          "title": "EMA European public assessment report: Byetta",
          "supports": "EU Byetta authorisation withdrawn 1 January 2026 for commercial reasons. This is not a blanket worldwide or molecule-wide withdrawal statement. EMA confirms prior type 2 diabetes indication. Do not equate a brand withdrawal with proof the molecule lacks biological activity or with current US availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22EXENATIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA021773 (BYETTA)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021773",
          "display_title": "FDA: BYETTA approval history"
        }
      ]
    },
    {
      "slug": "insulin-analogs-multiple",
      "name": "Insulin analogs (multiple)",
      "canonical_id": "insulin-analogs-multiple",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Insulin analogs is a family, including rapid-acting and long-acting modified insulins; it is not one molecule. Insulin glargine is one long-acting example.",
      "classification": "Family of therapeutic peptide/protein hormones",
      "regulatory_status": "United States: specific insulin analog products have FDA approvals. SEMGLEE insulin glargine-yfgn BLA761201 has an original approval dated 28 July 2021. This cannot be generalized to every named analog, formulation or compounded preparation.",
      "evidence_summary": "The additional LANTUS official label describes randomized active-controlled studies in adults and children with diabetes. Its findings apply to insulin glargine and diabetes management, not bodybuilding or wellness.",
      "evidence_level": "",
      "limitations": "Insulin products differ in pharmacology and interchangeability. Hypoglycemia can be severe. A family grouping must not imply that all insulin analog products are clinically interchangeable.",
      "reader_summary": {
        "why_people_are_interested": "Insulin analogues matter when the body cannot make enough insulin or needs help maintaining safe blood sugar.",
        "what_it_is_used_or_studied_for": "This is a family of medicines, including faster-acting and longer-acting products. Insulin glargine is one long-acting example used in diabetes care.",
        "what_human_evidence_shows": "Randomized studies in the Lantus label found blood-sugar improvement generally similar to NPH insulin across the studied diabetes populations. The result applies to that product and comparison, rather than every insulin analogue.",
        "important_drawbacks": "Insulin can cause dangerously low blood sugar, and products differ in how quickly and how long they act. It is not a bodybuilding or wellness supplement, and switching products requires careful clinical planning."
      },
      "sources": [
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a",
          "title": "LANTUS (INSULIN GLARGINE) INJECTION, SOLUTION LANTUS SOLOSTAR (INSULIN GLARGINE) INJECTION, SOLUTION [SANOFI-AVENTIS U.S. LLC]",
          "supports": "Identity, product-specific labeled indications and evidence scope; does not establish benefit for unrelated wellness uses.",
          "additional_document_vs_comparator": true,
          "source_kind": "official prescribing information"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22INSULIN+GLARGINE%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA761201 (SEMGLEE)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761201",
          "display_title": "FDA: SEMGLEE approval history"
        }
      ]
    },
    {
      "slug": "lixisenatide",
      "name": "Lixisenatide",
      "canonical_id": "lixisenatide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Lixisenatide; Lyxumia; Adlyxin are jurisdiction-specific product names",
      "classification": "GLP-1 receptor agonist peptide",
      "regulatory_status": "EU Lyxumia authorisation withdrawn 18 December 2025 at sponsor request for commercial reasons.",
      "evidence_summary": "Previously authorised for type 2 diabetes. Product-specific marketing status must be distinguished from clinical effects and from lixisenatide-containing combination products.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Lixisenatide is relevant to type 2 diabetes treatment and to the development of medicines that target the GLP-1 pathway.",
        "what_it_is_used_or_studied_for": "It was authorized as a blood-sugar medicine. A stand-alone product and a product combining it with insulin have separate treatment contexts.",
        "what_human_evidence_shows": "The regulator information confirms its historical diabetes indication. It does not establish a broad benefit for people without diabetes or a reason to choose it over every newer treatment.",
        "important_drawbacks": "The EU authorization for the stand-alone brand Lyxumia was withdrawn in December 2025 for commercial reasons. This is a product-and-region-specific change, not proof that every lixisenatide-containing medicine is unavailable worldwide."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia",
          "title": "EMA European public assessment report: Lyxumia",
          "supports": "EU Lyxumia authorisation withdrawn 18 December 2025 at sponsor request for commercial reasons. Previously authorised for type 2 diabetes. Product-specific marketing status must be distinguished from clinical effects and from lixisenatide-containing combination products.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22LIXISENATIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA208471 (ADLYXIN)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208471",
          "display_title": "FDA: ADLYXIN approval history"
        }
      ]
    },
    {
      "slug": "mecasermin",
      "name": "Mecasermin",
      "canonical_id": "mecasermin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Mecasermin; Increlex; not IGF-1 DES or IGF-1 LR 3",
      "classification": "Recombinant human IGF-1 protein",
      "regulatory_status": "EU-authorised Increlex for severe primary IGF-1 deficiency with growth failure in children/adolescents.",
      "evidence_summary": "EMA describes clinical studies in children with severe deficiency. This evidence does not establish bodybuilding, anti-aging or enhancement use in healthy adults.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Mecasermin is relevant to children whose poor growth results from severe deficiency of IGF-1, a hormone needed for normal growth.",
        "what_it_is_used_or_studied_for": "It replaces IGF-1 in a narrowly defined medical condition. It is not the same as giving growth hormone and is not a general height or muscle supplement.",
        "what_human_evidence_shows": "In studies of children with severe deficiency, average growth increased from 2.8 cm per year before treatment to 8.0 cm in the first year. Most studies did not include a comparison treatment, which limits certainty about the size of benefit.",
        "important_drawbacks": "Low blood sugar, headache and vomiting are common reported effects, and treatment is restricted in active abnormal cell growth. Benefits in severe deficiency do not establish safe bodybuilding, anti-aging or general enhancement use."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/increlex",
          "title": "EMA European public assessment report: Increlex",
          "supports": "EU-authorised Increlex for severe primary IGF-1 deficiency with growth failure in children/adolescents. EMA describes clinical studies in children with severe deficiency. This evidence does not establish bodybuilding, anti-aging or enhancement use in healthy adults.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22MECASERMIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA021839 (INCRELEX)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021839",
          "display_title": "FDA: Increlex approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce",
          "title": "DailyMed INCRELEX (MECASERMIN) INJECTION [ETON PHARMACEUTICALS, INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "pasireotide",
      "name": "Pasireotide",
      "canonical_id": "pasireotide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Pasireotide; Signifor; formulation-specific indications",
      "classification": "Cyclic somatostatin analogue peptide",
      "regulatory_status": "EU-authorised for specified adults with Cushing disease or acromegaly when relevant surgery/other treatments are unsuitable or inadequate.",
      "evidence_summary": "EMA assessment covers disease-specific human trials; hormonal indication, formulation and hyperglycaemia risks must not be collapsed into a general hormone-optimisation claim.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Pasireotide is relevant when excess hormone production causes Cushing disease or acromegaly and other treatments are unsuitable or insufficient.",
        "what_it_is_used_or_studied_for": "It reduces hormone-release signals. The particular formulation and indication matter because the treatment goals differ between these diseases.",
        "what_human_evidence_shows": "Human trials found normalization or reduction of excess cortisol in some Cushing-disease patients and improvement in growth-hormone-related measures in some patients with acromegaly. Many patients did not achieve the target response.",
        "important_drawbacks": "High blood sugar and diabetes are important risks; diarrhea, abdominal pain and gallstones also occur. It should not be described as general hormone optimization, and benefit needs to be balanced against disease-specific risks."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/signifor",
          "title": "EMA European public assessment report: Signifor",
          "supports": "EU-authorised for specified adults with Cushing disease or acromegaly when relevant surgery/other treatments are unsuitable or inadequate. EMA assessment covers disease-specific human trials; hormonal indication, formulation and hyperglycaemia risks must not be collapsed into a general hormone-optimisation claim.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PASIREOTIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA200677 (SIGNIFOR)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200677",
          "display_title": "FDA: SIGNIFOR approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74",
          "title": "DailyMed SIGNIFOR (PASIREOTIDE) INJECTION [RECORDATI RARE DISEASES, INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "pegvisomant",
      "name": "Pegvisomant",
      "canonical_id": "pegvisomant",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Pegvisomant; Somavert",
      "classification": "PEGylated growth-hormone analogue protein; receptor antagonist",
      "regulatory_status": "EU-authorised Somavert for specified adult acromegaly patients inadequately controlled by other interventions.",
      "evidence_summary": "This blocks the growth-hormone receptor; it is not a growth-hormone-releasing peptide. EMA discusses human IGF-1 normalisation and liver monitoring.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Pegvisomant is relevant to people with acromegaly whose excess growth-hormone activity remains inadequately controlled.",
        "what_it_is_used_or_studied_for": "It blocks growth-hormone receptors, rather than stimulating growth hormone. Treatment aims to bring IGF-1, a hormone downstream of growth hormone, into the normal range.",
        "what_human_evidence_shows": "In the regulator-reviewed 12-week study, IGF-1 normalized more often with pegvisomant than placebo, with results varying across treatment groups.",
        "important_drawbacks": "Headache, diarrhea and joint pain are common reported effects. Hormone normalization is a meaningful treatment goal but does not establish cure or eliminate the need for specialist follow-up. This is not an enhancement medicine for healthy adults."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/somavert",
          "title": "EMA European public assessment report: Somavert",
          "supports": "EU-authorised Somavert for specified adult acromegaly patients inadequately controlled by other interventions. This blocks the growth-hormone receptor; it is not a growth-hormone-releasing peptide. EMA discusses human IGF-1 normalisation and liver monitoring.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PEGVISOMANT%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA021106 (SOMAVERT)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021106",
          "display_title": "FDA: Somavert approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cbb485b-6df1-49ce-8747-592b395b1988",
          "title": "DailyMed SOMAVERT (PEGVISOMANT) KIT [PHARMACIA & UPJOHN COMPANY LLC]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "pramlintide",
      "name": "Pramlintide",
      "canonical_id": "pramlintide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Pramlintide is a synthetic 37-amino-acid analogue of human amylin, supplied as pramlintide acetate.",
      "classification": "Amylin analogue peptide",
      "regulatory_status": "United States: FDA application NDA021332 records original SYMLIN approval on 16 March 2005. Current SYMLINPEN labeling is adjunctive treatment for selected insulin-treated patients with type 1 or type 2 diabetes; the older vial product record is marked discontinued and does not settle current pen availability.",
      "evidence_summary": "An additional 29-week randomized placebo-controlled trial in 296 people with type 1 diabetes studied pramlintide with intensive insulin therapy. HbA1c reductions were similar between arms, while postprandial glucose and weight differed.",
      "evidence_level": "",
      "limitations": "Do not equate this with established weight-loss treatment for people without diabetes. The label warns about severe hypoglycemia with insulin.",
      "reader_summary": {
        "why_people_are_interested": "Pramlintide can be relevant when mealtime insulin alone is not achieving the desired diabetes control.",
        "what_it_is_used_or_studied_for": "It mimics amylin, a hormone that helps regulate blood sugar after meals, and is used alongside insulin in selected patients.",
        "what_human_evidence_shows": "A randomized type 1 diabetes trial found smaller after-meal blood-sugar rises and lower weight with pramlintide. Average long-term blood-sugar improvement was similar between the treatment and placebo groups.",
        "important_drawbacks": "The US label carries a boxed warning for severe low blood sugar when combined with insulin, particularly in type 1 diabetes. Benefits require careful treatment planning; it does not replace insulin or make unsupervised insulin changes safe."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/17003291/",
          "title": "A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.",
          "supports": "Direct randomized human trial in insulin-treated type 1 diabetes; disease-specific efficacy and adverse-event context.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "17003291",
          "doi": "10.2337/dc06-0042"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PRAMLINTIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA021332 (SYMLIN)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021332",
          "display_title": "FDA: SYMLIN approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff",
          "title": "SYMLINPEN (PRAMLINTIDE ACETATE) INJECTION [ASTRAZENECA PHARMACEUTICALS LP]",
          "supports": "Identity, product-specific labeled indications and evidence scope; does not establish benefit for unrelated wellness uses.",
          "additional_document_vs_comparator": false,
          "source_kind": "official prescribing information"
        }
      ]
    },
    {
      "slug": "secretin",
      "name": "Secretin",
      "canonical_id": "secretin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Synthetic human secretin is a 27-amino-acid peptide matching the human hormone; porcine secretin is a distinct product identity.",
      "classification": "Diagnostic gastrointestinal peptide hormone",
      "regulatory_status": "United States: CHIRHOSTIM synthetic human secretin NDA021256 original approval is recorded as 9 April 2004. Its labeled uses aid pancreatic/gastrinoma diagnosis and selected endoscopic identification; this is not general gastrointestinal treatment.",
      "evidence_summary": "A randomized crossover study in 12 healthy adults compared two methods of collecting pancreatic fluid after secretin stimulation. It evaluated diagnostic agreement, not therapeutic benefit.",
      "evidence_level": "",
      "limitations": "Healthy-subject diagnostic method validation does not establish treatment for digestive symptoms, autism or other unrelated conditions.",
      "reader_summary": {
        "why_people_are_interested": "Secretin can help doctors investigate pancreatic function and certain hormone-secreting tumors.",
        "what_it_is_used_or_studied_for": "Synthetic human secretin stimulates digestive secretions during diagnostic procedures. Its value is in helping a test answer a medical question, rather than treating everyday indigestion.",
        "what_human_evidence_shows": "The included small human study compared methods of collecting pancreatic fluid after stimulation. It assessed diagnostic agreement, not relief of symptoms or treatment of disease.",
        "important_drawbacks": "Some liver conditions can alter the response and mask pancreatic disease, according to the label. Results therefore need interpretation alongside other clinical information. Diagnostic authorization does not establish benefit as a general digestive supplement or treatment for unrelated conditions."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16454842/",
          "title": "A randomized crossover study of secretin-stimulated endoscopic and dreiling tube pancreatic function test methods in healthy subjects.",
          "supports": "Primary 12-subject randomized crossover comparison of secretin-stimulated endoscopic versus Dreiling-tube pancreatic function tests.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "16454842",
          "doi": "10.1111/j.1572-0241.2006.00407.x"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SECRETIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA021256 (CHIRHOSTIM)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021256",
          "display_title": "FDA: CHIRHOSTIM approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd",
          "title": "CHIRHOSTIM (HUMAN SECRETIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION CHIRHOSTIM 40 (HUMAN SECRETIN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [CHIRHOCLIN, INC.]",
          "supports": "Identity, product-specific labeled indications and evidence scope; does not establish benefit for unrelated wellness uses.",
          "additional_document_vs_comparator": false,
          "source_kind": "official prescribing information"
        }
      ]
    },
    {
      "slug": "somapacitan",
      "name": "Somapacitan",
      "canonical_id": "somapacitan",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Somapacitan; somapacitan-beco in US; Sogroya",
      "classification": "Long-acting human growth-hormone analogue protein",
      "regulatory_status": "EU-authorised for adult growth-hormone deficiency and paediatric growth failure from growth-hormone deficiency; US label has separately defined indications.",
      "evidence_summary": "EMA human assessment concerns replacement therapy in diagnosed deficiency. It does not support healthy-adult anti-aging claims.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Somapacitan is relevant to people with diagnosed growth-hormone deficiency who need replacement therapy.",
        "what_it_is_used_or_studied_for": "It is a longer-acting growth-hormone medicine. Specific approved growth-related conditions depend on the product label and country.",
        "what_human_evidence_shows": "Regulator-reviewed studies found reduced abdominal body fat in deficient adults compared with placebo, and growth in deficient children comparable to daily somatropin. These are replacement-treatment results in diagnosed patients.",
        "important_drawbacks": "Headache, swelling, joint pain and high blood sugar are reported effects. It must not be used in certain situations including active tumors or acute serious illness. Benefits in deficiency do not establish anti-aging or athletic enhancement in healthy people."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya",
          "title": "EMA European public assessment report: Sogroya",
          "supports": "EU-authorised for adult growth-hormone deficiency and paediatric growth failure from growth-hormone deficiency; US label has separately defined indications. EMA human assessment concerns replacement therapy in diagnosed deficiency. It does not support healthy-adult anti-aging claims.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SOMAPACITAN%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA761156 (SOGROYA)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156",
          "display_title": "FDA: SOGROYA approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eadd03b4-adc3-4b88-8a24-9d205c5b85aa",
          "title": "DailyMed SOGROYA (SOMAPACITAN-BECO) INJECTION, SOLUTION [NOVO NORDISK]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "somatropin-rhgh",
      "name": "Somatropin (rhGH)",
      "canonical_id": "somatropin-rhgh",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Somatropin; rhGH; Omnitrope is one product example",
      "classification": "Recombinant human growth-hormone protein family",
      "regulatory_status": "EU Omnitrope is an authorised somatropin biosimilar with specified growth-disorder and adult-deficiency indications. Other brands need their own labels.",
      "evidence_summary": "Somatropin names a family, not a unique molecule/product approval. EMA describes biosimilarity and disease-specific replacement indications, not general wellness.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Somatropin is relevant when a person has a diagnosed need for growth-hormone replacement or a specifically approved growth disorder.",
        "what_it_is_used_or_studied_for": "It is manufactured human growth hormone, available in different branded products with their own indications. It should not be treated as a single universal wellness product.",
        "what_human_evidence_shows": "In one regulator-reviewed comparison, children with growth-hormone deficiency grew similarly with the biosimilar Omnitrope and the reference product Genotropin.",
        "important_drawbacks": "Swelling, joint or muscle pain and tingling can occur, particularly in adults. Active tumors and certain acute life-threatening illnesses are important restrictions. Evidence for treating deficiency does not establish longer life, healthy-adult rejuvenation or safe bodybuilding use."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope",
          "title": "EMA European public assessment report: Omnitrope",
          "supports": "EU Omnitrope is an authorised somatropin biosimilar with specified growth-disorder and adult-deficiency indications. Other brands need their own labels. This comparator entry is a family, not a unique molecule/product approval. EMA describes biosimilarity and disease-specific replacement indications, not general wellness.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SOMATROPIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA021426 (OMNITROPE)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021426",
          "display_title": "FDA: OMNITROPE approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1058e17c-9261-459c-a3e6-fae38d196c14",
          "title": "DailyMed NORDITROPIN (SOMATROPIN) INJECTION, SOLUTION [NOVO NORDISK]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "efpeglenatide",
      "name": "Efpeglenatide",
      "canonical_id": "efpeglenatide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Efpeglenatide is a long-acting modified exendin GLP-1 receptor agonist conjugated to an immunoglobulin Fc fragment through a linker.",
      "classification": "Investigational GLP-1 receptor agonist peptide conjugate",
      "regulatory_status": "The verified sources establish clinical investigation; a current marketing authorization in any jurisdiction is not established by these sources. Do not label it approved or universally unavailable without a separate current regulator check.",
      "evidence_summary": "Two additional phase II randomized trials studied glycemic outcomes in metformin-treated type 2 diabetes and weight change in adults with overweight/obesity without diabetes. They are distinct from the AMPLITUDE-O cardiovascular publications.",
      "evidence_level": "",
      "limitations": "Short phase II biomarker/weight results do not establish long-term safety, broad use or current regulatory approval.",
      "reader_summary": {
        "why_people_are_interested": "Efpeglenatide attracts interest as a long-acting approach to improving blood sugar and body weight.",
        "what_it_is_used_or_studied_for": "It activates the GLP-1 pathway and has been studied in type 2 diabetes and in adults with overweight or obesity.",
        "what_human_evidence_shows": "A phase 2 placebo-controlled diabetes trial found improvements in average blood sugar and weight. A separate weight-management trial studied adults without diabetes alongside a reduced-calorie diet.",
        "important_drawbacks": "Short trials cannot establish long-term safety, durable weight loss or the best treatment for an individual. Publication of promising results does not itself establish current marketing authorization. The outcomes also need to be interpreted in the context of the study population and accompanying lifestyle intervention."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/32128957/",
          "title": "Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.",
          "supports": "Additional phase II randomized study of once-monthly efpeglenatide in type 2 diabetes; 16-week disease-specific glycemic and weight outcomes.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "32128957",
          "doi": "10.1111/dom.14020"
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6851541/",
          "title": "Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study",
          "supports": "BALANCE phase II randomized placebo-controlled 20-week study in 297 adults with overweight/obesity without diabetes, with a hypocaloric diet; weight and adverse events measured.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "31264757",
          "doi": "10.1111/dom.13824"
        }
      ]
    },
    {
      "slug": "mots-c",
      "name": "MOTS-c",
      "canonical_id": "mots-c",
      "entry_kind": "other",
      "aliases": [],
      "identity": "MOTS-c is a 16-amino-acid mitochondrial-derived peptide. Endogenous MOTS-c measurements, synthetic MOTS-c and investigational analogues must be distinguished.",
      "classification": "Mitochondrial-derived research peptide",
      "regulatory_status": "United States, checked 29 October 2026: no FDA-approved MOTS-c product is established by these sources. HHS has released a narrowly conditional 503A policy covering MOTS-c acetate; its Federal Register notice calls the policy draft and nonbinding, filed 28 October and scheduled for publication 30 October. This is not FDA approval or blanket access.",
      "evidence_summary": "An additional 2018 primary mechanistic paper studies stress-related nuclear translocation and gene regulation. FDA’s July 2026 assessment identifies major gaps in exogenous human exposure, pharmacokinetics and safety evidence; neither establishes clinical anti-aging or exercise benefit.",
      "evidence_level": "",
      "limitations": "Cell and rodent effects cannot be presented as proven benefit in people. Current conditional policy must be described separately from the scientific evidence; see the dated compounding-policy section in this guide.",
      "reader_summary": {
        "why_people_are_interested": "MOTS-c interests researchers studying how cells respond to metabolic stress and how mitochondria communicate with the rest of the cell.",
        "what_it_is_used_or_studied_for": "It is a mitochondrial-derived research peptide, discussed in connection with metabolism, exercise and aging.",
        "what_human_evidence_shows": "The included laboratory study examines how cells respond to stress, not whether treatment improves health in people. The FDA assessment identifies major gaps in what happens when manufactured MOTS-c is given to people, including how the body absorbs and clears it and whether it is safe.",
        "important_drawbacks": "Research on naturally occurring MOTS-c is different from showing that administering a manufactured product improves health. Conditional compounding policy is also separate from FDA approval and evidence of benefit. Human anti-aging or exercise benefits remain unestablished by these sources."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/29983246/",
          "title": "The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress.",
          "supports": "Mechanistic work on MOTS-c nuclear translocation and cellular metabolic-stress gene regulation; not a human treatment trial.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "29983246",
          "doi": "10.1016/j.cmet.2018.06.008"
        },
        {
          "url": "https://www.fda.gov/media/193347/download",
          "title": "FDA July 2026 PCAC scientific assessment: MOTS-c",
          "supports": "Review distinguishes nonclinical pharmacology from missing in-vivo pharmacokinetic and toxicology information; clinical benefit is not established.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary regulator scientific assessment"
        },
        {
          "url": "https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf",
          "title": "HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances",
          "supports": "Narrow conditional interim compounding policy and exact Appendix B identities, separate from drug approval and evidence of benefit.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary federal policy document"
        },
        {
          "url": "https://public-inspection.federalregister.gov/2026-22192.pdf",
          "title": "HHS notice of availability: FR Doc 2026-22192",
          "supports": "Draft/nonbinding status, filing 28 October 2026 and scheduled publication 30 October 2026.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary federal regulatory notice"
        }
      ]
    },
    {
      "slug": "compounded-tesamorelin",
      "name": "Tesamorelin (off-label)",
      "canonical_id": "tesamorelin",
      "entry_kind": "use-context",
      "aliases": [],
      "identity": "Off-label tesamorelin is the same 44-amino-acid modified GHRH analogue used in approved tesamorelin products. Compounded tesamorelin is a preparation category, not a separately approved molecule.",
      "classification": "GHRH analogue peptide; off-label/preparation distinction",
      "regulatory_status": "United States: EGRIFTA is FDA approved for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The current EGRIFTA WR label expressly says it is not indicated for weight-loss management. A compounded preparation does not inherit FDA product approval.",
      "evidence_summary": "A new 2024 primary publication analyzes an integrase-inhibitor subgroup from an existing randomized HIV-associated fatty-liver trial; it is a secondary analysis, not an independent clinical trial. A distinct FDA clinical approval memorandum explains the original labeled indication and why reduced visceral fat did not establish cardiovascular benefit. Findings in HIV-specific populations do not establish healthy-adult or general weight-loss benefit.",
      "evidence_level": "",
      "limitations": "Do not equate off-label prescribing of an approved product with regulatory approval of compounded copies. The paper is not evidence of benefit in healthy adults.",
      "alias_of": "tesamorelin",
      "reader_summary": {
        "why_people_are_interested": "Tesamorelin attracts interest for reducing deep abdominal fat, but the established medical setting is specific.",
        "what_it_is_used_or_studied_for": "In the US, Egrifta is approved for excess abdominal fat in adults with HIV-associated lipodystrophy. The label says it is not indicated for general weight-loss management.",
        "what_human_evidence_shows": "A subgroup analysis in people with HIV taking integrase-inhibitor medicines found reductions in deep abdominal and liver fat. It analyzed an existing trial rather than independently confirming the result in a new study.",
        "important_drawbacks": "Reduced fat does not establish reduced cardiovascular events. Findings in HIV populations do not establish benefit in healthy adults, and a compounded preparation does not inherit the approved product’s FDA authorization."
      },
      "sources": [
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TESAMORELIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA022505 (EGRIFTA)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505",
          "display_title": "FDA: Egrifta approval history"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/38905488/",
          "title": "Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.",
          "supports": "Distinct 2024 analysis of the integrase-inhibitor subgroup of an existing HIV/MASLD randomized trial. It is an additional publication, not an independent new trial or evidence in healthy adults.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific analysis",
          "pmid": "38905488",
          "doi": "10.1097/qad.0000000000003965"
        },
        {
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022505Orig1s000ODMemo.pdf",
          "title": "FDA Summary Basis for Regulatory Action: Egrifta (tesamorelin), 10 November 2010",
          "supports": "Approval rationale limited to HIV-associated lipodystrophy, distinction between visceral-fat surrogate changes and unproven cardiovascular benefit, and known/unknown risk discussion.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary regulator clinical assessment"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/31611038/",
          "title": "Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.",
          "supports": "Primary randomized trial in HIV-associated NAFLD; 60 randomized participants and liver-fat outcomes over 12 months.",
          "additional_document_vs_comparator": false,
          "source_kind": "primary published scientific study",
          "pmid": "31611038",
          "doi": "10.1016/s2352-3018(19)30338-8"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75",
          "title": "EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]",
          "supports": "Identity, product-specific labeled indications and evidence scope; does not establish benefit for unrelated wellness uses.",
          "additional_document_vs_comparator": false,
          "source_kind": "official prescribing information"
        }
      ]
    },
    {
      "slug": "humanin",
      "name": "Humanin",
      "canonical_id": "humanin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Humanin is a mitochondrial-associated small research peptide; modified analogues and endogenous biomarker concentrations are separate from administering a humanin product.",
      "classification": "Mitochondrial-associated research peptide",
      "regulatory_status": "A current therapeutic marketing approval for humanin is not established by the verified sources. They do not establish an approved treatment for Alzheimer disease or aging.",
      "evidence_summary": "Two additional original 2001 papers identified humanin-related protection in neuronal cell systems involving familial Alzheimer-associated genes. These are discovery and cell-mechanism experiments, not human clinical efficacy trials.",
      "evidence_level": "",
      "limitations": "The presence of human-derived cells or a human gene in an experiment does not make it a clinical study. These findings cannot support anti-aging or neuroprotection claims in people.",
      "reader_summary": {
        "why_people_are_interested": "Humanin interests researchers investigating why some nerve cells resist damage associated with Alzheimer-related biology.",
        "what_it_is_used_or_studied_for": "It is a small mitochondrial-associated peptide studied in cell-protection experiments. Natural humanin levels and treatment with a manufactured peptide are separate questions.",
        "what_human_evidence_shows": "The included discovery studies found protection in neuronal cell systems involving Alzheimer-associated genes. Human genes or human-derived cells in an experiment do not make it a clinical treatment trial.",
        "important_drawbacks": "These studies do not show that administering humanin prevents dementia, restores memory or slows aging in people. Clinical effectiveness, appropriate treatment conditions and safety require direct human evidence, beyond an interesting cell-survival mechanism."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11371646/",
          "title": "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta.",
          "supports": "Original cell-screening/discovery work involving neuronal death models and Alzheimer-associated genes.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "11371646",
          "doi": "10.1073/pnas.101133498"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/11327724/",
          "title": "Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein.",
          "supports": "Primary cellular mechanism study involving Swedish-mutant amyloid precursor protein.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "11327724",
          "doi": "10.1006/bbrc.2001.4765"
        }
      ]
    },
    {
      "slug": "abaloparatide",
      "name": "Abaloparatide",
      "canonical_id": "abaloparatide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Abaloparatide; Eladynos in EU; Tymlos in US",
      "classification": "Parathyroid-hormone-related peptide analogue",
      "regulatory_status": "EU-authorised Eladynos for osteoporosis in postmenopausal women at increased fracture risk.",
      "evidence_summary": "EMA assesses fracture outcomes in women with osteoporosis. Do not generalise to healthy adults, athletic recovery or all osteoporosis populations.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Abaloparatide is relevant to people with osteoporosis who face an increased risk of fractures.",
        "what_it_is_used_or_studied_for": "It stimulates bone formation. The European product Eladynos is authorized for postmenopausal women with osteoporosis at increased fracture risk.",
        "what_human_evidence_shows": "In a main study, new spinal fractures occurred in 0.5% with abaloparatide versus 4.2% with placebo after 18 months. This is a direct fracture outcome, rather than only a change in a laboratory measurement.",
        "important_drawbacks": "High calcium in the urine and dizziness are common effects; palpitations can also occur. Important restrictions apply, including some kidney problems and bone-cancer risks. These disease-specific results do not establish athletic-recovery or healthy-adult enhancement benefits."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos",
          "title": "EMA European public assessment report: Eladynos",
          "supports": "EU-authorised Eladynos for osteoporosis in postmenopausal women at increased fracture risk. EMA assesses fracture outcomes in women with osteoporosis. Do not generalise to healthy adults, athletic recovery or all osteoporosis populations.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ABALOPARATIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA208743 (TYMLOS)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208743",
          "display_title": "FDA: Tymlos approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8",
          "title": "DailyMed TYMLOS (ABALOPARATIDE) INJECTION, SOLUTION [RADIUS HEALTH, INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "calcitonin-salmon",
      "name": "Calcitonin-salmon",
      "canonical_id": "calcitonin-salmon",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Calcitonin-salmon is a 32-amino-acid calcitonin receptor agonist; nasal and injectable formulations have different product-specific uses and risks.",
      "classification": "Therapeutic peptide hormone analogue",
      "regulatory_status": "United States: FDA Drugs@FDA includes approved calcitonin-salmon products, including ANDA219196 original approval on 9 July 2025. This database record does not establish stock or every formulation’s indication. EU use restrictions and United States labeling must be kept jurisdiction-specific.",
      "evidence_summary": "An additional randomized study in 50 older women after a pertrochanteric hip fracture measured bone turnover and bone density and followed subsequent fractures. It is a small disease-specific study, not proof of broad fracture prevention or recovery enhancement.",
      "evidence_level": "",
      "limitations": "Do not transfer findings from nasal salmon calcitonin to all formulations or present one small older study as overriding regulator assessments. Product labeling and contraindications matter.",
      "reader_summary": {
        "why_people_are_interested": "Salmon calcitonin is relevant to bone health because it slows the activity of cells that break down bone.",
        "what_it_is_used_or_studied_for": "Specific nasal and injectable medicines have been used for particular bone and calcium disorders. Their indications differ by formulation and country.",
        "what_human_evidence_shows": "A small randomized study in fifty older women after a hip fracture found differences in bone-turnover measurements and bone density. That study alone cannot establish broad prevention of future fractures.",
        "important_drawbacks": "Nasal and injectable findings are not interchangeable. The injection label includes serious allergic reactions, and safety information differs between formulations. This is a disease-specific medicine rather than a general bone-strengthening or exercise-recovery treatment."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/15125121/",
          "title": "The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial.",
          "supports": "Primary 50-patient randomized trial of nasal salmon calcitonin after pertrochanteric fracture; bone markers/BMD and longer follow-up.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "15125121",
          "doi": "10.1302/0301-620x.86b3.14300"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22CALCITONIN%22&limit=5",
          "title": "FDA Drugs@FDA application record: ANDA219196 (CALCITONIN-SALMON)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219196",
          "display_title": "FDA: CALCITONIN-SALMON approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26caf31f-7f7c-48a8-a1ac-35d2ceefda2b",
          "title": "MIACALCIN (CALCITONIN SALMON) INJECTION, SOLUTION [MYLAN INSTITUTIONAL LLC]",
          "supports": "Calcitonin-salmon injection identity and serious hypersensitivity risk, including anaphylaxis; label applies to Miacalcin injection, not every nasal product.",
          "additional_document_vs_comparator": true,
          "source_kind": "official prescribing information",
          "read_scope": "Actual cached DailyMed structured product label XML read: description, contraindications and mechanism. Contraindications explicitly include hypersensitivity reactions including anaphylaxis, bronchospasm and swelling. Cached106-label.xml and106-label.json."
        }
      ]
    },
    {
      "slug": "etelcalcetide",
      "name": "Etelcalcetide",
      "canonical_id": "etelcalcetide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Etelcalcetide is a synthetic peptide calcium-sensing receptor agonist supplied as a hydrochloride salt.",
      "classification": "Calcimimetic peptide",
      "regulatory_status": "United States: PARSABIV NDA208325 original approval is recorded as 7 February 2017; the labeled population is adults with secondary hyperparathyroidism and chronic kidney disease receiving hemodialysis. European Union: EMA records Parsabiv authorization on 11 November 2016 for the specified hemodialysis population.",
      "evidence_summary": "The additional FDA application database establishes approved product identity and original approval history. The official label summarizes two 26-week randomized placebo-controlled studies in the hemodialysis population.",
      "evidence_level": "",
      "limitations": "Approval is for a specific disease and route/product; it does not establish benefit for healthy calcium regulation, osteoporosis or wellness.",
      "reader_summary": {
        "why_people_are_interested": "Etelcalcetide addresses a complication of advanced kidney disease: excessive parathyroid hormone, which disrupts the body’s calcium and phosphate balance.",
        "what_it_is_used_or_studied_for": "The approved medicine Parsabiv is used for secondary hyperparathyroidism in adults receiving hemodialysis, a treatment that filters the blood when kidneys cannot do so adequately.",
        "what_human_evidence_shows": "The EMA describes controlled studies in dialysis patients showing greater reductions in parathyroid hormone than placebo. These are findings in a specific kidney-disease population.",
        "important_drawbacks": "Lowering a hormone measurement does not itself prove fewer fractures or better survival. Low blood calcium, muscle spasms, nausea and vomiting are recognized risks. These results do not establish a benefit for healthy adults."
      },
      "sources": [
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ETELCALCETIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA208325 (PARSABIV)",
          "supports": "Application number, exact active ingredient/product identity, original approval submission dates and database marketing category. A Prescription category is not proof of current inventory or local availability.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208325",
          "display_title": "FDA: Parsabiv approval history"
        },
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/parsabiv",
          "title": "EMA Parsabiv European public assessment overview",
          "supports": "EU-authorised etelcalcetide for adult secondary hyperparathyroidism with chronic kidney disease on hemodialysis; overview summarizes three 26-week studies involving 1,706 patients and reduction in parathyroid hormone.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary regulator assessment"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd270093-c6a8-4596-a4ab-e6aa0a2c8a0c",
          "title": "PARSABIV (ETELCALCETIDE) INJECTION, SOLUTION [AMGEN, INC]",
          "supports": "Identity, product-specific labeled indications and evidence scope; does not establish benefit for unrelated wellness uses.",
          "additional_document_vs_comparator": false,
          "source_kind": "official prescribing information"
        }
      ]
    },
    {
      "slug": "palopegteriparatide",
      "name": "Palopegteriparatide",
      "canonical_id": "palopegteriparatide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Palopegteriparatide; Yorvipath; TransConPTH development name",
      "classification": "Prodrug releasing PTH 1-34",
      "regulatory_status": "EU-authorised Yorvipath for adults with chronic hypoparathyroidism.",
      "evidence_summary": "EMA assessment describes an 84 patient controlled study of calcium regulation and conventional-therapy requirements. This is hormone replacement for a defined disorder, not a generic bone-building or longevity peptide.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "People with chronic hypoparathyroidism cannot produce enough parathyroid hormone, making normal calcium control difficult and often requiring substantial supplement treatment.",
        "what_it_is_used_or_studied_for": "Palopegteriparatide, sold as Yorvipath, releases a hormone fragment that replaces part of this missing signaling. It is approved for adults with chronic hypoparathyroidism.",
        "what_human_evidence_shows": "In an eighty-four-person study summarized by the EMA, substantially more treated participants maintained normal calcium without their usual active vitamin D and high-dose calcium treatment than participants receiving placebo.",
        "important_drawbacks": "The findings concern diagnosed hormone deficiency, not general wellness. Injection-site reactions, headache and unusual sensations such as pins and needles were common. The medicine is unsuitable for a related condition in which tissues do not respond properly to parathyroid hormone."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/yorvipath",
          "title": "EMA European public assessment report: Yorvipath",
          "supports": "EU-authorised Yorvipath for adults with chronic hypoparathyroidism. EMA assessment describes an 84 patient controlled study of calcium regulation and conventional-therapy requirements. This is hormone replacement for a defined disorder, not a generic bone-building or longevity peptide.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PALOPEGTERIPARATIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA216490 (YORVIPATH)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216490",
          "display_title": "FDA: Yorvipath approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1fa23fd-c434-443e-9a17-5750578c8602",
          "title": "DailyMed YORVIPATH (PALOPEGTERIPARATIDE) INJECTION, SOLUTION [ASCENDIS PHARMA, ENDOCRINOLOGY, INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label",
          "reader_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1fa23fd-c434-443e-9a17-5750578c8602",
          "display_title": "DailyMed: Yorvipath prescribing information"
        }
      ]
    },
    {
      "slug": "parathyroid-hormone",
      "name": "Parathyroid hormone",
      "canonical_id": "parathyroid-hormone",
      "entry_kind": "other",
      "aliases": [],
      "identity": "PTH; recombinant PTH 1-84/Natpar/Natpara; distinct from teriparatide 1-34",
      "classification": "Endogenous parathyroid hormone; full-length recombinant replacement product example",
      "regulatory_status": "EMA reports Natpar authorisation withdrawn 1 July 2026 because of product-specific unresolved supply issues.",
      "evidence_summary": "The natural hormone, full-length recombinant drug and shorter PTH analogues must remain distinct. The regulatory record establishes a specific product history, not current availability of every PTH therapy.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Parathyroid hormone helps regulate blood calcium, so replacing a deficiency can address a specific endocrine disorder rather than simply adding another calcium supplement.",
        "what_it_is_used_or_studied_for": "Full-length replacement hormone, including the former Natpar product, must be distinguished from shorter fragments such as teriparatide and from medicines that release those fragments.",
        "what_human_evidence_shows": "FDA approval history establishes a specific replacement product. It does not show that every product carrying the parathyroid-hormone name has the same clinical effects or evidence.",
        "important_drawbacks": "Availability is an important practical limitation: the EMA reports Natpar’s European authorization was withdrawn in July 2026 because of supply issues. Historical approval is separate from current access, and findings cannot be transferred between different hormone products."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/natpar",
          "title": "EMA European public assessment report: Natpar",
          "supports": "EMA reports Natpar authorisation withdrawn 1 July 2026 because of product-specific unresolved supply issues. The natural hormone, full-length recombinant drug and shorter PTH analogues must remain distinct. The regulatory record establishes a specific product history, not current availability of every PTH therapy.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PARATHYROID+HORMONE%22&limit=5",
          "title": "FDA Drugs@FDA application record: BLA125511 (NATPARA)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125511",
          "display_title": "FDA: NATPARA approval history"
        }
      ]
    },
    {
      "slug": "teriparatide",
      "name": "Teriparatide",
      "canonical_id": "teriparatide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Teriparatide; Forsteo/Forteo",
      "classification": "PTH 1-34 peptide analogue",
      "regulatory_status": "EU-authorised Forsteo for specified patients with osteoporosis at elevated fracture risk.",
      "evidence_summary": "EMA assesses human bone/fracture outcomes in osteoporosis populations. It is not interchangeable with full-length PTH 1-84 or palopegteriparatide simply because all activate the PTH pathway.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Teriparatide is relevant to osteoporosis because it stimulates bone formation, offering a different approach from medicines that mainly slow bone breakdown.",
        "what_it_is_used_or_studied_for": "Approved products are used for particular patients with osteoporosis and increased fracture risk. Teriparatide is a short fragment of parathyroid hormone, rather than the full-length hormone.",
        "what_human_evidence_shows": "In a controlled trial in postmenopausal women with osteoporosis, new spine fractures detected on X-rays occurred in 5.0% receiving FORTEO versus 14.3% receiving placebo; both groups also received calcium and vitamin D.",
        "important_drawbacks": "The FORTEO label lists nausea and joint pain among common adverse reactions and warns about raised blood calcium and temporary drops in blood pressure on standing. Findings in osteoporosis do not establish general exercise-recovery benefits."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/forsteo",
          "title": "EMA European public assessment report: Forsteo",
          "supports": "EU-authorised Forsteo for specified patients with osteoporosis at elevated fracture risk. EMA assesses human bone/fracture outcomes in osteoporosis populations. It is not interchangeable with full-length PTH 1-84 or palopegteriparatide simply because all activate the PTH pathway.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TERIPARATIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA218771 (TERIPARATIDE)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218771",
          "display_title": "FDA: teriparatide (selected product) approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0",
          "title": "DailyMed FORTEO (TERIPARATIDE) INJECTION, SOLUTION [ELI LILLY AND COMPANY]",
          "supports": "FORTEO human postmenopausal osteoporosis trial: new radiographic vertebral fractures5.0% versus14.3%placebo, both with calcium/vitaminD; common nausea/arthralgia and warnings about hypercalcemia and transient orthostatic hypotension.",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label",
          "read_scope": "Actual cached official DailyMed structured product label XML reread29Oct2026: section14.1 effect on fracture incidence (radiographic vertebral outcome,444versus448women inanalysis), sections5.3hypercalcemia,5.5orthostatic hypotension and6adverse reactions listing arthralgia,pain,nausea. Cached110-label.xml and110-label.json. No dosing included in reader profile.",
          "reader_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0",
          "display_title": "DailyMed: Forteo prescribing information"
        }
      ]
    },
    {
      "slug": "vosoritide",
      "name": "Vosoritide",
      "canonical_id": "vosoritide",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Vosoritide; Voxzogo",
      "classification": "C-type natriuretic peptide analogue",
      "regulatory_status": "EU-authorised Voxzogo for achondroplasia in patients aged 4 months and older whose bones are still growing.",
      "evidence_summary": "EMA describes paediatric controlled growth studies. These results do not establish adult height enhancement or general growth promotion.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Vosoritide is relevant to achondroplasia, a genetic condition affecting bone growth, because it targets a signaling pathway involved in that condition.",
        "what_it_is_used_or_studied_for": "The approved medicine Voxzogo is used in children whose growth plates remain open; the European authorization includes children from four months of age.",
        "what_human_evidence_shows": "In a controlled study of children aged five to seventeen, treated children grew about 1.57 centimeters more over a year than those receiving placebo. A separate younger-child study also found improved growth measures.",
        "important_drawbacks": "These results do not establish adult height enhancement or general growth promotion. Injection-site reactions, vomiting and reduced blood pressure are recognized side effects. Longer-term functional outcomes are a different question from one-year growth rate."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo",
          "title": "EMA European public assessment report: Voxzogo",
          "supports": "EU-authorised Voxzogo for achondroplasia in patients aged 4 months and older whose bones are still growing. EMA describes paediatric controlled growth studies. These results do not establish adult height enhancement or general growth promotion.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22VOSORITIDE%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA214938 (VOXZOGO)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214938",
          "display_title": "FDA: Voxzogo approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=228e8560-04a4-4bb1-a81f-29531a9e4d27",
          "title": "DailyMed VOXZOGO 0.4 MG (VOSORITIDE) KIT VOXZOGO 0.56 MG (VOSORITIDE) KIT VOXZOGO 1.2 MG (VOSORITIDE) KIT [BIOMARIN PHARMACEUTICAL INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "zilucoplan",
      "name": "Zilucoplan",
      "canonical_id": "zilucoplan",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Zilucoplan; Zilbrysq",
      "classification": "Cyclic peptide complement-C 5 inhibitor",
      "regulatory_status": "EU-authorised Zilbrysq as add-on treatment for adults with generalised myasthenia gravis who are anti-acetylcholine-receptor antibody positive.",
      "evidence_summary": "EMA describes a 174 adult controlled study and meningococcal-infection precautions. Do not generalise to non-autoimmune muscle weakness or athletic performance.",
      "evidence_level": "",
      "limitations": "Educational identity/evidence comparison, no dosing or treatment protocol. Regulator assessment is not an independent new efficacy trial. Jurisdiction and product boundaries preserved.",
      "reader_summary": {
        "why_people_are_interested": "Zilucoplan is relevant to myasthenia gravis because it blocks part of the immune process that disrupts communication between nerves and muscles.",
        "what_it_is_used_or_studied_for": "The approved medicine Zilbrysq is an additional treatment for adults with generalized myasthenia gravis who have particular acetylcholine-receptor antibodies.",
        "what_human_evidence_shows": "In a study of 174 adults, treated patients improved more than placebo on a scale measuring how the disease affects daily activities. That is clinical symptom evidence in a defined autoimmune condition.",
        "important_drawbacks": "Blocking this immune pathway increases the risk of meningococcal infection. Vaccination and other safeguards are important parts of the product’s restrictions. These findings do not support using it for ordinary muscle weakness or athletic performance."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/zilbrysq",
          "title": "EMA European public assessment report: Zilbrysq",
          "supports": "EU-authorised Zilbrysq as add-on treatment for adults with generalised myasthenia gravis who are anti-acetylcholine-receptor antibody positive. EMA describes a 174 adult controlled study and meningococcal-infection precautions. Do not generalise to non-autoimmune muscle weakness or athletic performance.",
          "additional_document_vs_comparator": true,
          "source_kind": "regulator assessment"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ZILUCOPLAN%22&limit=5",
          "title": "FDA Drugs@FDA application record: NDA216834 (ZILBRYSQ)",
          "supports": "Exact product/ingredient identity and original approval submission history. The database marketing category does not establish current stock or override a separate withdrawal/supply notice.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216834",
          "display_title": "FDA: Zilbrysq approval history"
        },
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f1d53d6-e495-4a3a-8bb9-680a15d25034",
          "title": "DailyMed ZILBRYSQ (ZILUCOPLAN) INJECTION, SOLUTION [UCB, INC.]",
          "supports": "Identity/description and product-specific indication; clinical study context only for named product",
          "additional_document_vs_comparator": false,
          "source_kind": "US structured product label"
        }
      ]
    },
    {
      "slug": "tb-500",
      "name": "TB-500",
      "canonical_id": "tb-500",
      "entry_kind": "other",
      "aliases": [],
      "identity": "TB-500 in the current HHS Appendix B means N-acetylated seven-amino-acid LKKTETQ acetate. It is distinct from full-length 43-amino-acid thymosin beta-4 and from the non-acetylated fragment.",
      "classification": "Synthetic acetylated thymosin beta-4 fragment",
      "regulatory_status": "United States, checked 29 October 2026: the HHS policy includes the specified TB-500 acetate identity under narrow conditional 503A discretion. The companion notice calls it draft and nonbinding and is scheduled for 30 October publication. Compounded TB-500 remains unapproved; no blanket approval or ban follows from old Category 2 status.",
      "evidence_summary": "FDA’s additional July 2026 assessment explains why full-length thymosin beta-4 and non-acetylated fragment experiments cannot be directly transferred to acetylated TB-500. Available cell/animal metabolism and wound studies do not establish clinical healing benefit.",
      "evidence_level": "",
      "limitations": "Commercial TB-500 naming can be ambiguous. Treat exact identity as essential, and do not claim that whole thymosin beta-4 clinical trials validate this seven-residue fragment.",
      "reader_summary": {
        "why_people_are_interested": "Interest centers on tissue repair, because TB-500 contains a short sequence related to a natural protein involved in cell movement.",
        "what_it_is_used_or_studied_for": "Here, TB-500 means the acetylated seven-amino-acid fragment, rather than full-length thymosin beta-4. Researchers have examined its chemistry and metabolism in laboratory and animal experiments.",
        "what_human_evidence_shows": "The reviewed FDA assessment does not establish that this fragment improves healing in people. Human findings involving the full-length protein cannot simply be transferred to the fragment.",
        "important_drawbacks": "Acetylation changes the molecule. Even results with a non-acetylated fragment may differ. The dated HHS conditional compounding policy is separate from FDA approval and proof of clinical benefit."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/media/193349/download",
          "title": "FDA July 2026 PCAC scientific assessment: TB-500",
          "supports": "Exact identity distinctions, limited preclinical evidence and inability to extrapolate non-acetylated fragment effects to acetylated TB-500.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary regulator scientific assessment"
        },
        {
          "url": "https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf",
          "title": "HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances",
          "supports": "Narrow conditional interim compounding policy and exact Appendix B identities, separate from drug approval and evidence of benefit.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary federal policy document"
        },
        {
          "url": "https://public-inspection.federalregister.gov/2026-22192.pdf",
          "title": "HHS notice of availability: FR Doc 2026-22192",
          "supports": "Draft/nonbinding status, filing 28 October 2026 and scheduled publication 30 October 2026.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary federal regulatory notice"
        }
      ]
    },
    {
      "slug": "cjc-1295",
      "name": "CJC-1295",
      "canonical_id": "cjc-1295",
      "entry_kind": "other",
      "aliases": [],
      "identity": "CJC-1295 terminology can refer to chemically distinct forms, including DAC-modified and non-DAC substances and different salts. These identities must not be treated as interchangeable.",
      "classification": "GHRH analogue research peptide",
      "regulatory_status": "FDA’s December 2024 assessment concerns bulk-substance evaluation and does not constitute FDA product approval. A current approved CJC-1295 therapeutic product is not established by the verified sources; current compounding status requires separate dated policy review.",
      "evidence_summary": "The additional FDA review found small human studies apparently involving CJC-1295 DAC of unspecified salt in healthy adults. They measured hormonal responses and did not establish efficacy for growth hormone deficiency. A separate additional 2009 publication analyzed serum-protein changes in 11 healthy men; it provides exploratory biomarker evidence rather than an independent disease-efficacy trial.",
      "evidence_level": "",
      "limitations": "Do not transfer pharmacokinetic or efficacy claims across DAC/non-DAC identities. Hormone increases do not prove improvements in muscle, recovery, aging or clinical disease.",
      "reader_summary": {
        "why_people_are_interested": "CJC-1295 attracts attention because it can stimulate release of growth hormone, a hormone involved in growth and metabolism.",
        "what_it_is_used_or_studied_for": "Human studies have investigated long-acting forms linked to an albumin-binding modification called DAC. Products described as being without DAC are chemically different.",
        "what_human_evidence_shows": "Small studies in healthy adults found hormone changes. Another publication examined changes in blood proteins in eleven men. These measurements did not establish treatment benefits for growth hormone deficiency, muscle recovery or aging.",
        "important_drawbacks": "Reported effects in small healthy-adult studies included injection-site reactions, headache, flushing and temporary low blood pressure. The exact chemical forms were not always clear. Long-term safety remains uncertain, and hormone changes do not prove improved strength, function or recovery."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/media/183819/download",
          "title": "FDA December 2024 PCAC scientific assessment: CJC-1295-related substances",
          "supports": "Small healthy-adult studies apparently involving DAC-modified CJC-1295 reported injection-site reactions, headache, flushing and transient low blood pressure. Molecular forms were uncertain; long-term safety unestablished.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary regulator scientific assessment / public statement",
          "read_scope": "Actual primary PDF clinical safety sections at pages40 and45 read.",
          "checked_on": "2026-10-29"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/19386527/",
          "title": "Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.",
          "supports": "Exploratory serum-proteomic biomarker analysis in 11 healthy young adult men before and one week after CJC-1295; no clinical efficacy endpoint. This is a distinct analysis/publication, not evidence of an independent efficacy trial.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "19386527",
          "doi": "10.1016/j.ghir.2009.03.001"
        }
      ]
    },
    {
      "slug": "ipamorelin",
      "name": "Ipamorelin",
      "canonical_id": "ipamorelin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Ipamorelin is a synthetic growth hormone secretagogue/ghrelin receptor agonist peptide. Free base and acetate are distinct bulk substance forms.",
      "classification": "Research peptide growth hormone secretagogue",
      "regulatory_status": "FDA’s October 2024 scientific assessment did not establish an FDA-approved ipamorelin product. The historical bulk-substance assessment is not itself a current blanket determination about all compounding.",
      "evidence_summary": "The additional FDA assessment found one clinical efficacy publication involving intravenous ipamorelin of unspecified form for postoperative ileus. Its primary and secondary efficacy comparisons were not statistically significant; this cannot support subcutaneous wellness or body-composition claims.",
      "evidence_level": "",
      "limitations": "Route, salt and population differences prevent simple extrapolation. Early hormone-response or animal findings do not establish patient benefit.",
      "reader_summary": {
        "why_people_are_interested": "Ipamorelin is of interest because it activates the ghrelin receptor, a signaling system connected with growth hormone release and digestive movement.",
        "what_it_is_used_or_studied_for": "A human randomized trial tested intravenous ipamorelin after bowel surgery, hoping to speed recovery of normal eating and bowel function.",
        "what_human_evidence_shows": "The key eating-recovery outcome and secondary recovery outcomes did not differ significantly from placebo. The FDA assessment discusses this negative overall result and the limits of subgroup findings.",
        "important_drawbacks": "In the surgical trial, low potassium and high blood sugar were more frequent with ipamorelin. Surgery and underlying illness complicate interpretation. These findings do not establish the safety of injections under the skin, or demonstrate fat loss, muscle gain or general recovery benefits."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/media/182088/download",
          "title": "FDA October 2024 PCAC scientific assessment: ipamorelin-related substances",
          "supports": "In the bowel-surgery trial, low potassium and high blood sugar occurred more often in the ipamorelin group. Surgery and underlying disease complicate causality; intravenous study cannot establish subcutaneous safety.",
          "additional_document_vs_comparator": true,
          "source_kind": "Primary regulator scientific assessment / public statement",
          "read_scope": "Actual primary PDF pages35–38 clinical safety discussion read, including causal uncertainty.",
          "checked_on": "2026-10-29",
          "reader_url": "https://www.fda.gov/media/182088/download",
          "display_title": "FDA: ipamorelin research and safety review (2024)"
        },
        {
          "url": "https://precision.fda.gov/uniisearch/srs/unii/Y9M3S784Z6",
          "title": "FDA UNII Y9M3S784Z6: Ipamorelin",
          "supports": "Ipamorelin preferred name, molecular identity and NNC 26-0161 synonym mappings; this identity record does not establish safety, effectiveness or approval.",
          "additional_document_vs_comparator": true,
          "source_kind": "official curated substance identity record"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/25331030/",
          "title": "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.",
          "supports": "Randomized postoperative bowel-resection study with no statistically significant primary or secondary efficacy result; intravenous route does not establish subcutaneous wellness benefit.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary published human research; PubMed abstract",
          "read_scope": "Abstract-level verification; not an independent full-article review.",
          "pmid": "25331030",
          "checked_on": "2026-10-29",
          "doi": "10.1007/s00384-014-2030-8",
          "reader_url": "https://pubmed.ncbi.nlm.nih.gov/25331030/",
          "display_title": "Randomized trial of ipamorelin after bowel surgery"
        }
      ]
    },
    {
      "slug": "sermorelin",
      "name": "Sermorelin",
      "canonical_id": "sermorelin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Sermorelin is growth hormone-releasing factor human (1–29) peptide amide, also mapped as groliberin in the FDA substance identity record.",
      "classification": "GHRH fragment analogue peptide",
      "regulatory_status": "United States: historical GEREF approvals covered pituitary growth-hormone-release testing and childhood idiopathic growth hormone deficiency with growth failure. The products were discontinued and their NDA approvals withdrawn in 2009 at the sponsor’s request. FDA determined in 2013 that withdrawal from sale was not for safety or effectiveness reasons. Current compounded preparations do not inherit approval from those historical products.",
      "evidence_summary": "The additional FDA identity record establishes the molecule and synonyms; a separate FDA application database establishes historical GEREF approvals and discontinued product listings. Neither establishes healthy-adult anti-aging or muscle-enhancement efficacy.",
      "evidence_level": "",
      "limitations": "Historical approved GEREF products, discontinued product listings and current compounded preparations are distinct. A UNII identifier and historical product approval do not establish current compounded-product approval or wellness benefit.",
      "reader_summary": {
        "why_people_are_interested": "Sermorelin copies part of the body’s signal that tells the pituitary gland to release growth hormone. Its established history concerns evaluating growth-hormone release and treating a specific childhood growth disorder.",
        "what_it_is_used_or_studied_for": "Historical GEREF products were approved to evaluate the pituitary gland’s ability to release growth hormone, and to treat unexplained growth hormone deficiency in children with growth failure.",
        "what_human_evidence_shows": "Those narrow medical uses are different from claims about energy, muscle building or slowing aging in otherwise healthy adults. The historical approvals do not establish those adult wellness benefits.",
        "important_drawbacks": "GEREF products were discontinued. FDA determined in 2013 that they had not been withdrawn from sale for safety or effectiveness reasons. That finding does not make today’s compounded sermorelin preparations FDA-approved or establish their benefit for another purpose."
      },
      "sources": [
        {
          "url": "https://precision.fda.gov/uniisearch/srs/unii/89243S03TE",
          "title": "FDA UNII 89243S03TE: Sermorelin",
          "supports": "Identity as human growth hormone-releasing factor (1–29) peptide amide and synonym mappings; no approval or efficacy inference.",
          "additional_document_vs_comparator": true,
          "source_kind": "official curated substance identity record"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22SERMORELIN%22&limit=5",
          "title": "FDA Drugs@FDA records: GEREF sermorelin acetate, NDA019863 and NDA020443",
          "supports": "Historical original approvals 28 December 1990 (NDA019863) and 26 September 1997 (NDA020443); products currently marked discontinued in this database. Distinct from the comparator 2013 Federal Register determination.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator approval database",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863",
          "display_title": "FDA: GEREF approval history"
        },
        {
          "url": "https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm",
          "title": "FDA determination concerning discontinued GEREF products, Federal Register, 4 March 2013",
          "supports": "Historical diagnostic and pediatric treatment indications; sponsor discontinuation, 2009 NDA withdrawal and FDA finding that withdrawal from sale was not for safety or effectiveness.",
          "additional_document_vs_comparator": false,
          "source_kind": "Primary regulator record / prescribing information",
          "read_scope": "Full official Federal Register notice read, including historical indications and withdrawal determination.",
          "checked_on": "2026-10-29"
        }
      ]
    },
    {
      "slug": "mk-677-ibutamoren",
      "name": "MK-677 (ibutamoren)",
      "canonical_id": "mk-677-ibutamoren",
      "entry_kind": "other",
      "aliases": [],
      "identity": "MK-677 is ibutamoren, often studied as ibutamoren mesylate. It is a non-peptide small-molecule ghrelin receptor agonist, not a peptide or SARM.",
      "classification": "Non-peptide research growth hormone secretagogue",
      "regulatory_status": "United States: FDA’s 23 September 2025 laboratory-backed safety notification explicitly identifies ibutamoren/MK-677 as an active ingredient not approved by FDA. The October 2024 bulk-substance scientific review was not a marketing authorization. Other jurisdictions require separate checks.",
      "evidence_summary": "The additional FDA review found insufficient evidence of clinically meaningful effectiveness across the nominated uses, including growth hormone deficiency, osteoporosis, hip fracture, sarcopenia, obesity and Alzheimer disease. Hormone or lean-mass changes alone do not establish those benefits.",
      "evidence_level": "",
      "limitations": "Do not classify MK-677 as a peptide or convert surrogate endocrine findings into longevity or performance claims. The review’s date and scope must remain explicit. FDA also warns about potential glucose/insulin effects, fluid retention and increased congestive-heart-failure risk in some people; long-term effects remain unknown.",
      "reader_summary": {
        "why_people_are_interested": "Ibutamoren, also called MK-677, interests researchers because it stimulates a receptor linked to growth hormone release and appetite.",
        "what_it_is_used_or_studied_for": "It has been investigated for several conditions, including growth hormone deficiency, muscle loss and recovery after hip fracture. It is a small molecule, not a peptide or a SARM.",
        "what_human_evidence_shows": "The FDA review found insufficient evidence of meaningful clinical benefit for the proposed uses. Changes in hormone levels or lean mass alone did not establish improved function or recovery.",
        "important_drawbacks": "FDA identifies ibutamoren as unapproved and warns about fluid retention, altered glucose control and possible heart-failure risk in some people. Long-term effects remain uncertain."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/media/182087/download",
          "title": "FDA October 2024 PCAC scientific assessment: ibutamoren mesylate",
          "supports": "Non-peptide small-molecule classification and regulator conclusions about insufficient clinical effectiveness evidence for the nominated uses.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary regulator scientific assessment"
        },
        {
          "url": "https://www.fda.gov/drugs/medication-health-fraud-notifications/agebox-ikids-growth-day-formula-may-be-harmful-due-hidden-ingredient",
          "title": "FDA: Agebox iKids Growth Day Formula may be harmful due to hidden ingredient",
          "supports": "FDA reports laboratory detection of undeclared ibutamoren, identifies MK-677 as an unapproved active ingredient and describes potential adverse effects and unknown long-term effects.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary regulator laboratory finding and safety notification"
        }
      ]
    },
    {
      "slug": "thymosin-beta-4",
      "name": "Thymosin beta-4",
      "canonical_id": "thymosin-beta-4",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Thymosin beta-4 is an actin-binding peptide. Human UniProt P62328 has a 44-residue translated sequence with the initiator methionine removed, yielding the 43-residue chain. It is distinct from acetylated seven-residue TB-500.",
      "classification": "Endogenous peptide / investigational therapeutic identity",
      "regulatory_status": "The verified additional sources establish molecular identity and basic actin biology, not therapeutic marketing approval. The HHS policy naming TB-500 must not be applied automatically to full-length thymosin beta-4.",
      "evidence_summary": "An additional original biochemical study sequenced the actin-sequestering peptide Fx and identified it with thymosin beta-4. It is not a human healing or performance trial.",
      "evidence_level": "",
      "limitations": "Clinical studies of a particular full-length formulation cannot validate unspecified commercial TB-500 products, fragments or other routes.",
      "reader_summary": {
        "why_people_are_interested": "Thymosin beta-4 is scientifically interesting because it binds actin, a protein that helps cells maintain their shape and move.",
        "what_it_is_used_or_studied_for": "Researchers study its role in cell behavior and tissue repair. The full-length natural peptide is different from the short fragment often called TB-500.",
        "what_human_evidence_shows": "The additional sources reviewed establish its sequence and its actin-binding activity. Those biochemical findings do not by themselves demonstrate that administering it improves healing in people.",
        "important_drawbacks": "Human trials involving a particular full-length formulation cannot validate every product using a related name. Fragments, preparations and delivery routes may behave differently. Molecular identity is useful context, but it is separate from clinical effectiveness and safety."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/1999398/",
          "title": "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable.",
          "supports": "Primary sequencing and actin-polymerization experiments identifying Fx with thymosin beta-4.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "1999398",
          "doi": "10.1016/s0021-9258(20)64278-8"
        },
        {
          "url": "https://www.uniprot.org/uniprotkb/P62328/entry",
          "title": "UniProtKB P62328: Thymosin beta-4",
          "supports": "Human protein identity, Fx synonym and mature-chain boundaries 2–44 after initiator methionine removal.",
          "additional_document_vs_comparator": true,
          "source_kind": "official curated protein identity record"
        }
      ]
    },
    {
      "slug": "follistatin-344",
      "name": "Follistatin-344",
      "canonical_id": "follistatin-344",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Follistatin-344 denotes the 344-amino-acid human precursor, including a 29-residue signal peptide; the processed product is follistatin-315. It is a protein, and AAV-mediated gene delivery is a distinct intervention from administering protein.",
      "classification": "Activin/myostatin-binding protein precursor; gene-therapy construct distinction",
      "regulatory_status": "The additional primary structure and curated protein records do not establish an approved follistatin-344 medicine. Regulatory approval and general muscle-enhancement use are not established.",
      "evidence_summary": "An additional original 1988 gene-structure paper identified 344- and 317-residue precursor forms from alternative splicing. UniProt provides the precursor/processed-chain distinction. Neither demonstrates clinical benefit from injectable follistatin-344.",
      "evidence_level": "",
      "limitations": "Do not present gene-therapy trials as evidence that a research protein vial has the same delivery, safety or effectiveness.",
      "reader_summary": {
        "why_people_are_interested": "Follistatin attracts research interest because it can block signals that limit muscle growth, making it relevant to investigations of muscle disease.",
        "what_it_is_used_or_studied_for": "Follistatin-344 describes a protein precursor. Some clinical research has instead delivered a gene so cells produce follistatin; that is a different intervention from administering a protein.",
        "what_human_evidence_shows": "The additional sources reviewed explain the human gene and its different protein forms. They do not establish muscle-growth benefits from injecting a commercially offered follistatin-344 product.",
        "important_drawbacks": "The precursor is processed into a shorter protein, so names can obscure important differences. Findings from gene delivery cannot establish the same effects, safety or duration for a protein preparation. An approved enhancement use is not established."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/3380788/",
          "title": "Primary structure of the human follistatin precursor and its genomic organization.",
          "supports": "Original human cDNA/genomic study identifies 344- and 317-residue precursors and alternative splicing.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "3380788",
          "doi": "10.1073/pnas.85.12.4218"
        },
        {
          "url": "https://www.uniprot.org/uniprotkb/P19883/entry",
          "title": "UniProtKB P19883: Follistatin",
          "supports": "344-residue precursor identity, signal peptide 1–29, processed chain 30–344 and FS315/FS288 isoform naming.",
          "additional_document_vs_comparator": true,
          "source_kind": "official curated protein identity record"
        }
      ]
    },
    {
      "slug": "ghrp-2",
      "name": "GHRP-2",
      "canonical_id": "ghrp-2",
      "entry_kind": "other",
      "aliases": [],
      "identity": "GHRP-2, also called pralmorelin, is a synthetic growth hormone-releasing peptide acting through the ghrelin receptor.",
      "classification": "Research/diagnostic growth hormone secretagogue peptide",
      "regulatory_status": "Japan: PMDA’s July 2025 prescribing information lists GHRP KAKEN100 Injection (pralmorelin hydrochloride), approval number 21600AMZ00573, as a prescription diagnostic agent for growth hormone deficiency. This does not establish approval for chronic treatment, performance use or any other jurisdiction.",
      "evidence_summary": "An additional double-blind randomized human physiology study in 19 lean or obese participants measured appetite, food intake and endocrine responses during short infusions. It did not test long-term strength, recovery, anti-aging or disease outcomes. The separate Japanese PMDA label establishes a specific diagnostic use, not general therapeutic or performance use.",
      "evidence_level": "",
      "limitations": "Acute hormone or appetite changes are not evidence of safe chronic performance use.",
      "reader_summary": {
        "why_people_are_interested": "GHRP-2, also called pralmorelin, stimulates growth hormone release. That makes it useful for studying how the hormone system responds to a challenge.",
        "what_it_is_used_or_studied_for": "Japan has a prescription pralmorelin-hydrochloride product used to diagnose growth hormone deficiency. This diagnostic use is different from long-term hormone treatment.",
        "what_human_evidence_shows": "A separate small human physiology study measured appetite, food intake and hormone responses during short experimental infusions. It did not establish lasting improvements in muscle, recovery or aging.",
        "important_drawbacks": "An acute hormone response is not proof of clinical benefit from repeated use. Japan’s diagnostic authorization does not establish approval for other purposes or in other countries; the exact product and intended use matter."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/16861611/",
          "title": "Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake.",
          "supports": "Additional randomized double-blind human GHRP-2 infusion study in lean and obese participants; appetite/food intake and hormonal endpoints.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "16861611",
          "doi": "10.1038/oby.2006.121"
        },
        {
          "url": "https://www.pmda.go.jp/PmdaSearch/iyakuDetail/200022_7223407D2023_1_01",
          "title": "PMDA: GHRP KAKEN100 Injection (pralmorelin hydrochloride) prescribing information",
          "supports": "Japan-specific prescription diagnostic product for growth hormone deficiency, approval number 21600AMZ00573; not approval for chronic muscle enhancement or wellness.",
          "additional_document_vs_comparator": true,
          "source_kind": "official regulator product labeling"
        }
      ]
    },
    {
      "slug": "ghrp-6",
      "name": "GHRP-6",
      "canonical_id": "ghrp-6",
      "entry_kind": "other",
      "aliases": [],
      "identity": "GHRP-6 is a synthetic hexapeptide growth hormone secretagogue; it is distinct from GHRP-2 and hexarelin.",
      "classification": "Research growth hormone secretagogue peptide",
      "regulatory_status": "A current therapeutic marketing approval is not established by the verified additional sources; they report experimental human physiology.",
      "evidence_summary": "Two additional small human studies examined growth hormone responses in younger and older adults, and responses around exercise with cholinergic modulation. These are acute endocrine experiments.",
      "evidence_level": "",
      "limitations": "Neither study establishes clinical improvement in muscle, exercise recovery or aging, and short hormonal responses do not establish long-term safety.",
      "reader_summary": {
        "why_people_are_interested": "GHRP-6 stimulates growth hormone release and has helped researchers explore how that hormone responds to age, exercise and other signals.",
        "what_it_is_used_or_studied_for": "It is a synthetic six-amino-acid peptide, distinct from GHRP-2 and hexarelin. The additional studies reviewed involved short experiments in small groups of people.",
        "what_human_evidence_shows": "One study compared younger and older adults; another examined hormone responses around exercise in healthy men. They measured acute endocrine responses, rather than improvements in strength, injury recovery or daily function.",
        "important_drawbacks": "These experiments do not establish a useful long-term treatment or enhancement benefit. Short observation periods and small samples cannot settle chronic safety, and changing a hormone level does not establish a better health outcome."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/7734029/",
          "title": "Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.",
          "supports": "Primary acute hormone-response study in nine younger and nine older adults comparing GHRP-6/GHRH stimulation.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "7734029",
          "doi": "10.1111/j.1365-2265.1995.tb01861.x"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/9135702/",
          "title": "Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release.",
          "supports": "Primary randomized-order endocrine experiment in 11 healthy men examining GHRP-6, exercise and cholinergic tone.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "9135702",
          "doi": "10.1046/j.1365-2265.1997.1080919.x"
        }
      ]
    },
    {
      "slug": "hexarelin",
      "name": "Hexarelin",
      "canonical_id": "hexarelin",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Hexarelin, also known as examorelin, is a synthetic hexapeptide growth hormone secretagogue.",
      "classification": "Research growth hormone secretagogue peptide",
      "regulatory_status": "The verified additional sources establish experimental administration in healthy volunteers; they do not establish current therapeutic approval in any jurisdiction.",
      "evidence_summary": "Two additional 1994 studies examined acute growth hormone responses and route-related activity in small groups of healthy men/volunteers. They measured endocrine surrogate outcomes rather than patient-important clinical outcomes.",
      "evidence_level": "",
      "limitations": "Do not infer established muscle gain, cardiac benefit, recovery or healthy aging from acute hormone-response experiments.",
      "reader_summary": {
        "why_people_are_interested": "Hexarelin, also called examorelin, interests researchers because it can trigger release of growth hormone and illuminate the signaling behind that response.",
        "what_it_is_used_or_studied_for": "It is a synthetic six-amino-acid research peptide. Early human experiments examined the magnitude of the hormone response and differences between administration routes.",
        "what_human_evidence_shows": "Two small studies in healthy volunteers measured acute growth hormone release. These are observations in people, but they did not establish better muscle function, recovery, heart health or aging outcomes.",
        "important_drawbacks": "A short-term hormone response cannot show the benefits or risks of repeated use. Different routes may produce different effects. The reviewed sources do not establish an approved treatment or justify performance-enhancement claims."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/7957536/",
          "title": "Growth hormone-releasing activity of hexarelin in humans. A dose-response study.",
          "supports": "Primary double-blind placebo-controlled dose-response experiment in 12 healthy men; acute GH-response outcome.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "7957536",
          "doi": "10.1007/bf00191904"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/8126144/",
          "title": "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.",
          "supports": "Primary study of acute hexarelin endocrine activity by different administration routes in 12 healthy young volunteers.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "8126144",
          "doi": "10.1210/jcem.78.3.8126144"
        }
      ]
    },
    {
      "slug": "igf-1-des",
      "name": "IGF-1 DES",
      "canonical_id": "igf-1-des",
      "entry_kind": "other",
      "aliases": [],
      "identity": "IGF-1 DES commonly refers to des(1–3)IGF-I, the 67-amino-acid IGF-I form lacking its first three residues. It is distinct from mecasermin and Long R3 IGF-I.",
      "classification": "Truncated IGF-I research growth factor peptide",
      "regulatory_status": "The verified additional studies do not establish an approved human des(1–3)IGF-I therapeutic product. Mecasermin approval cannot be transferred to this modified molecule.",
      "evidence_summary": "Additional primary experiments investigated effects in cultured rat pituitary cells and distribution/clearance in rats. They do not establish human pharmacokinetics, safety or clinical benefit.",
      "evidence_level": "",
      "limitations": "Animal pharmacokinetics and cultured-cell potency must not be represented as validated human dosing, recovery or muscle-enhancement evidence.",
      "reader_summary": {
        "why_people_are_interested": "Des(1–3)IGF-I interests researchers because removing a small part of insulin-like growth factor can change how it interacts with binding proteins.",
        "what_it_is_used_or_studied_for": "Often called IGF-1 DES, this modified growth factor is different from the approved native IGF-I medicine mecasermin and from the longer LR3 analogue.",
        "what_human_evidence_shows": "The additional studies reviewed used rat cells and rats to investigate hormone secretion, distribution and clearance. They were not human treatment studies and do not establish human benefits.",
        "important_drawbacks": "Results in rats cannot establish a human duration of action, a safe regimen or improved muscle recovery. Approval of mecasermin does not transfer to this altered molecule, and laboratory potency is separate from clinical effectiveness."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/1715381/",
          "title": "The effects of insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I, a potent IGF analogue, on growth hormone and IGF-binding protein secretion from cultured rat anterior pituitary cells.",
          "supports": "Primary cultured rat anterior pituitary-cell study of GH/IGF-binding-protein secretion.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "1715381",
          "doi": "10.1677/joe.0.1300093"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/2005410/",
          "title": "Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats.",
          "supports": "Primary rat clearance and tissue-distribution comparison of IGF-I, IGF-II and des(1–3)IGF-I.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "2005410",
          "doi": "10.1677/joe.0.1280197"
        }
      ]
    },
    {
      "slug": "igf-1-lr3",
      "name": "IGF-1 LR3",
      "canonical_id": "igf-1-lr3",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Long R3 IGF-I / IGF-1 LR3 is an engineered IGF-I analogue with an N-terminal extension and an Arg substitution at position 3 of the IGF-I sequence. It is distinct from native IGF-I, mecasermin and des(1–3)IGF-I.",
      "classification": "Engineered IGF-I research growth factor peptide",
      "regulatory_status": "The verified additional sources do not establish a current approved human LR3 therapeutic product. An approved native IGF-I product does not establish approval of LR3.",
      "evidence_summary": "An additional original molecular-characterization study examined recombinant analogues and receptor/binding-protein interactions in cell systems. A separate primary study investigated LR3 distribution and clearance in pregnant rats.",
      "evidence_level": "",
      "limitations": "Binding-protein effects or rat exposure cannot establish a human half-life, safe regimen, muscle gain or clinical benefit.",
      "reader_summary": {
        "why_people_are_interested": "Long R3 IGF-I interests researchers because changes to the natural growth factor alter its interactions with binding proteins and receptors.",
        "what_it_is_used_or_studied_for": "Also called IGF-1 LR3, it is an engineered analogue rather than native IGF-I. Researchers have examined its molecular behavior and distribution in animals.",
        "what_human_evidence_shows": "The additional evidence reviewed includes laboratory characterization and experiments in pregnant rats. It does not establish human absorption, duration of action, safety or treatment benefit.",
        "important_drawbacks": "Animal distribution and cellular activity cannot support a reliable human half-life or claims of muscle growth and recovery. It is also different from mecasermin and IGF-1 DES; evidence or approval for one molecule cannot establish the same for another."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/1378742/",
          "title": "Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency.",
          "supports": "Original recombinant analogue characterization, including Long Arg3 IGF-I, in cell/receptor-binding systems.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "1378742",
          "doi": "10.1677/jme.0.0080213"
        },
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/7693845/",
          "title": "Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats.",
          "supports": "Primary LR3 versus IGF-I clearance and tissue-distribution experiments in pregnant rats.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "7693845",
          "doi": "10.1677/joe.0.1380327"
        }
      ]
    },
    {
      "slug": "mechano-growth-factor",
      "name": "Mechano growth factor",
      "canonical_id": "mechano-growth-factor",
      "entry_kind": "other",
      "aliases": [],
      "identity": "Mechano growth factor (MGF) names IGF-I splice-variant/E-domain biology; commercial MGF and PEG-MGF labels do not describe one uniform validated product. Species-specific splice-variant naming also differs.",
      "classification": "IGF-I splice-variant / research E-peptide grouping",
      "regulatory_status": "The verified additional sources do not establish an approved human MGF or PEG-MGF therapeutic product. Endogenous expression does not establish approval of an injected commercial preparation.",
      "evidence_summary": "An additional human study measured muscle IGF-I splice-variant mRNA after growth hormone and resistance training; it did not administer MGF peptide. A separate mouse study measured changes in MGF mRNA after growth hormone or altered GH signaling.",
      "evidence_level": "",
      "limitations": "Do not describe these studies as human trials of injected MGF, or equate gene-expression changes with proven muscle repair, growth or performance benefits.",
      "reader_summary": {
        "why_people_are_interested": "Mechano growth factor is relevant to muscle research because the body can change expression of certain IGF-I gene variants after growth-related signals.",
        "what_it_is_used_or_studied_for": "The name describes splice-variant and protein-fragment biology. Products labeled MGF or PEG-MGF do not necessarily represent the same precisely defined substance.",
        "what_human_evidence_shows": "A human muscle-biopsy study measured gene expression after growth hormone and resistance training; it did not administer MGF. A separate mouse study also measured expression after altered growth-hormone signaling.",
        "important_drawbacks": "These findings do not establish that injected MGF repairs injuries, builds muscle or improves performance in people. Measuring the body’s own gene activity is different from testing an administered product, and animal findings remain separate from human outcomes."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/14565994/",
          "title": "The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men.",
          "supports": "Human muscle-biopsy study of IGF-I splice-variant mRNA following recombinant GH and resistance training; no administered MGF intervention.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "14565994",
          "doi": "10.1113/jphysiol.2003.051722"
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1665252/",
          "title": "Muscle mechano growth factor is preferentially induced by growth hormone in growth hormone-deficient lit/lit mice",
          "supports": "Mouse GH-signaling and MGF-mRNA expression experiments; no human MGF administration or clinical efficacy outcome.",
          "additional_document_vs_comparator": true,
          "source_kind": "primary published scientific study",
          "pmid": "15308683",
          "doi": "10.1113/jphysiol.2004.069500"
        }
      ]
    },
    {
      "slug": "angiotensin-ii",
      "name": "Angiotensin II",
      "canonical_id": "angiotensin-ii",
      "entry_kind": "molecule",
      "aliases": [
        "Giapreza"
      ],
      "identity": "Angiotensin II is a hormone-matching medicine used to raise blood pressure in selected hospital shock care. EMA describes Giapreza as an authorised product for adults whose low blood pressure persists despite other treatments.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Giapreza. Indication: Refractory hypotension in adults with septic or other distributive shock despite other available treatments. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Angiotensin II is a hormone-matching medicine used to raise blood pressure in selected hospital shock care. EMA describes Giapreza as an authorised product for adults whose low blood pressure persists despite other treatments.",
      "evidence_level": "human regulatory assessment",
      "limitations": "EMA authorisation is jurisdiction-specific; hospital shock treatment is not a general cardiovascular or wellness use. The EMA source does not establish US indications or local supply; the separate FDA product record must be read within its stated scope. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "The reason to consider angiotensin II is an emergency: dangerously low blood pressure that has not responded adequately to other hospital treatments. It is not a supplement for everyday circulation.",
        "what_it_is_used_or_studied_for": "Giapreza is an EU-authorised medicine for adults with septic or other distributive shock, where blood vessels remain too relaxed to maintain adequate pressure.",
        "what_human_evidence_shows": "In a 344-person study, adding Giapreza helped more patients reach the blood-pressure target after three hours than adding placebo. That finding does not by itself prove longer survival.",
        "important_drawbacks": "Important risks include blood clots and temporarily excessive blood pressure. Treatment requires hospital monitoring; the evidence applies to critically ill adults."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/giapreza",
          "title": "Giapreza — EMA European public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22ANGIOTENSIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: ANGIOTENSIN ll ACETATE (ANDA216966)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216966",
          "display_title": "FDA: ANGIOTENSIN ll ACETATE approval history"
        }
      ]
    },
    {
      "slug": "bivalirudin",
      "name": "Bivalirudin",
      "canonical_id": "bivalirudin",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Bivalirudin is a direct thrombin inhibitor used as an anticoagulant during percutaneous coronary intervention. Its US injection label describes a specific procedural indication and a risk of bleeding.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: US labelled prescription product. Product: Bivalirudin injection. Indication: Anticoagulation during percutaneous coronary intervention, including the labelled HIT/HITTS populations. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Bivalirudin is a direct thrombin inhibitor used as an anticoagulant during percutaneous coronary intervention. Its US injection label describes a specific procedural indication and a risk of bleeding.",
      "evidence_level": "human regulatory label",
      "limitations": "This injection label does not support unsupervised use, general clot-prevention claims or a statement that bleeding risk is absent. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Bivalirudin is considered when doctors need to limit clotting during a procedure to open narrowed heart arteries. The intended benefit is procedural protection against unwanted blood clots.",
        "what_it_is_used_or_studied_for": "It blocks thrombin, a protein involved in forming clots. Its US injection label covers percutaneous coronary intervention, often called coronary angioplasty, including specified patients with heparin-related clotting complications.",
        "what_human_evidence_shows": "Human clinical evidence supports this defined procedural use. It does not establish a benefit from taking bivalirudin for general cardiovascular health or routine prevention outside that setting.",
        "important_drawbacks": "Bleeding is a major drawback. The balance between bleeding and clotting risk depends on the procedure, other medicines and the patient's condition."
      },
      "sources": [
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91cf9d00-29e0-4357-a184-f70026c47edb",
          "title": "Bivalirudin injection — US prescribing information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "NLM DailyMed product label"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22BIVALIRUDIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: BIVALIRUDIN (ANDA206551)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206551",
          "display_title": "FDA: BIVALIRUDIN approval history"
        }
      ]
    },
    {
      "slug": "desirudin",
      "name": "Desirudin",
      "canonical_id": "desirudin",
      "entry_kind": "molecule",
      "aliases": [
        "Iprivask"
      ],
      "identity": "Desirudin is described in a historical FDA Iprivask label for prevention of deep-vein thrombosis after elective hip replacement. FDA’s current application dataset lists Iprivask as discontinued, so its historical approval must not be read as proof of current availability.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: Historical FDA-approved product; Iprivask is listed as discontinued. Product: Iprivask (desirudin), historical 2014 label. Indication: Prevention of deep-vein thrombosis after elective hip replacement surgery. Availability: FDA’s October 28, 2026 dataset lists Iprivask as discontinued. Local stock is not established.",
      "evidence_summary": "Desirudin is described in a historical FDA Iprivask label for prevention of deep-vein thrombosis after elective hip replacement. FDA’s current application dataset lists Iprivask as discontinued, so its historical approval must not be read as proof of current availability.",
      "evidence_level": "human historical regulatory label",
      "limitations": "The opened 2014 label establishes the historical indication, not current marketing, stock or a complete current safety review. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Desirudin was developed to prevent dangerous leg-vein clots after planned hip replacement. Such clots can travel to the lungs, so prevention is a specific surgical need.",
        "what_it_is_used_or_studied_for": "The historical US Iprivask label describes this clot-prevention use. Desirudin blocks thrombin, part of the body's clot-forming system.",
        "what_human_evidence_shows": "Human studies supported its historical approval for hip-replacement patients. That does not establish a role in general circulation, wellness or every type of surgery.",
        "important_drawbacks": "Bleeding is an important risk, including potentially disabling bleeding around the spine with spinal or epidural procedures. Iprivask is listed as discontinued, so historical approval should not be confused with a currently marketed treatment."
      },
      "sources": [
        {
          "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021271s006lbl.pdf",
          "title": "Iprivask (desirudin): historical FDA prescribing information, 2014",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA historical regulatory label"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DESIRUDIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: IPRIVASK (BLA021271)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021271",
          "display_title": "FDA: IPRIVASK approval history"
        }
      ]
    },
    {
      "slug": "desmopressin",
      "name": "Desmopressin",
      "canonical_id": "desmopressin",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Desmopressin injection has antidiuretic and selected haemostatic indications. Its label distinguishes central from nephrogenic diabetes insipidus and restricts the bleeding-disorder populations to defined criteria.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: US labelled injection product. Product: Desmopressin acetate injection. Indication: Central diabetes insipidus and selected haemophilia A and type I von Willebrand disease uses under the injection label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Desmopressin injection has antidiuretic and selected haemostatic indications. Its label distinguishes central from nephrogenic diabetes insipidus and restricts the bleeding-disorder populations to defined criteria.",
      "evidence_level": "human regulatory label",
      "limitations": "Route and product matter. Injection evidence must not be transferred to every nasal/oral preparation or used as a universal bleeding-treatment rule. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Desmopressin can be useful when the body needs help retaining water or, in selected bleeding disorders, temporarily improving clotting. These are distinct medical reasons for interest.",
        "what_it_is_used_or_studied_for": "The injection label covers central diabetes insipidus, a condition causing excessive urine production because a water-regulating hormone is lacking, and defined patients with haemophilia A or type I von Willebrand disease.",
        "what_human_evidence_shows": "Human evidence supports those specific uses. It does not support treating every cause of thirst, frequent urination or bleeding, and findings for an injection cannot automatically be applied to other formulations.",
        "important_drawbacks": "A major danger is dangerously low blood sodium, which can cause severe illness. Fluid balance and sodium require clinical oversight."
      },
      "sources": [
        {
          "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84dbb392-4535-4cbc-af60-75abb494f26e",
          "title": "Desmopressin acetate injection — US prescribing information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "NLM DailyMed product label"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DESMOPRESSIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: DESMOPRESSIN ACETATE (ANDA210218)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210218",
          "display_title": "FDA: DESMOPRESSIN ACETATE approval history"
        }
      ]
    },
    {
      "slug": "echinocandins",
      "name": "Echinocandins",
      "canonical_id": "echinocandins",
      "entry_kind": "drug class",
      "aliases": [
        "caspofungin",
        "micafungin",
        "anidulafungin",
        "rezafungin"
      ],
      "identity": "Echinocandins are a class of antifungal medicines, not one peptide molecule. CDC lists caspofungin, micafungin, anidulafungin and rezafungin and describes their action on fungal cell-wall synthesis.",
      "classification": "drug class",
      "regulatory_status": "Jurisdiction: US clinical guidance. Label: Drug class; no single product approval applies. Product: Echinocandin antifungals. Indication: Fungal infections; selection depends on the organism and clinical context. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Echinocandins are a class of antifungal medicines, not one peptide molecule. CDC lists caspofungin, micafungin, anidulafungin and rezafungin and describes their action on fungal cell-wall synthesis.",
      "evidence_level": "human clinical guidance",
      "limitations": "Class membership does not make the members interchangeable or establish one shared FDA indication, dose or resistance profile. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "People may encounter echinocandins when a fungal infection needs prescription treatment. The potential benefit is killing susceptible fungi by disrupting the protective wall around their cells.",
        "what_it_is_used_or_studied_for": "Echinocandins are a medicine class, including caspofungin, micafungin, anidulafungin and rezafungin. They are not one compound with a single shared set of uses.",
        "what_human_evidence_shows": "These medicines have established clinical roles, but the right choice depends on the fungus and infection site. The cited CDC overview explains their action; it does not provide one success rate that applies to every member or infection.",
        "important_drawbacks": "Antifungal treatment can cause side effects and requires careful selection. Class membership does not make different products interchangeable or establish a benefit for routine wellness."
      },
      "sources": [
        {
          "url": "https://www.cdc.gov/fungal/hcp/clinical-care/",
          "title": "Clinical Treatment of Fungal Diseases: Antifungals",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "CDC clinical guidance"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22CASPOFUNGIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: CASPOFUNGIN ACETATE (NDA206110)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206110",
          "display_title": "FDA: CASPOFUNGIN ACETATE approval history"
        }
      ]
    },
    {
      "slug": "eptifibatide",
      "name": "Eptifibatide",
      "canonical_id": "eptifibatide",
      "entry_kind": "molecule",
      "aliases": [
        "Eptifibatide Accord"
      ],
      "identity": "Eptifibatide is an antiplatelet medicine. EMA describes Eptifibatide Accord as a generic of Integrilin used in defined acute coronary care alongside other antithrombotic treatment.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Eptifibatide Accord. Indication: Prevention of heart attack in the specified unstable-angina/non-Q-wave myocardial-infarction populations. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Eptifibatide is an antiplatelet medicine. EMA describes Eptifibatide Accord as a generic of Integrilin used in defined acute coronary care alongside other antithrombotic treatment.",
      "evidence_level": "human regulatory assessment",
      "limitations": "EMA product evidence is not a blanket indication for all heart disease; the EMA source does not establish US indications or local supply; the separate FDA product record must be read within its stated scope. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Eptifibatide is considered in hospital heart care when preventing an additional blood clot may reduce the risk of a heart attack. It works on platelets, the blood cells that stick together to form clots.",
        "what_it_is_used_or_studied_for": "EMA describes Eptifibatide Accord for defined adults with unstable angina or a particular type of recent heart attack, alongside other antithrombotic treatment.",
        "what_human_evidence_shows": "Its clinical rationale and authorisation concern these acute, higher-risk patients. The generic product relies on the established evidence for its reference medicine; this is not evidence of benefit for every person with heart disease.",
        "important_drawbacks": "Bleeding risk and kidney function affect suitability. It belongs in monitored specialist treatment, rather than general heart-health self-care."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord",
          "title": "Eptifibatide Accord — EMA public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22EPTIFIBATIDE%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: EPTIFIBATIDE (ANDA206127)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206127",
          "display_title": "FDA: EPTIFIBATIDE approval history"
        }
      ]
    },
    {
      "slug": "motixafortide",
      "name": "Motixafortide",
      "canonical_id": "motixafortide",
      "entry_kind": "molecule",
      "aliases": [
        "Aphexda"
      ],
      "identity": "Motixafortide is the active ingredient in Aphexda. FDA’s trial snapshot describes its use with filgrastim for collecting stem cells before autologous transplantation in multiple myeloma and the population studied for its original approval.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA-approved product; original approval snapshot. Product: Aphexda(motixafortide). Indication: With filgrastim to mobilise stem cells for collection and autologous transplantation in adults with multiple myeloma. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Motixafortide is the active ingredient in Aphexda. FDA’s trial snapshot describes its use with filgrastim for collecting stem cells before autologous transplantation in multiple myeloma and the population studied for its original approval.",
      "evidence_level": "human approval trial evidence",
      "limitations": "Stem-cell mobilisation is the named use. A trial snapshot does not establish benefit in other cancers or replace the full current prescribing information. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Motixafortide helps solve a practical problem before a stem-cell transplant: collecting enough of a patient's own blood-forming stem cells. Its benefit is preparation for treatment, rather than directly curing the cancer.",
        "what_it_is_used_or_studied_for": "Aphexda is used with filgrastim in adults with multiple myeloma, a cancer of certain immune cells, before a transplant using their own cells.",
        "what_human_evidence_shows": "In the 122-person GENESIS trial, 67.5% receiving the combination reached the specified collection target within two collection sessions, compared with 9.5% receiving placebo plus filgrastim.",
        "important_drawbacks": "Injection-site reactions, itching, flushing and rash were common. The collection result does not by itself show better cancer survival or establish benefits in other cancers."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-aphexda",
          "title": "Drug Trials Snapshots: APHEXDA",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22MOTIXAFORTIDE%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: APHEXDA (NDA217159)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217159",
          "display_title": "FDA: APHEXDA approval history"
        }
      ]
    },
    {
      "slug": "nesiritide",
      "name": "Nesiritide",
      "canonical_id": "nesiritide",
      "entry_kind": "molecule",
      "aliases": [
        "Natrecor"
      ],
      "identity": "Nesiritide is recombinant human B-type natriuretic peptide studied in hospital heart-failure care. FDA withdrew approval of Natrecor effective June 15, 2020 after the applicant reported that it was no longer marketed. Historical short-term haemodynamic trial findings must not be mistaken for a currently marketed product or long-term outcome benefit.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: Natrecor approval withdrawn effective June 15, 2020. Product: Natrecor (nesiritide), NDA 020920. Indication: Historically studied as intravenous human B-type natriuretic peptide in symptomatic decompensated heart failure. Availability: The official withdrawal followed the applicant’s report that the product was no longer marketed. FDA’s October 28, 2026 dataset separately lists it as discontinued; current local supply is not established.",
      "evidence_summary": "Nesiritide is recombinant human B-type natriuretic peptide studied in hospital heart-failure care. FDA withdrew approval of Natrecor effective June 15, 2020 after the applicant reported that it was no longer marketed. Historical short-term haemodynamic trial findings must not be mistaken for a currently marketed product or long-term outcome benefit.",
      "evidence_level": "human randomised controlled trial",
      "limitations": "The withdrawal notice records an applicant-requested withdrawal after marketing ceased; it must not be described as a safety ban without separate evidence. Historical study findings are not current treatment advice. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Nesiritide attracted interest as a hospital treatment for worsening heart failure, aiming to ease the pressure burden on a struggling heart. It is a manufactured version of a hormone the body produces.",
        "what_it_is_used_or_studied_for": "Historical studies examined intravenous nesiritide in symptomatic decompensated heart failure, meaning heart failure that has worsened enough to require urgent treatment.",
        "what_human_evidence_shows": "A 103-person trial found improvements in heart and circulation measurements during a 24-hour infusion. These short-term measurements did not establish longer survival or lasting improvement.",
        "important_drawbacks": "Natrecor's FDA approval was withdrawn effective June 15, 2020 after its manufacturer reported that it was no longer marketed. That withdrawal should not be described as a proven safety ban."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/10400005/",
          "title": "Nesiritide in heart failure: randomised placebo-controlled haemodynamic trial, 1999",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed human randomised trial, indexedPubMed",
          "pmid": "10400005",
          "doi": "10.1016/s0735-1097(99)00184-9"
        },
        {
          "url": "https://www.govinfo.gov/content/pkg/FR-2020-05-14/pdf/2020-10367.pdf",
          "title": "FDA withdrawal of 16 new drug applications: Federal Register, May 14, 2020",
          "supports": "Lists Natrecor (nesiritide), NDA 020920, among applications whose approval was withdrawn effective June 15, 2020 after the applicants reported that the products were no longer marketed.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA legalnotice published by the US Government Publishing Office"
        }
      ]
    },
    {
      "slug": "pegcetacoplan",
      "name": "Pegcetacoplan",
      "canonical_id": "pegcetacoplan",
      "entry_kind": "molecule",
      "aliases": [
        "Aspaveli"
      ],
      "identity": "Pegcetacoplan is the active ingredient in Aspaveli, a complement-targeting medicine. EMA describes product-specific uses in paroxysmal nocturnal haemoglobinuria and certain complement-mediated kidney diseases.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Aspaveli. Indication: PNH-associated anaemia and specified complement-mediated kidney diseases under the current EMA product record. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Pegcetacoplan is the active ingredient in Aspaveli, a complement-targeting medicine. EMA describes product-specific uses in paroxysmal nocturnal haemoglobinuria and certain complement-mediated kidney diseases.",
      "evidence_level": "human regulatory assessment",
      "limitations": "Systemic Aspaveli evidence must not be transferred to an ocular formulation or every complement disorder. The EMA record reports important infection risks; US product metadata does not establish the complete US indication or safety label. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Pegcetacoplan is considered when an overactive part of the immune system, called complement, damages blood cells or kidney tissue. The treatment aims to reduce that specific damage.",
        "what_it_is_used_or_studied_for": "EMA describes Aspaveli for paroxysmal nocturnal haemoglobinuria, or PNH, and specified complement-related kidney diseases. In PNH, red blood cells break down too quickly and can cause anaemia.",
        "what_human_evidence_shows": "In an 80-person PNH study, patients switched to Aspaveli had higher haemoglobin levels and needed fewer transfusions than those continuing eculizumab. These findings apply to the studied PNH population.",
        "important_drawbacks": "Blocking complement increases important infection risks. Systemic Aspaveli and eye formulations are different treatments; evidence for one cannot simply establish the benefits or safety of another."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli",
          "title": "Aspaveli — EMA public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22PEGCETACOPLAN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: EMPAVELI (NDA215014)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215014",
          "display_title": "FDA: EMPAVELI approval history"
        }
      ]
    },
    {
      "slug": "rusfertide",
      "name": "Rusfertide",
      "canonical_id": "rusfertide",
      "entry_kind": "molecule",
      "aliases": [
        "Mimrylo"
      ],
      "identity": "Rusfertide is a hepcidin-mimicking medicine. FDA announced approval of Mimrylo on August 28, 2026 for adults with polycythaemia vera, describing a treatment approach that limits iron available for excess red-cell production.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA-approved product; August 28, 2026 announcement. Product: Mimrylo (rusfertide). Indication: Adults with polycythaemia vera as specified in the FDA approval announcement. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Rusfertide is a hepcidin-mimicking medicine. FDA announced approval of Mimrylo on August 28, 2026 for adults with polycythaemia vera, describing a treatment approach that limits iron available for excess red-cell production.",
      "evidence_level": "human regulatory approval announcement",
      "limitations": "This approval is disease- and product-specific; it does not support iron manipulation, bodybuilding or general longevity use. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Rusfertide may interest adults with polycythaemia vera who need repeated blood-removal procedures to control excess red blood cells. The hoped-for practical benefit is reducing that treatment burden.",
        "what_it_is_used_or_studied_for": "FDA approved Mimrylo in August 2026 for adults with this blood disorder. It mimics hepcidin, a hormone that controls how much iron is available for making red blood cells.",
        "what_human_evidence_shows": "The supporting trial included 293 adults needing frequent blood removal despite standard treatment. Rusfertide helped substantially more patients avoid meeting the need for further procedures during the trial's assessment period than placebo.",
        "important_drawbacks": "Injection-site reactions and anaemia were common. This disease-specific benefit does not support manipulating iron for athletic performance or general longevity."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-its-kind-polycythemia-vera-rare-blood-disorder",
          "title": "FDA approval of Mimrylo (rusfertide) for polycythaemia vera, August 28, 2026",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22RUSFERTIDE%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: MIMRYLO (NDA220605)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220605",
          "display_title": "FDA: MIMRYLO approval history"
        }
      ]
    },
    {
      "slug": "vancomycin",
      "name": "Vancomycin",
      "canonical_id": "vancomycin",
      "entry_kind": "glycopeptide antibiotic",
      "aliases": [],
      "identity": "Vancomycin is a glycopeptide antibiotic. The independently authored MedlinePlus oral-drug guide explains its intestinal infection use and explicitly distinguishes oral treatment from killing bacteria elsewhere in the body.",
      "classification": "glycopeptide antibiotic",
      "regulatory_status": "Jurisdiction: US. Label: Oral medicine described; FDA application record verified. Product: Oral vancomycin; selected FDA-approved product record. Indication: Colitis caused by certain bacteria, with oral-route limitations stated in the patient guide. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Vancomycin is a glycopeptide antibiotic. The independently authored MedlinePlus oral-drug guide explains its intestinal infection use and explicitly distinguishes oral treatment from killing bacteria elsewhere in the body.",
      "evidence_level": "human medicine information",
      "limitations": "Oral and intravenous uses cannot be interchanged. This oral source does not establish a systemic-infection indication, dosing or current formulation availability. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Vancomycin is an antibiotic, not a recovery or wellness supplement. People may encounter its oral form when certain bacteria cause inflammation of the intestine, sometimes after another antibiotic.",
        "what_it_is_used_or_studied_for": "The cited patient guide describes oral vancomycin for this intestinal infection setting. Oral and intravenous vancomycin have different treatment roles and should not be treated as interchangeable.",
        "what_human_evidence_shows": "The established benefit described here is treating susceptible bacteria in the intestine. Oral vancomycin does not kill bacteria elsewhere in the body, and antibiotics do not treat viral colds or flu.",
        "important_drawbacks": "Nausea, vomiting and abdominal symptoms can occur, along with potentially serious reactions. Unnecessary antibiotic use also contributes to infections that resist treatment."
      },
      "sources": [
        {
          "url": "https://medlineplus.gov/druginfo/meds/a604038.html",
          "title": "Vancomycin: oral medicine information from MedlinePlus",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "ASHP patient medication information hosted by the US National Library of Medicine"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22VANCOMYCIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: VANCOMYCIN HYDROCHLORIDE (ANDA214913)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214913",
          "display_title": "FDA: VANCOMYCIN HYDROCHLORIDE approval history"
        }
      ]
    },
    {
      "slug": "vasopressin",
      "name": "Vasopressin",
      "canonical_id": "vasopressin",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Vasopressin was compared with norepinephrine in the 409-person VANISH trial in septic shock. Early vasopressin did not improve the primary kidney-failure-free-day outcome; the study does not support replacing norepinephrine as initial therapy on that basis.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US regulatory record; UK human trial. Label: FDA prescription product record; clinical trial evidence is separate. Product: Vasopressin; selected FDA-approved product record. Indication: The cited VANISH study examined early vasopressor treatment in adult septic shock; the FDA application metadata does not contain the full current indication. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Vasopressin was compared with norepinephrine in the 409-person VANISH trial in septic shock. Early vasopressin did not improve the primary kidney-failure-free-day outcome; the study does not support replacing norepinephrine as initial therapy on that basis.",
      "evidence_level": "human randomised controlled trial",
      "limitations": "This is a specific negative primary-outcome finding, not proof that vasopressin has no clinical uses or a recommendation for an individual patient. Regulatory indication and availability need separate sources. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Vasopressin attracts interest in intensive care because it can tighten blood vessels when septic shock causes dangerously low blood pressure. The important question is whether improving circulation also improves patient outcomes.",
        "what_it_is_used_or_studied_for": "The VANISH trial studied early vasopressin against norepinephrine in 409 adults with septic shock, a life-threatening response to infection with circulatory failure.",
        "what_human_evidence_shows": "Vasopressin did not improve the trial's main measure: days alive without kidney failure. The study therefore did not support replacing norepinephrine as initial treatment on the basis of kidney protection.",
        "important_drawbacks": "This was an intensive-care comparison, not a wellness study. A negative result for this particular outcome does not mean vasopressin has no medical uses."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/27483065/",
          "title": "Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: VANISH",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed human randomised trial, indexedPubMed",
          "pmid": "27483065",
          "doi": "10.1001/jama.2016.10485"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22VASOPRESSIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: VASOPRESSIN (NDA212593)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212593",
          "display_title": "FDA: VASOPRESSIN approval history"
        }
      ]
    },
    {
      "slug": "balixafortide",
      "name": "Balixafortide",
      "canonical_id": "balixafortide",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Balixafortide was studied with eribulin in the phase 3 FORTRESS breast-cancer trial. The official registry marks that study terminated and states that it was stopped early for failure to meet its primary endpoint.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: ClinicalTrials.gov multinational registry. Label: Investigational human trial; FDA approval not established. Product: Balixafortide with eribulin. Indication: FORTRESS phase 3 research in HER2-negative locally recurrent or metastatic breast cancer. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Balixafortide was studied with eribulin in the phase 3 FORTRESS breast-cancer trial. The official registry marks that study terminated and states that it was stopped early for failure to meet its primary endpoint.",
      "evidence_level": "human phase 3 trial registry",
      "limitations": "A terminated trial is not an approval, clinical recommendation or proof of benefit. Registry information is sponsor-reported; other indications or later programmes require their own evidence. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Balixafortide has been investigated to change how cells respond to chemical signals, including in cancer treatment and stem-cell mobilisation. Interest in a mechanism is different from proof that patients benefit.",
        "what_it_is_used_or_studied_for": "The phase 3 FORTRESS trial tested balixafortide with eribulin against eribulin alone in people with HER2-negative, locally recurrent or metastatic breast cancer.",
        "what_human_evidence_shows": "The trial was stopped early because it failed to meet its main endpoint. A separate human stem-cell study addresses another research question and cannot reverse that negative breast-cancer result.",
        "important_drawbacks": "A successful approved treatment role is not established by these sources. The failed larger trial is a central limitation, rather than a minor detail to set aside when discussing possible benefits."
      },
      "sources": [
        {
          "url": "https://clinicaltrials.gov/study/NCT03786094",
          "title": "FORTRESS balixafortide plus eribulin phase 3 study record",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "ClinicalTrials.gov trialregistry"
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5209880/",
          "title": "Balixafortide for stem-cell mobilisation: a dose-escalation trial in healthy volunteers",
          "supports": "A separate early human study examined balixafortide for mobilisation of blood-forming stem cells in healthy volunteers; it does not establish cancer efficacy or regulatory approval.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed original research; full text in PMC",
          "pmid": "28049490",
          "doi": "10.1186/s12967-016-1107-2"
        }
      ]
    },
    {
      "slug": "selepressin",
      "name": "Selepressin",
      "canonical_id": "selepressin",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Selepressin is a selective vasopressin V1A receptor agonist investigated in septic shock. A 53-person phase IIa trial explored blood-pressure and vasopressor effects; its exploratory findings do not establish routine clinical benefit.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: Multinational human research. Label: Investigational human and animal research; FDA approval not established. Product: Selepressin. Indication: Exploratory septic-shock vasopressor research. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Selepressin is a selective vasopressin V1A receptor agonist investigated in septic shock. A 53-person phase IIa trial explored blood-pressure and vasopressor effects; its exploratory findings do not establish routine clinical benefit.",
      "evidence_level": "human exploratory trial plus preclinical sheep experiment",
      "limitations": "The small pilot must not override larger or later evidence. No current FDA approval, survival benefit or treatment recommendation is established by this source. Educational reference only; no dosing, administration protocol or individual treatment recommendation. The second source is an animal experiment and does not add a second human trial or establish clinical benefit.",
      "reader_summary": {
        "why_people_are_interested": "Selepressin was designed to raise blood pressure in septic shock while targeting a particular vasopressin receptor. Researchers hoped this selectivity might help circulation with fewer unwanted effects.",
        "what_it_is_used_or_studied_for": "Early human research explored blood-pressure support in septic shock. The later SEPSIS-ACT trial tested whether adding selepressin to standard care helped critically ill adults spend more days alive without breathing machines or blood-pressure medicines.",
        "what_human_evidence_shows": "SEPSIS-ACT analysed 828 treated patients and found no significant improvement in that main outcome or 90-day mortality. It stopped early for futility, meaning the results did not justify continuing toward the planned benefit.",
        "important_drawbacks": "The larger negative trial limits the meaning of earlier encouraging blood-pressure findings. A small earlier trial also stopped one higher-exposure group after a possible safety concern."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/28807037/",
          "title": "Selepressin: a phase IIa randomised trial in septic shock",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed human phase IIa trial, indexedPubMed",
          "pmid": "28807037",
          "doi": "10.1186/s13054-017-1798-7",
          "pmcid": "PMC5557574"
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4684247/",
          "title": "Selepressin in an ovine septic-shock model",
          "supports": "Preclinical sheep research examined haemodynamics and organ-injury measures. Animal findings must not be presented as human survival benefit.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed original research; full text in PMC",
          "pmid": "26496451",
          "doi": "10.1097/ccm.0000000000001380"
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6802260/",
          "title": "Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial",
          "checked_on": "2026-10-29",
          "additional_document_vs_comparator": false,
          "supports": "In adult septic-shock patients receiving norepinephrine, 868 were randomised and 828 treated patients formed the primary analysis cohort. The trial stopped for futility at the end of part 1. There was no statistically significant improvement in ventilator- and vasopressor-free days within 30 days, or the specified secondary outcomes including 90-day mortality.",
          "read_scope": "Opened actual full-text article through web reader and certificate-verified cloud HTTP; read abstract, primary analysis results and conclusions. Cached HTML and plain-text receipts.",
          "source_kind": "Peer-reviewed original randomised clinical trial; full text in PubMed Central"
        }
      ]
    },
    {
      "slug": "cetrorelix",
      "name": "Cetrorelix",
      "canonical_id": "cetrorelix",
      "entry_kind": "molecule",
      "aliases": [
        "Cetrotide"
      ],
      "identity": "Cetrorelix is the active ingredient in Cetrotide. EMA describes its use to prevent premature ovulation during fertility treatment by blocking the hormonal signal that triggers egg release.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Cetrotide. Indication: Prevention of premature ovulation during ovarian stimulation for assisted reproduction. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Cetrorelix is the active ingredient in Cetrotide. EMA describes its use to prevent premature ovulation during fertility treatment by blocking the hormonal signal that triggers egg release.",
      "evidence_level": "human regulatory assessment",
      "limitations": "This fertility-treatment context does not support general hormone optimisation or unsupervised use; the EMA source does not establish US indications or local supply; the separate FDA product record must be read within its stated scope. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Cetrorelix is considered during fertility treatment to prevent eggs being released before they can be collected. Timing matters because eggs released too early may be unsuitable for planned treatment.",
        "what_it_is_used_or_studied_for": "Cetrotide blocks the hormonal signal that triggers ovulation. EMA authorises it for women receiving ovarian stimulation, where medicines encourage several eggs to develop.",
        "what_human_evidence_shows": "Human fertility studies supported its ability to prevent premature ovulation, and EMA judged it an effective alternative to existing treatments. Preventing early egg release does not guarantee pregnancy or a live birth.",
        "important_drawbacks": "Injection-site reactions can occur, and severe allergic reactions are an important concern. Ovarian overstimulation can also occur within the wider fertility-treatment process."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/cetrotide",
          "title": "Cetrotide — EMA public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22CETRORELIX%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: CETRORELIX ACETATE (ANDA218740)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218740",
          "display_title": "FDA: CETRORELIX ACETATE approval history"
        }
      ]
    },
    {
      "slug": "degarelix",
      "name": "Degarelix",
      "canonical_id": "degarelix",
      "entry_kind": "molecule",
      "aliases": [
        "Firmagon"
      ],
      "identity": "Degarelix is the active ingredient in Firmagon, a medicine for specified hormone-dependent prostate cancer settings. EMA describes testosterone-lowering treatment and explains that this GnRH antagonist differs from agonists that initially stimulate the pathway.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Firmagon. Indication: Specified hormone-dependent prostate cancer settings. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Degarelix is the active ingredient in Firmagon, a medicine for specified hormone-dependent prostate cancer settings. EMA describes testosterone-lowering treatment and explains that this GnRH antagonist differs from agonists that initially stimulate the pathway.",
      "evidence_level": "human regulatory assessment",
      "limitations": "Cancer setting and product label govern use. The EMA overview does not establish US indications or support general testosterone suppression. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Degarelix is considered when prostate cancer depends on testosterone to grow. Its purpose is to reduce that hormonal support, rather than raise testosterone or improve general vitality.",
        "what_it_is_used_or_studied_for": "Firmagon blocks the hormone-signalling pathway that drives testosterone production. EMA describes its use in specified hormone-dependent prostate-cancer settings, including treatment around radiotherapy.",
        "what_human_evidence_shows": "Human studies found it effective at lowering testosterone. In a separate 244-person study, prostate shrinkage before radiotherapy was similar to that with goserelin plus bicalutamide.",
        "important_drawbacks": "Hot flushes and injection-site pain or redness are common. Benefits and burdens belong in the context of cancer care; testosterone reduction is not a general health benefit for otherwise healthy people."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/firmagon",
          "title": "Firmagon — EMA public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22DEGARELIX%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: FIRMAGON (NDA022201)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022201",
          "display_title": "FDA: FIRMAGON approval history"
        }
      ]
    },
    {
      "slug": "ganirelix",
      "name": "Ganirelix",
      "canonical_id": "ganirelix",
      "entry_kind": "molecule",
      "aliases": [
        "Orgalutran"
      ],
      "identity": "Ganirelix is the active ingredient in Orgalutran. EMA describes its use to prevent premature ovulation during controlled ovarian stimulation in fertility treatment.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Orgalutran. Indication: Prevention of premature ovulation in ovarian stimulation for fertility treatment. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Ganirelix is the active ingredient in Orgalutran. EMA describes its use to prevent premature ovulation during controlled ovarian stimulation in fertility treatment.",
      "evidence_level": "human regulatory assessment",
      "limitations": "Evidence belongs to the named fertility protocol and product; it does not establish benefit for general reproductive enhancement or current US availability. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Ganirelix helps fertility teams control when ovulation happens. Its role is to stop eggs being released prematurely while the ovaries are being stimulated to develop eggs for assisted reproduction.",
        "what_it_is_used_or_studied_for": "EMA describes Orgalutran for women undergoing controlled ovarian stimulation. It blocks a hormonal signal that would otherwise trigger early egg release.",
        "what_human_evidence_shows": "Human studies supported its ability to prevent premature ovulation, leading to EU authorisation. This is a treatment-process benefit; it should not be interpreted as a promise that an individual will become pregnant.",
        "important_drawbacks": "Redness and swelling at the injection site are common. It forms part of a monitored fertility-treatment programme, and its benefits cannot be transferred to unrelated hormone or wellness goals."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/orgalutran",
          "title": "Orgalutran — EMA public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22GANIRELIX%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: FYREMADEL (ANDA204246)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204246",
          "display_title": "FDA: FYREMADEL approval history"
        }
      ]
    },
    {
      "slug": "goserelin",
      "name": "Goserelin",
      "canonical_id": "goserelin",
      "entry_kind": "molecule",
      "aliases": [
        "Zoladex"
      ],
      "identity": "Goserelin is a hormone-pathway medicine used in selected cancers. NCI identifies FDA-approved uses in prostate cancer and certain advanced breast-cancer settings and explains that continued treatment reduces sex-hormone production.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA-approved medicine for specified cancer uses. Product: Goserelin acetate. Indication: Specified advanced breast cancer and prostate cancer uses described by NCI. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Goserelin is a hormone-pathway medicine used in selected cancers. NCI identifies FDA-approved uses in prostate cancer and certain advanced breast-cancer settings and explains that continued treatment reduces sex-hormone production.",
      "evidence_level": "human government medicine summary",
      "limitations": "Indications depend on product, population and combination treatment. NCI’s educational summary is not a full current label or proof of local supply. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Goserelin is considered when lowering sex hormones can help control a hormone-sensitive cancer. The aim is to slow cancer growth or relieve its effects, rather than improve hormone levels in a healthy person.",
        "what_it_is_used_or_studied_for": "NCI describes approved uses in prostate cancer and advanced breast cancer in specified women before or around menopause. Some prostate-cancer uses involve other treatments as well.",
        "what_human_evidence_shows": "With continued treatment, goserelin lowers testosterone or oestrogen, reducing signals that some cancer cells need to grow. Approved uses are specific to the cancer and treatment setting.",
        "important_drawbacks": "Hormone levels initially rise before falling. The intended hormone suppression is itself a major treatment change, and the brief NCI overview is not a complete account of side effects."
      },
      "sources": [
        {
          "url": "https://www.cancer.gov/about-cancer/treatment/drugs/goserelinacetate",
          "title": "Goserelin acetate: NCI cancer-drug information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "National Cancer Institute medicine summary"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22GOSERELIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: ZOLADEX (NDA020578)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020578",
          "display_title": "FDA: ZOLADEX approval history"
        }
      ]
    },
    {
      "slug": "histrelin",
      "name": "Histrelin",
      "canonical_id": "histrelin",
      "entry_kind": "molecule",
      "aliases": [
        "Supprelin LA"
      ],
      "identity": "Histrelin is a GnRH agonist supplied as an implant in the cited MedlinePlus guide. The guide describes its use for central precocious puberty and its effect on hormone levels.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA prescription product record; childhood indication described. Product: Supprelin LA (histrelin implant). Indication: Central precocious puberty in children. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Histrelin is a GnRH agonist supplied as an implant in the cited MedlinePlus guide. The guide describes its use for central precocious puberty and its effect on hormone levels.",
      "evidence_level": "human medicine information",
      "limitations": "The current patient guide supports the childhood indication only. It must not be used to claim that a historical prostate-cancer product remains marketed or that all hormone-suppression uses are approved. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Histrelin may be considered for children whose puberty starts abnormally early because the normal puberty-signalling system switches on too soon. The goal is to slow that premature progression.",
        "what_it_is_used_or_studied_for": "The cited patient guide describes a histrelin implant for central precocious puberty, which can cause early sexual development and faster-than-normal bone growth.",
        "what_human_evidence_shows": "The medicine reduces the hormones driving puberty. Its established clinical role concerns children with this diagnosed condition, rather than a general benefit from suppressing hormones or delaying normal development.",
        "important_drawbacks": "The implant requires insertion and removal procedures. Pain, swelling or scarring can occur, and puberty signs can temporarily worsen at the start. Serious reactions, including seizures, are also described."
      },
      "sources": [
        {
          "url": "https://medlineplus.gov/druginfo/meds/a601146.html",
          "title": "Histrelin Implant — MedlinePlus Drug Information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "ASHP patient medication information hosted by the US National Library of Medicine"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22HISTRELIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: SUPPRELIN LA (NDA022058)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022058",
          "display_title": "FDA: SUPPRELIN LA approval history"
        }
      ]
    },
    {
      "slug": "human-chorionic-gonadotropin",
      "name": "Human chorionic gonadotropin",
      "canonical_id": "human-chorionic-gonadotropin",
      "entry_kind": "hormone family; includes recombinant products",
      "aliases": [
        "hCG",
        "choriogonadotropin alfa"
      ],
      "identity": "Human chorionic gonadotropin is a hormone name used across different preparations, rather than one small-peptide product. EMA describes choriogonadotropin alfa in Ovitrelle as a recombinant copy used to trigger ovulation in selected fertility-treatment settings.",
      "classification": "hormone family; includes recombinant products",
      "regulatory_status": "Jurisdiction: EU indication source; US product record. Label: EU-authorised product; a separate US FDA prescription record is verified. Product: Ovitrelle (choriogonadotropin alfa); Pregnyl is a separate US product record. Indication: Triggering ovulation in the specified fertility-treatment populations. Us approval scope: The US dataset lists a matched product with an approved original submission and prescription marketing status. Indications described by EMA remain EU-specific; application metadata does not replace the current US label. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Human chorionic gonadotropin is a hormone name used across different preparations, rather than one small-peptide product. EMA describes choriogonadotropin alfa in Ovitrelle as a recombinant copy used to trigger ovulation in selected fertility-treatment settings.",
      "evidence_level": "human regulatory assessment",
      "limitations": "A product-specific fertility approval does not cover every hCG preparation, weight-loss claim or testosterone-treatment adjunct. US family-wide approval is not established. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Human chorionic gonadotropin, or hCG, is of interest in fertility treatment because it can trigger the final steps leading to egg release. It is a hormone used in different preparations, not one interchangeable product.",
        "what_it_is_used_or_studied_for": "EMA describes Ovitrelle, a manufactured version called choriogonadotropin alfa, for specified women receiving fertility treatment or needing help to ovulate.",
        "what_human_evidence_shows": "Studies in fertility patients found Ovitrelle similarly effective to urinary-derived hCG at triggering ovulation. Egg release is an intermediate result, not a guarantee of pregnancy or live birth.",
        "important_drawbacks": "Ovarian hyperstimulation can cause illness when the ovaries overrespond. Abdominal symptoms and injection-site reactions also occur. These findings do not establish weight-loss or general wellness benefits."
      },
      "sources": [
        {
          "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/ovitrelle",
          "title": "Ovitrelle — EMA public assessment report",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "EMA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22CHORIONIC%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: PREGNYL (BLA017692)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017692",
          "display_title": "FDA: PREGNYL approval history"
        }
      ]
    },
    {
      "slug": "leuprolide",
      "name": "Leuprolide",
      "canonical_id": "leuprolide",
      "entry_kind": "molecule",
      "aliases": [
        "leuprolide acetate"
      ],
      "identity": "Leuprolide is a hormone-pathway medicine. NCI identifies leuprolide acetate as FDA approved for palliative treatment of advanced prostate cancer; other products and indications need separate documentation.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA-approved medicine for the cited cancer use. Product: Leuprolide acetate. Indication: Palliative treatment of advanced prostate cancer. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Leuprolide is a hormone-pathway medicine. NCI identifies leuprolide acetate as FDA approved for palliative treatment of advanced prostate cancer; other products and indications need separate documentation.",
      "evidence_level": "human government medicine summary",
      "limitations": "Do not collapse paediatric, gynaecologic and oncology formulations into one indication or assume a current local supply from this educational summary. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Leuprolide is considered in advanced prostate cancer because reducing hormonal stimulation can help control the disease and its effects. This is a cancer-treatment goal, not a way to enhance normal hormone function.",
        "what_it_is_used_or_studied_for": "NCI identifies leuprolide acetate as approved for palliative treatment of advanced prostate cancer. Palliative treatment aims to control disease effects and symptoms; it does not mean the medicine cures the cancer.",
        "what_human_evidence_shows": "Its established role is specific to that clinical context. Other leuprolide products or uses may have their own evidence and authorisations, which cannot be assumed from this cancer summary.",
        "important_drawbacks": "Treatment involves a substantial change in hormone signalling. The short NCI overview does not fully describe side effects or individual suitability."
      },
      "sources": [
        {
          "url": "https://www.cancer.gov/about-cancer/treatment/drugs/leuprolideacetate",
          "title": "Leuprolide acetate: NCI cancer-drug information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "National Cancer Institute medicine summary"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22LEUPROLIDE%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: LEUPROLIDE ACETATE (ANDA215336)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215336",
          "display_title": "FDA: LEUPROLIDE ACETATE approval history"
        }
      ]
    },
    {
      "slug": "lutetium-lu-177-vipivotide-tetraxetan",
      "name": "Lutetium Lu-177 vipivotide tetraxetan",
      "canonical_id": "lutetium-lu-177-vipivotide-tetraxetan",
      "entry_kind": "targeted radiopharmaceutical",
      "aliases": [
        "Pluvicto"
      ],
      "identity": "Lutetium Lu-177 vipivotide tetraxetan is the targeted radiopharmaceutical Pluvicto. FDA’s July 31, 2026 approval notice describes its use with androgen-receptor-pathway inhibitor therapy in a specifically defined PSMA-positive metastatic prostate-cancer population.",
      "classification": "targeted radiopharmaceutical",
      "regulatory_status": "Jurisdiction: US. Label: FDA-approved expanded indication; July 31, 2026. Product: Pluvicto. Indication: With androgen-receptor-pathway inhibitor therapy in adults with PSMA-positive metastatic androgen-pathway-modulation-naive or sensitive prostate cancer. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Lutetium Lu-177 vipivotide tetraxetan is the targeted radiopharmaceutical Pluvicto. FDA’s July 31, 2026 approval notice describes its use with androgen-receptor-pathway inhibitor therapy in a specifically defined PSMA-positive metastatic prostate-cancer population.",
      "evidence_level": "human regulatory approval announcement",
      "limitations": "A radioligand cancer therapy must not be presented as an injectable wellness peptide. Eligibility, radiation handling and the complete label require specialist clinical care. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Lutetium Lu-177 vipivotide tetraxetan, sold as Pluvicto, is considered for particular prostate cancers because it delivers radiation to cells carrying a target called PSMA. It is a specialist cancer medicine.",
        "what_it_is_used_or_studied_for": "FDA's July 2026 notice covers its combination with androgen-receptor-pathway treatment in a specifically defined group with PSMA-positive prostate cancer that has spread.",
        "what_human_evidence_shows": "In the 1,144-person PSMAddition trial, adding Pluvicto delayed worsening seen on scans compared with the hormone-pathway treatment alone. Overall survival results were not mature at that analysis.",
        "important_drawbacks": "Risks include radiation exposure, reduced blood-cell production, kidney damage and infertility. A scan-based benefit is not yet proof that this particular combination makes patients live longer."
      },
      "sources": [
        {
          "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy",
          "title": "FDA approval of Pluvicto with androgen-receptor-pathway inhibitor therapy, July 31, 2026",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "FDA regulator"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22VIPIVOTIDE%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: PLUVICTO (NDA215833)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833",
          "display_title": "FDA: PLUVICTO approval history"
        }
      ]
    },
    {
      "slug": "nafarelin",
      "name": "Nafarelin",
      "canonical_id": "nafarelin",
      "entry_kind": "molecule",
      "aliases": [
        "Synarel"
      ],
      "identity": "Nafarelin is a GnRH agonist given as a nasal medicine in the cited patient guide. MedlinePlus describes endometriosis and central precocious puberty uses and explains its hormone-lowering action.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA prescription nasal product record; patient-guide uses described. Product: Synarel (nafarelin nasal spray). Indication: Endometriosis and central precocious puberty. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Nafarelin is a GnRH agonist given as a nasal medicine in the cited patient guide. MedlinePlus describes endometriosis and central precocious puberty uses and explains its hormone-lowering action.",
      "evidence_level": "human medicine information",
      "limitations": "This is not a general fertility or anti-ageing intervention. Product-specific precautions and clinician guidance remain necessary; the guide is not a complete regulatory or availability record. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Nafarelin is considered when lowering certain reproductive hormones can address endometriosis or puberty that starts too early. These are different diagnosed conditions, rather than general reasons to suppress hormones.",
        "what_it_is_used_or_studied_for": "The nasal medicine is used to manage endometriosis, where tissue similar to the womb lining grows elsewhere, and central precocious puberty in children.",
        "what_human_evidence_shows": "Its established clinical purpose is to reduce hormone stimulation relevant to those conditions. That does not mean it cures infertility or benefits people with normal hormone function.",
        "important_drawbacks": "Hot flushes, mood changes, headaches and nasal irritation can occur. Bone density can fall, increasing fracture concerns, and early puberty signs may initially worsen in children."
      },
      "sources": [
        {
          "url": "https://medlineplus.gov/druginfo/meds/a601082.html",
          "title": "Nafarelin Nasal Spray — MedlinePlus Drug Information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "ASHP patient medication information hosted by the US National Library of Medicine"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22NAFARELIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: SYNAREL (NDA019886)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019886",
          "display_title": "FDA: SYNAREL approval history"
        }
      ]
    },
    {
      "slug": "oxytocin",
      "name": "Oxytocin",
      "canonical_id": "oxytocin",
      "entry_kind": "hormone",
      "aliases": [],
      "identity": "Oxytocin is included in WHO guidance on uterotonics for prevention of postpartum haemorrhage. That obstetric evidence must be kept separate from claims about social bonding, sexual enhancement or general wellness.",
      "classification": "hormone",
      "regulatory_status": "Jurisdiction: US regulatory record; WHO international guidance. Label: FDA prescription product record; obstetric guideline use described. Product: Oxytocin; selected FDA prescription injection record. Indication: Uterotonic prevention of postpartum haemorrhage in WHO guidance. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Oxytocin is included in WHO guidance on uterotonics for prevention of postpartum haemorrhage. That obstetric evidence must be kept separate from claims about social bonding, sexual enhancement or general wellness.",
      "evidence_level": "human clinical guideline",
      "limitations": "A guideline is not a product approval or an individual treatment plan. The source does not establish benefit for consumer intranasal or behavioural uses. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Oxytocin has an important medical role after childbirth: helping the womb contract to reduce the risk of excessive bleeding. That benefit is more specific than popular claims about bonding or wellbeing.",
        "what_it_is_used_or_studied_for": "WHO includes oxytocin in guidance on medicines that prevent postpartum haemorrhage, meaning dangerous bleeding after birth. These medicines are called uterotonics because they stimulate womb contractions.",
        "what_human_evidence_shows": "The supported human benefit here is prevention of bleeding in maternity care. The cited guidance does not establish that consumer oxytocin products improve relationships, sexual wellbeing or general mood.",
        "important_drawbacks": "Its effects depend on the obstetric setting, formulation and clinical oversight. A recognised role in childbirth is not evidence that unsupervised or unrelated use is beneficial."
      },
      "sources": [
        {
          "url": "https://www.who.int/publications/i/item/9789241550420",
          "title": "WHO recommendations: uterotonics for prevention of postpartum haemorrhage",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "WorldHealthOrganization guideline"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22OXYTOCIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: OXYTOCIN (ANDA091676)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091676",
          "display_title": "FDA: OXYTOCIN approval history"
        }
      ]
    },
    {
      "slug": "triptorelin",
      "name": "Triptorelin",
      "canonical_id": "triptorelin",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Triptorelin is a GnRH agonist. MedlinePlus describes long-acting injection products used for certain prostate cancers and central precocious puberty, while noting that hormone changes require clinical monitoring.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: US. Label: FDA prescription product record; patient-guide uses described. Product: Triptorelin; Trelstar is the selected FDA product record. Indication: Specified prostate cancer and central precocious puberty uses. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Triptorelin is a GnRH agonist. MedlinePlus describes long-acting injection products used for certain prostate cancers and central precocious puberty, while noting that hormone changes require clinical monitoring.",
      "evidence_level": "human medicine information",
      "limitations": "Product, population and formulation must remain explicit. This guide does not establish that every international triptorelin use is FDA approved or appropriate for an individual. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Triptorelin is considered when reducing hormone signals can help manage certain prostate cancers or stop puberty progressing abnormally early. The intended benefit depends on the patient's diagnosed condition.",
        "what_it_is_used_or_studied_for": "The cited patient guide describes different long-acting injection products for prostate cancer and central precocious puberty, where children begin puberty too soon.",
        "what_human_evidence_shows": "Its established treatment role comes from lowering hormones that drive these conditions. The cancer and childhood-puberty uses should not be combined into a general claim that lowering hormones improves health.",
        "important_drawbacks": "Hot flushes, changes in sexual function, mood changes and injection reactions can occur. Serious heart or neurological reactions are described, and puberty signs can temporarily worsen when treatment begins."
      },
      "sources": [
        {
          "url": "https://medlineplus.gov/druginfo/meds/a611047.html",
          "title": "Triptorelin Injection — MedlinePlus Drug Information",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "ASHP patient medication information hosted by the US National Library of Medicine"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22TRIPTORELIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: TRELSTAR (NDA020715)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020715",
          "display_title": "FDA: TRELSTAR approval history"
        }
      ]
    },
    {
      "slug": "kisspeptin-10",
      "name": "Kisspeptin-10",
      "canonical_id": "kisspeptin-10",
      "entry_kind": "molecule",
      "aliases": [],
      "identity": "Kisspeptin-10 is a short kisspeptin fragment studied for effects on reproductive-hormone signalling. An early human experiment observed changes in luteinising-hormone responses and pulse patterns; it did not establish treatment benefit in infertility or long-term safety.",
      "classification": "molecule",
      "regulatory_status": "Jurisdiction: UK human endocrine research. Label: Exploratory human research; FDA approval not established. Product: Kisspeptin-10. Indication: Acute and short-infusion hormone-response experiments in healthy men. Availability: Not established by this dossier; regulatory history or an educational listing is not local stock.",
      "evidence_summary": "Kisspeptin-10 is a short kisspeptin fragment studied for effects on reproductive-hormone signalling. An early human experiment observed changes in luteinising-hormone responses and pulse patterns; it did not establish treatment benefit in infertility or long-term safety.",
      "evidence_level": "human first-in-human exploratory study",
      "limitations": "Small healthy-volunteer endocrine responses are not clinical efficacy, approval or support for self-administration. Do not transfer evidence from kisspeptin-54 without explicitly identifying the different molecule. Educational reference only; no dosing, administration protocol or individual treatment recommendation. The second study compares distinct kisspeptin isoforms; it does not permit silently treating kisspeptin-54 and kisspeptin-10 as interchangeable.",
      "reader_summary": {
        "why_people_are_interested": "Kisspeptin-10 interests researchers because it helps control reproductive-hormone signalling. Understanding that pathway could matter for future fertility treatments, but a hormonal response is only an early research step.",
        "what_it_is_used_or_studied_for": "Small human studies examined how kisspeptin-10 changes luteinising hormone, a signal involved in reproductive function, and compared it with other hormone signals in healthy men.",
        "what_human_evidence_shows": "Researchers observed short-term increases and changes in hormone pulses. These experiments did not establish improved fertility, pregnancy rates or lasting symptom relief in patients.",
        "important_drawbacks": "Long-term safety and a treatment benefit remain unestablished by these studies. Kisspeptin-10 and kisspeptin-54 are different forms, and findings for one should not automatically be assigned to the other."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/21632807/",
          "title": "Kisspeptin-10 and luteinising-hormone pulse frequency in men",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed first-in-human endocrine study",
          "pmid": "21632807",
          "doi": "10.1210/jc.2011-0089",
          "pmcid": "PMC3380939"
        },
        {
          "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4507333/",
          "title": "Direct comparison of kisspeptin-10, kisspeptin-54 and GnRH in healthy men",
          "supports": "A second small human physiology study directly compared kisspeptin-10 with kisspeptin-54 andGnRH; endocrine responses are not evidence of treatment success in infertility.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed original research; full text in PMC",
          "pmid": "26089302",
          "doi": "10.1093/humrep/dev143"
        }
      ]
    },
    {
      "slug": "compounded-gonadorelin",
      "name": "Gonadorelin (compounded)",
      "canonical_id": "gonadorelin",
      "entry_kind": "use context; compounded preparation not a separate molecule",
      "aliases": [],
      "identity": "The gonadorelin entry concerns a formulation and use context, not a new molecule. A small, short study evaluated pulsatile GnRH in congenital hypogonadotropic hypogonadism; FDA’s dataset lists historical gonadorelin products as discontinued. Neither source establishes approval or benefit for a compounded TRT adjunct.",
      "classification": "use context; compounded preparation not a separate molecule",
      "regulatory_status": "Jurisdiction: US regulatory record; China disease-specific human research. Label: Historical gonadorelin products discontinued; compounded TRT-adjunct approval not established. Product: Pulsatile GnRH research preparation; historical Factrel FDA record. Indication: Congenital hypogonadotropic hypogonadism research; not a testosterone-replacement-therapy adjunct indication. Availability: The selected FDA gonadorelin product is listed as discontinued. No current approved compounded TRT-adjunct product is established.",
      "evidence_summary": "The gonadorelin entry concerns a formulation and use context, not a new molecule. A small, short study evaluated pulsatile GnRH in congenital hypogonadotropic hypogonadism; FDA’s dataset lists historical gonadorelin products as discontinued. Neither source establishes approval or benefit for a compounded TRT adjunct.",
      "evidence_level": "human small self-controlled clinical study",
      "limitations": "Disease-specific pump research cannot establish the identity, potency, sterility or approved status of a compounded preparation. The short uncontrolled study is not long-term clinical evidence. Educational reference only; no dosing, administration protocol or individual treatment recommendation.",
      "reader_summary": {
        "why_people_are_interested": "Gonadorelin interests researchers because it can replace a missing reproductive-hormone signal in particular disorders. The important question is whether that benefit applies to a proposed preparation and patient group.",
        "what_it_is_used_or_studied_for": "A study examined pulsatile GnRH treatment in 28 men born with deficient hormone signalling, a condition called congenital hypogonadotropic hypogonadism. Pulsatile means delivery in timed bursts.",
        "what_human_evidence_shows": "Over seven days, reproductive-hormone levels increased. The small study had no separate control group and did not establish long-term fertility outcomes or benefit as an add-on to testosterone replacement.",
        "important_drawbacks": "Historical Factrel products are discontinued. These findings do not establish that a compounded preparation is approved, reliably sterile or effective for a different use."
      },
      "sources": [
        {
          "url": "https://pubmed.ncbi.nlm.nih.gov/34277762/",
          "title": "Pulsatile GnRH therapy in congenital hypogonadotropic hypogonadism: a multicentre clinical study",
          "supports": "Supports the entry’s bounded identity, named indication or study context, and the limitations described in the summary. Read the source within its stated jurisdiction, population and document date.",
          "additional_document_vs_comparator": true,
          "source_kind": "Peer-reviewed human multicentre clinical study",
          "pmid": "34277762",
          "doi": "10.21037/atm-21-1632",
          "pmcid": "PMC8267282"
        },
        {
          "url": "https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name%3A%22GONADORELIN%22&limit=100",
          "title": "FDA Drugs@FDA application metadata: FACTREL (NDA018123)",
          "supports": "Supports the matched ingredient and selected product, the original submission’s approval status and date, and the dataset’s marketing status. It does not establish the full current indication, safety information or local supply.",
          "additional_document_vs_comparator": true,
          "source_kind": "US Food and Drug Administration, Drugs@FDA via official openFDA endpoint",
          "reader_url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018123",
          "display_title": "FDA: FACTREL approval history"
        }
      ]
    }
  ]
}